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Scope of this thesis 
1.1 INTRODUCTION 
The first observations indicative of a role of genetic factors in carcinogenesis 
were made as early as 1912, when Rous demonstrated that a filterable agent 
(i.e. virus) could induce cancer in chicken (Rous 1965). In 1914, Boveri 
postulated a "genetic" theory on carcinogenesis by hypothesizing that the 
development of malignant tumor cells is caused by either the predominance 
of chromosomes which promote cell division, or by the elimination of chro-
mosomes which inhibit cell division (Boveri, 1914). 
In the last decade, research techniques in molecular biology have ad-
vanced rapidly. As a result, biological science has recently made huge steps 
forward in understanding the human genome. The disclosure of the human 
genome seems imminent, as, in February 2001, two research groups (the 
Human Genome Project (HGP) and Celera Genomics) published their draft 
sequences of the near complete human genome (Lander, Linton et al. 2001; 
Venter, Adams et al. 2001). With the knowledge of the human genome se-
quence and new molecular research techniques it is now possible to monitor 
gene expression levels on a genomic scale. These new data promise to en-
hance the fundamental understanding of life at the molecular level. 
As, in general, genetic alterations are thought to play a major role in 
tumor development and tumor progression ((Fearon and Vogel stein 1990); 
(Knudson 1993)), knowledge of molecular genetics seems essential in under-
standing the etiology and the biological behavior of cancer. 
Endometrial cancer ranks among the most common gynecologic malignan-
cies in the Netherlands and North America, alongside ovarian cancer (Bris-
tow 1999). In the Netherlands, each year approximately 1300 new cases are 
diagnosed, compared to 1400 for ovarian cancer and 700 for cervical can-
cer (1995) (Statistics Netherlands Ministry of Health, Welfare and Sports, 
1999). In the majority of cases, approximately 75%, the tumor is confined to 
the uterus at the time of diagnosis and has a relatively good prognosis. This 
has let to the general perception of endometrial cancer to be a relative benign 
cancer type. However, in the Netherlands 370 women still die of endometrial 
cancer every year, compared to 234 of cervical cancer and 986 of ovarian 
cancer (in 1997) (Statistics Netherlands Ministry of Health, Welfare and 
Sports, 1999). 
In order to predict the prognosis and to select optimal therapeutical re-
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gimes, endometrial carcinomas are divided into subgroups. A surgical and 
histological staging system of the International Federation of Gynecology 
and Obstetrics (FIGO) (Pecorelli, Benedet et al. 1999) (http://www.figo.org) 
is at the present time the standard. However, 17-25% of the endometrial 
cancer deaths are accounted for by patients with low surgical-pathological 
stage (stage 1 and 2) whom are therefore misguidedly taken to have a good 
prognosis (Abeler and Kjorstad 1991). Patients with advanced/recurrent dis-
ease count for the other part of the deaths. In these patients response rates 
to treatment (surgery combined with radiotherapy) is low, indicated by a 
five-years survival rate of only 26% (Abeler and Kjorstad 1991). Hormone 
therapy (progesterone) or chemotherapy is given to these patients as a pallia-
tive treatment, however also with low response rates of only 10-30% (Lentz 
1994; Rose 1996). 
To improve the outcome of patients with endometrial cancer tvvo strategies 
can be followed: improvement of tumor classification in order to facilitate a 
more accurate estimation of individual prognosis and tailored therapeutic 
options; improvement of treatment by identifying new therapeutic targets and 
regimes. 
This thesis concerns itself with the possible role of molecular genetics 
with regard to these tvvo strategies. The studies undertaken were designed to 
answer four questions: 
Tumor classification 
In general, tumor development and tumor progression are thought to be 
driven by genetic alterations. Integration of factors related to the biological 
behavior of the tumor, such as gene expression profiles, seems promising and 
may lead to a more accurate classification system of cancers. In this thesis 
the value of gene expression profiling in classifying human endometrial tu-
mors was studied, answering the following question: 
1. What degree of clinical utility and subsequent diagnostic value of gene expres-
sion profiling of endometrial tumors can be ascertained? 
New therapeutic targets and regimes 
Progesterone has a profound effect on mature human endometrium. In a 
Scope of this thesis 
complex interaction with estradiol, progesterone controls proliferation and 
differentiation of endometrial epithelium during the menstrual cycle (Mar-
tin, Das et al. 1973). In clinical practice, progesterone is used as a palliative 
management of advanced and recurrent endometrial cancer. However, the 
response~rate of progesterone treatment in these patients is not very high 
(10-15%) (Lentz 1994; Rose 1996). The low response rate likely stems from 
the transition from hormone controlled growth towards hormone indepen-
dent growth in advanced endometrial tumors. Understanding of the molecu-
lar mechanism underlying progesterone-induced growth inhibition of endo-
metrial cancer cells and identification of genes responsible for the growth 
inhibiting properties of progesterone, may help to find tools to restore the 
progesterone-induced growth inhibition of endometrial cancer and subse-
quently lead to new therapeutic targets. In this respect thi thesis addresses 
the following questions: 
2. Is it possible to identifY genes that are differential expressed between proges-
terone-sensitive and progesterone-insensitive endometrial cancer cells? 
3. What functional differences between the two human progesterone receptor 
(hPR) isoforms (hPRA and hPRB) in endometrial cancer cells can be estab-
lished? 
4. What effects of progesterone can be measured on gene expression and cell 
growth of endometrial cancer cell-lines expressing hPRA or hPRB or both? 
1.2 OUTLINE OF THIS THESIS 
In Chapter 2 the biological and clinical characteristics of endometrial 
cancer are described. An overview is presented on genes possibly involved 
in endometrial cancer development. Chapter 2 also describes the biological 
characteristics of progesterone and its receptors. 
In Chapter 3 gene expression profiles of human endometrial cancer tis-
sue samples were obtained using a eDNA expression array technique. Subse-
quently, a method to analyze the gene expression data was established. 
In Chapter 4 the clinical utility and the diagnostic value of gene expres-
sion profiling in endometrial cancer tissue samples was studied. 
In Chapter 5 genes were identified which are differential expressed 
between progesterone-sensitive and progesterone-insensitive endometrial 
cancer cells. 
5 
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In Chapter 6 functional differences between the two human progester-
one receptor (hPR) isoforms (hPRA and hPRB) in endometrial cancer cells 
was studied. 
In Chapter 7 progesterone effects on gene expression and cell growth 
were studied in several different endometrial cancer cell-lines expressing 
hPRA or hPRB or both. 
1.3 MODEL SYSTEMS USED IN THIS THESIS 
Endometrial cancer tissue bank 
To establish the value of gene expression profiling in classifying human en-
dometrial tumors, human endometrial tissue samples were used. An endo-
metrial carcinoma tissue bank was established using hysterectomy specimen 
obtained from patients attending hospital' for treatment of endometrial 
cancer. Approval by the human subjects review boards was obtained in the 
participating hospital. Where possible, benign endometrial and myometrial 
samples were taken from the same patients. Benign endometrial samples 
from hysterectomy material of patients with a uterus myomatosis or men-
strual bleeding disorders without a uterine carcinoma were furthermore col-
lected. The age of the patient, the histological type and grade of the tumor 
and 5 years follow-up data were registered. 
Endometrial cancer cell lines 
To study the growth inhibiting properties of progesterone on endometrial 
cancer cells, several progesterone responsive endometrial carcinoma cell 
lines were constructed. Using stable transfection techniques, both the hu-
man progesterone receptor isoforms (hPRA and hPRB) were reintroduced 
into a well-differentiated human endometrial cancer cell line (a hPR nega-
tive sub-clone of the Ishikawa cell line). Several Ishikawa sub-cell lines were 
1 Department of Obstetrics & Gynecology of the Erasmus MC Rotterdam and depart-
ment of Obstetrics & Gynecology of five affiliated hospitals: Saint Franciscus Hospital 
Rotterdam, Medical Center Rijnmond Zuid Rotterdam, Ikazia Hospital Rotterdam, Rei-
nier de Graaf Group Delft and Albert Schweitzer Hospital Dordrecht. 
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constructed, each expressing different levels of either hPRA, or hPRB or both 
hPRA and hPRB. 
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Figure 2.1.1: Sagittal section of the pelvis of an adult woman. 
(copy of figure 297 page 203 of Sobotta Atlas of Human Anatomy, 1Oth edition 1982, Urban & 
Scharzenberg, with permission) 
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2.1 ENDOMETRIUM AND ENDOMETRIAL CANCER 
2.1.1 The normal endometrium 
Morphology of the endometrium 
The endometrium is the inner layer of the uterus, covering the uterine cavity 
(Figure 2.1.1). During the menstrual cycle it undergoes extensive morpho-
logical changes in order to prepare for implantation of the embryo, in case 
fertilization would occur. The endometrium consists of two distinct layers or 
zones, which differ from each other both in histological characteristics and 
in function: a basal layer and a functional layer. The basal layer is in direct 
contact with the myometrium, and undergoes little change throughout the 
menstrual cycle. During menses the basal layer stays intact. The functional 
layer surrounds the lumen of the uterine cavity and changes extensively 
throughout the menstrual cycle (figure 2.1.2). With every menstrual flow 
this layer is been sloughed. Afterwards, the new functional layer arises from 
the basal layer. The functional layer of the endometrium exists of two differ-
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Figure 2.1.2:Cyclic changes of the endometrium. Cyclic changes in thickness and in form 
of glands and aJteries of the endometrium and the relation of these changes to those of the 
ovarian cycle {from Williams Obstetrics Appleton&Lange 1993 p95, with permission). 
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ent cell-types: the glandular cells, which form the endometrial glands and 
cover the surface of the endometrium, and the surrounding stromal cells 
(Ludwig & Spornitz, 1991). 
The blood supply of the endometrium consists of a network of arterial 
and venous channels. The arteries responsible for the blood supply of the en-
dometrium, the spiral arteries, arise within the myometrium from branches 
of the uterine artery, subsequently pass through the basal endometrial layer, 
and extend into the functional zone. The proximal portion of these spiral 
arteries distributes blood to tissues of the basal layer and is not influenced by 
hormonal changes. However, the distal part of the spiral arteries, distribut-
ing blood to the functional layer, undergoes cyclic regeneration and degen-
eration during each menstrual cycle in response to hormonal changes. 
Hormonal regulated changes of the normal endometrium 
The endometrial cycle can be subdivided into three major phases: the prolif-
erative or follicular phase, the secretory or luteal phase and the menstrual 
phase (Figure 2.1.2). During the preovulatory or proliferative phase estra-
diol stimulates proliferation and gland formation as well as vascular gro'Wth 
in the functional layer of the endometrium. Moreover, estrogens exhibit a 
pro-inflammatory effect on the endometrium with an influx of neutrophils 
and macrophages and stimulation of tissue edema (De & Wood, 1990; 
Kachkache eta!., 1991; Quarmby & Korach, 1984). After the LH/FSH surge 
and the subsequent ovulation, progesterone is secreted by the corpus luteum, 
resulting in an increase of serum progesterone levels and the start of the 
secretory phase (Baird eta!., 1975; McNatty eta!., 1979). During this phase, 
progesterone stimulates differentiation of the glandular cells. Glycogen-rich 
vacuoles are formed in the glandular cells, which subsequently secrete their 
contents into the glandular lumen. In the stroma, progesterone induces 
pseudodecidual changes (Song & Fraser, 1995). Figure 2.1.3 illustrates these 
morphologic changes, correlated with the day of the menstrual cycle. In the 
absence of pregnancy, the corpus luteum regresses and the serum levels of 
estradiol and progesterone will drop (McNatty eta!., 1979). In response to 
these hormonal changes, the spiral arteries in the endometrium constrict, 
leading to stasis, tissue ischaemia and sloughing of the functional layer of 
the endometrium (Noyes eta!., 1950). 
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Figure 2.1.3:Morphological changes of the endometrium. Typical morphological findings 
correlated with the day of the menstrual cycle during a hypothetical 28-day ovarian cycle 
(from Noyes et al., 1950 with permission) 
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Progesterone effects on the endometrium 
Progesterone has been observed to antagonize the proliferative and pro-
inflammatory activity of estrogen on the human endometrium and sub-
sequently causes gland differentiation, with glycogen secretion, stromal 
decidualization and suppression of immune responses (Song & Fraser, 1995; 
Clemens eta!., 1979; Siiteri eta!., 1977). These observations have been con-
firmed in progesterone receptor (PR) knockout mice, in which endometrial 
epithelium hyperplasia, stromal hypocellularity, and uterine inflammation 
has been observed (Lydon eta!., 1996; Tibbetts eta!., 1999). Other effects 
of progesterone include inhibition of uterine contractions, increased viscos-
ity of cervical mucus, and extra-uterine effects such as glandular develop-
ment of the breast, and increase in basal body temperature (Humphreys et 
a!., 1997; Lofgren & Backstrom, 1994; Stachenfeld eta!., 2000). Prolonged 
stimulation of the endometrium with progestins lead to glandular atrophy 
and stromal necrosis, resulting in an atrophic endometrium (Ludwig, 1982; 
Song & Fraser, 1995). 
2.1.2 Endometrial hyperplasia 
Endometrial hyperplasia is an overgrowth of endometrial glands and endo-
metrial stroma, and is characterized by a proliferative glandular pattern with 
varying degrees of atypia (Welch & Scully, 1977). Hyperplasia demonstrating 
atypia may develop into endometrial cancer (Kurman eta!., 1985). Relative 
estrogen excess seems to induce hyperplasia. Women exposed to excess of 
estrogens such as in polycystic ovarian syndrome, estrogen-secreting ovarian 
tumors, obesity and unopposed exogenous estrogens are at risk (Kreiger et 
a!., 1986; Baanders-van Halewyn eta!., 1996). Atypical hyperplasia is treated 
with progestins to antagonize the estrogenic effects or with surgery (hyster-
ectomy). Without treatment, patients with atypical hyperplasia have a 25% 
risk of developing endometrial carcinoma (Kurman eta!., 1985). 
2.1.3 Endometrial cancer 
Incidence and mortality 
Endometrial cancer ranks as the most common gynecologic malignancy 
in Europe and North America, alongside ovarian cancer. It was estimated 
that in the United States 37,000 new cases and 6400 deaths occur per year 
General Introduction 
(Bristow, 1999). In the Netherlands, the incidence of endometrial cancer 
for 1995 has been set on 1337 cases, compared to 1447 for ovarian cancer 
and 706 for cervical cancer. In 1997, 370 women died of endometrial cancer 
compared to 234 of cervical cancer and 986 of ovarian cancer (reported by 
the Central Office of Statistics, Ministry of Public Health, The Netherlands, 
1999). The highest incidence was found in the age category 65-85 years. 
Histopathologic classification of endometrial cancers 
The majority of endometrial cancers arises from glandular cells and is known 
as adenocarcinoma, which can be subdivided into endometrioid and non-en-
dometrioid adenocarcinoma. Stromal cells of the endometrium can become 
malignant and develop into endometrial stromal sarcomas, however this is a 
rare event. Sometimes a combination of stromal sarcoma and adenocarcino-
ma is observed and these endometrial tumors are typed as mixed carcinosarco-
ma. According to the WHO!ISGP (World Health Organization/International 
Society of Gynecological Pathology) histopathologic classification, endome-
trium carcinomas can be divided into different subgroups, which are shown 
in Table 2.1.1. Endometrioid adenocarcinoma is the most common form of 
endometrium carcinoma (90%) (Platz & Benda, 1995), followed by papil-
lary serous adenocarcinoma (3-10%) (Bristow, 1999; Nicklin & Copeland, 
1996). Other histopathologic subtypes of endometrial cancer are very rare. 
Etiology 
The etiology of endometrial cancer has been suggested to differ between the 
endometrioid and the non-endometrioid adenocarcinoma (Sherman, 2000). 
Endogenous (anovulation) and exogenous (hormonal therapy) sources of 
estrogen are well accepted as a cause for increasing the risk of endometrioid 
adenocarcinoma (Antunes eta!., 1979; Gordon eta!., 1977). Moreover, the 
risk factors linked to endometrial cancer are associated with an excess of 
estradioL Endometrial cancer risk factors include: obesity, polycystic ovary 
disease, estrogen-producing ovarian tumors, early menarche and late meno-
pause, nulli-parity. pure estrogen containing oral anticonceptiva or hor-
monal substitution, and diabetes mellitus (Rose, 1996). Excess of estrogens, 
without the differentiating effects of progesterone, are thought to give rise 
to atypical endometrial hyperplasia, which can develop into endometrioid 
adenocarcinoma (Lindahl & Willen, 1991; Kurman et a!., 1985). Non-en-
dometrioid adenocarcinoma, on the other hand, shows no association with 
15 
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Table2.1.1: FIGOStaging<198S 
Stage 0 
Stage I 
carcinoma in situ. Histological findings suspicious of malignancy. 
The carcinoma is confined to the corpus. 
Stage Ia The length of the uterine cavity is 8 em or less. 
Stage lb The length of the uterine cavity is greater than 8 em 
It is desirable that Stage 7 cases be sub-grouped with regard to the histological type of the 
adenocarcinoma as follows: 
G7 Highly differentiated adenomatous carcinoma. 
G2 Differentiated adenomatous carcinoma with partly solid area. 
G3 Predominantly solid or entirely undifferentiated carcinoma 
Stage II 
Stage Ill 
Stage IV 
The carcinoma has involved the corpus and the cervix. 
The carcinoma has extended outside the uterus but not outside the pelvis. 
The carcinoma has extended outside the pelvis or has obviously involved 
the mucosa of the bladder or rectum 
(FIGO staging endometrial cancer 1971-1988, (Mikuta, 1993)) 
unopposed estrogen exposure or with endometrial hyperplasia. Endometrial 
intraepithelial carcinoma (EIC), in which epithelium cells show high grade 
nuclear atypia, is often seen in non-endometrioid adenocarcinoma and is 
rare in endometrioid adenocarcinoma (Ambros et al., 1995). 
The use of the anti-estrogen Tamoxifen (TAM) has been associated with 
an increased risk of endometrial cancer (Bergman et al., 2000). TAM is suc-
cessfully used in the management of women with breast cancers. However, 
long term use of TAM gives a 2-7 fold increase of the relative risk for endo-
metrial cancer (Bergman et al., 2000; Bernstein et al., 1999). The endome-
trial tumor, which develops in these patients, appears to be associated with 
the non-endometrioid histological type, high stage, and with low expression 
of the estrogen receptor (Bergman et al., 2000; Ramondetta et al., 1998; Ku-
washima et al., 1998). 
So far, a genetic predisposition for endometrial cancer has only been 
shown for members of families with HNPCC (Hereditary Non-Polyposis 
Colorectal Carcinoma) (Mecklin & Jarvinen, 1991). Women carrying mu-
tations in the DNA repair genes known to be associated with HNPCC (e.g. 
hMSH2, hMLH1, hPMS2 and hMSH6 gene) are found to have a 22-43% life-
time risk of developing endometrial cancer, which is significant higher than 
the lifetime risk in the general Dutch or USA female population (1.7-3.3%) 
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Table2.1.2: FIGO Staging;, 1988 
Histopathologic dassification: 
• Endometrioid carcinoma 
-adenocarcinoma 
- adenocanthoma 
- adenosquamous carcinoma 
·Mucinous adenocarcinoma 
·Papillary serous adenocarcinoma 
·Clear-cell carcinoma 
• Adenosquamous carcinoma 
·Undifferentiated carcinoma 
·Mixed carcinoma 
Histological grade (G) 
GX Grade cannot be assessed 
G1 Well differentiated 
G2 Moderate differentiated 
G3 poorly or undifferentiated 
Surgical staging (Stage) 
::; 5% non-squamous or non-morular solid growth 
pattern 
6-50% non-squamous or non-morular solid 
growth pattern 
~50% non-squamous or non-morular solid 
growth pattern 
Ia Tumor limited to the endometrium 
lb Invasion to less than half ofthe myometrium 
lc Invasion equal to or more than half ofthe myometrium 
lla Endocervical glandular involvement only 
lib Cervical stromal invasion 
lila Tumor invades serosa of the corpus uteri and/or adnexa and/or positive 
cytological findings 
lllb Vaginal metastases 
lllc Metastases to pelvic and/or para-aortic lymph nodes 
IVa Tumor invasion of bladder and/or bowel mucosa 
IVb Distant metastases, including intra-abdominal metastases and/or inguinal lymph 
nodes 
((Pecorelli et al., 1999), http://www.figo.org) 
(Watson & Lynch, 1993; Aarnio et aL, 1995; Dunlop et aL, 1997; Visser et 
aL, 1998). 
Diagnosis and screening 
Endometrium tumors are usually diagnosed at an early stage, as the disease 
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presents itself with an alarming early symptom: abnormal vaginal bleeding. 
Endometrial-biopsy is used to diagnose endometrial cancer. Recently, ultra-
sonography has been demonstrated to exhibit diagnostic value in the triage 
of patients with postmenopausal bleeding (Gull eta!., 2000; Kinkel eta!., 
1999; Karlsson et a!., 1995). When endometrial-biopsy is not conclusive, 
endometrial-curettage sampling and hysteroscopy is performed to confirm 
or exclude the diagnosis 
Staging and prognostic factors 
Endometrial carcinomas are divided into subgroups in order to create a sys-
tem to predict the prognosis and to select optimal therapeutic regimes. Gen-
erally, the FIGO (International Federation of Gynecology and Obstetrics) 
staging system is used. Before 1988 the FIGO staging used clinical criteria; 
including fractional curettage and pelvic examination, to stage endometrial 
tumors (Table 2.1.1). As more information became available with regard to 
risk factors associated with natural behavior of endometrial cancer and sur-
vival, the staging system changed. Identified as risk factors were histological 
grade, depth of myometrial invasion, extension into the cervical canal, vas-
cular space invasion, pelvic node metastases, aortic node metastases, adnexal 
metastases, penetration of uterine serosa and positive peritoneal cytological 
findings. In 1988 a new FIGO staging system was introduced, including 
these risk factors. This new staging system assumes that most patients will 
be treated by a primary surgical approach and the staging is performed after 
surgery and is based on the surgicopathological findings (Table 2.1.2). If ra-
diation has been applied prior to surgery, the former clinical staging system 
is used. 
The surgical staging, as described by the FIGO staging system of 1988, 
includes lymph node sampling (lymphadenectomy) and pelvic washing or 
samples of ascitic fluid. However, no consensus has been established on the 
value of lymphadenectomy, neither in the staging process nor as a part of 
the treatment (Podratz eta!., 1998). As a result, in several clinics and some 
countries, lymphadenectomy is not used as a standard in staging endometrial 
cancers. 
The FIGO staging system criteria have significantly changed between the 
periods prior to and after 1988. However, the nomenclature in the two sys-
tems is identical. Therefore, when comparing research data involving FIGO-
staged endometrial cancers knowledge of the date of the staging system used 
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is essential. In a Norwegian population-based study, the five-years survival 
rates for the different staging groups were established using both the FIGO 
clinical staging system and a 'surgicopathological' staging system (not fur-
ther specified by the authors) (Abeler & Kjorstad, 1991). They found the 
five-years survival rate to be: clinical Stage l ~ 83%, clinical Stage II ~ 73%, 
clinical Stage Ill ~ 52% and clinical Stage IV ~ 27%, compared to surgico-
pathological Stage I ~ 83%, surgicopathological Stage II~ 75%, surgicopatho-
logical Stage Ill~ 41% and surgicopathological Stage IV~ 26%. 
Several studies have shown that the prognosis of patients with endo-
metrial cancer is correlated with various factors other than FIGO stage. 
Morphometric nuclear grade (Salvesen et al., 1998), lymph-vascular space 
invasion (Feltmate et al., 1999), DNA ploidy (Evans & Podratz, 1996; Lim 
et al., 1999), estrogen/progesterone receptor status (Creasman, 1993) and 
p53 overexpression (Soong et al., 1996) have been shown to be independent 
prognostic factors. Evaluating the prognosis by integrating FIGO staging 
system with factors related to the biological behavior of the tumor seems 
promising. However, a useful model has yet to be established. 
Therapy 
Surgery is the primary treatment in the majority of women with endometrial 
cancer. Radiotherapy is generally used when adjuvant therapy is indicated. 
However, indication for adjuvant therapy differs around the world. Chemo-
therapy and hormonal treatment are only given in clinical trial contexts or 
as palliation in case of an advanced disease. The FIGO staging and the health 
condition of the patient generally guide the choice of treatment. 
Stages I and II: Hysterectomy with bilateral salpingo-oophorectomy has a 
high curation rate in patients with a stage 1/11 disease (Cirisano et al., 2000). 
The value of adjuvant radiotherapy in stage I patients remains unclear. In 
a recent Dutch randomized trial including 715 patients from 19 radiation 
oncology centers (PORTEC Study Group, (Creutzberg et al., 2000)) patients 
with Stage-I endometrial carcinoma were randomized to pelvic radiotherapy 
( 46 Gy) versus no further treatment, following total abdominal hysterectomy 
and bilateral salpingo-oophorectomy (without lymphadenectomy). From this 
study it was concluded that postoperative radiotherapy in Stage-! endometri-
al carcinoma reduces loco-regional recurrence but has no impact on overall 
survival. Moreover, radiotherapy increases treatment-related morbidity. 
Stages III and IV: The cornerstone in treatment of these patients consists 
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of abdominal hysterectomy with bilateral salpingo-oophorectomy in combi-
nation with postoperative radiotherapy. In the presence of metastasis out-
side the pelvic area, chemotherapy or hormonal treatment with progestins 
is optional. 
2.1.4 Hormone responsiveness of endometrial cancer 
The normal endometrium is highly sensitive to hormonal influences. All 
morphological changes of the endometrium during the menstrual cycle are 
induced by the ovarian hormones estradiol and progesterone (discussed in 
paragraph 2.1.1). Also, a high responsiveness to hormonal treatment (e.g. 
progestins) is found for benign functional endometrial disorders, such as 
menorrhargy, metrorrhargy, endometriosis and endometrial hyperplasia 
(Lindahl & Willen, 1991). However, hormonal treatment (e.g. progestins) 
of patients with endometrial cancer (FIGO-Stage III/IV) results in low re-
sponse rates of only 10-30% (Lentz, 1994). Even more, in a meta-analysis 
of six randomized controlled trials no association was found at all between 
progesterone treatment of endometrial cancer patients and reduction in 
relapse time or overall survival rate (Martin-Hirsch et al., 1996). However, 
no discrimination was made between different clinical stages or histological 
grades. Other studies have indicated that well differentiated tumors (ex-
pressing estrogen- and progesterone receptors) respond better than poorly 
differentiated tumors (Gurpide, 1981; Boman et al., 1993). 
2.2 PROGESTERONE AND ITS RECEPTORS 
2.2.1 Progesterone biosynthesis 
Progesterone belongs to the group of steroid hormones. Other steroid hor-
mones are estrogens, androgens, glucocorticoids and mineralocorticoids. Ste-
roid hormones are mainly produced in steroidogenic glands (e.g. ovaries, tes-
tes and adrenals) and are secreted into the circulation. Some peripheral tis-
sues can locally produce steroids from steroid precursors. Steroid hormones 
are important molecules, and are involved in regulating critical physiologic 
events such as cellular differentiation, growth and death. 
A perhydro-1,2-cyclopentanophenanthrene-ring structure is the basic 
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carbon skeleton for all steroid hormones. The steroidogenic glands synthe-
size the steroids from cholesterol. These glands are able to synthesize choles-
terol de novo from 2-carbon precursors ( cholesteryl esters) but can also use 
cholesterol from circulating low-density lipoproteins (LDL). The 27-carbon 
cholesterol molecule is subsequently converted to pregnenolone by removal 
of a six-carbon fragment to form the 21-carbon steroid molecule. Preg-
nenolone serves as a precursor molecule from which all the steroids can be 
formed. Enzymatic reactions are needed to convert pregnenolone into differ-
ent steroids. Several enzymes are involved in this process: 3j3-hydroxysteroid-
dehydrogenase for conversion of D-.5 to 6.4 steroids; 17a-hydroxylase/ C17_20 
lyase enzyme systems for conversion of c, to C19 steroids, 17~-hydroxyster­
oid-dehydrogenase, and aromatase activity for conversion of androgens to 
estrogens. 
The biochemical pathways of steroid hormone biosynthesis, including the 
major enzymes, are similar in all steroidogenic glands. However, different 
cell types express different amounts of these enzymes, so that the predomi-
nant steroids produced differ in the various cells. Even within one gland, the 
different cell types may produce different steroid hormones. This phenom-
enon resulted in the tvvo-cell theory for steroid hormone production in the 
ovary. The theca and granulosa cells of the ovarian follicles were thought to 
have a specific role in synthesis of steroids (Makris & Ryan, 1977). In this 
theory, the theca cells convert cholesterol to androstenedione and testoster-
one. Granulosa cells are particularly rich in aromatase activity and can con-
vert androgens to estrogen. The androgens synthesized within the theca cells 
were thought to be transported to the granulosa cells where they can be used 
as substrate for estrogen production. In the luteal phase, the corpus luteum 
granulosa cells are thought to convert cholesterol to progesterone and 17u-
hydroxyprogesterone. Later, McNatty eta!. (McNatty eta!., 1979) postulated 
that the ovarian steroid synthesis might not be so rigidly compartmentalized. 
Additional to the two-cell theory, the steroids secreted by the granulosa and 
theca cells are now thought to enter different cellular compartments before 
leaving the ovary. As a result, the different steroid-producing tissues of the 
follicle may exert their primary effects at different sites. 
Gonadotropin hormones control the biosynthesis of steroids in the ovary. 
Luteinizing hormone (LH) acts primarily to regulate the first step in steroid 
hormone biosynthesis, namely the conversion of cholesterol to pregneno-
lone, and also induces subsequent enzymes in the pathway. In the follicular 
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Figure 2.2.1: Steroid biosynthesis. Pathways for steroid biosynthesis involve several differ-
ent enzyme systems. Enzyme 1: 3f3-hydroxysteroid-dehydrogenase,enzyme 2: 17a-hydroxy-
lase, enzyme 3: 17,20-lyase, enzyme 4: 17f3-hydroxysteroid-dehydrogenase,and enzyme 5: 
aromatase. 
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phase this results in stimulation of the production of androgens by theca 
cells. During the luteal phase, LH facilitates the production of progesterone 
by the corpus luteum (McNatty eta!., 1980). In granulosa cells, aromatiza-
tion of androgens into estrogens is regulated by follicle-stimulating hormone 
(FSH) (Sjogren et al., 1987), Montgomery Rice eta!., 1998). 
2.2.2 Secretion and metabolism of progesterone 
The secretory activity of progesterone producing cells is closely coupled to 
HIGHER EJR.0.:1N CENTERS 
~ HYPOTHALAMUS GnRH 
'"""
0
' '?·if.--..\ 
QONAP<lTROPINS STeROID FEEOa.ACOC: 
Figure 2.2.2: Changes in pituitary gonatropins FSH and LH,and ovarian hormones estra-
diol and progesterone throughout the menstrual cycle. Diagrammatic representation of 
the menstrual cycle showing the relationship and feedback system of the hypothalamic and 
pituitary hormones {gonadotropin-releasing hormone GnRH, FSH and LH) with the ovarian 
hormones (estradiol and progesterone},and the response of the endometrium to the change 
in steroid concentration. (from Kistner's Gynecology 6th edition, 1995, Mosby-year book, p13 
figure 3-1, with permission) 
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their synthesis activity, since little is stored in the cells. When released into 
the circulation, progesterone is bound by plasma transport proteins. The 
most important transport protein for progesterone is cortico~steroid-bind­
ing globulin (CBG). Progesterone binds only weakly to albumin. The serum 
concentration of progesterone in women changes throughout the menstrual 
cycle (Figure 2.2.2). 
During the follicular phase, ovarian progesterone production is low and 
circulating progesterone originates mainly from synthesis in the adrenal 
gland or from conversion of circulating precursors in peripheral tissues. After 
ovulation, the corpus luteum produces high levels of progesterone. In case of 
pregnancy, the syncytiotrophoblast takes over the progesterone production 
from the corpus luteum after 6-8 weeks. The trophoblast utilizes maternal 
plasma low-density lipoprotein (LDL) cholesterol to synthesize progesterone, 
as de novo synthesis of cholesterol is limited in these cells. Progesterone 
produced by the trophoblast is released into the maternal circulation, giving 
rise to increasing maternal serum levels of progesterone during pregnancy. 
The trophoblast also produces pregnenolone, which is released into the fetal 
circulation. The fetal liver and adrenals subsequently convert pregnenolone 
into other steroids. 
Progesterone is cleared from the circulation by conversion into pregnane-
diol and by glucuronidation in the liver. In this process 20o:-hydroxyproges-
terone, a metabolite of progesterone, is formed which can act as progestagin, 
although with only 20% of the activity of progesterone. The end-product 
pregnanediol glucuronide is excreted in the urine. 
2.2.3 The progesterone receptors 
The family of steroid hormone receptors: 
Progesterone mediates its function via a specific intracellular receptor, the 
progesterone receptor (PR). There exist two functional progesterone receptor 
isoforms (PRA and PRB), which are closely related to other steroid receptors, 
such as the glucocorticoid receptor (GR), the mineralocorticoid receptor 
(MR), the androgen receptor (AR), and to a lesser extent, the estrogen recep-
tor (ER) (Evans, 1988). These steroid hormone receptors act as hormone-
dependent transcription regulators and belong to the superfamily of nuclear 
receptors (NR). 
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Progesterone receptor gene? mRNAs and proteins: 
The human progesterone receptor protein exists as two isoforms hPRA and 
hPRB (Horwitz & Alexander, 1983). The hPRA is a truncated form of the 
hPRB and lacks the first 164 N-terminal amino-acid residues. The two iso-
forms are transcribed from the same gene. Originally, the two isoforms were 
thought to be the result of alternative translation initiation from two in-
frame ATG codons from the same mRNA, producing a PRA-protein of 94 kDa 
and a PRB-protein of 114 kDa (Conneely et a!., 1987). However, transfec-
tion experiments have shown that vectors containing both the first and the 
second ATG codon produce exclusively the hPRB form (Kastner eta!., 1990). 
The hPRA is generated from vectors containing only the second ATG. These 
findings argue against the hypothesis that the two isoforms are the product 
of alternative translation initiation and suggest that hPRA and hPRB are 
generated as a result of transcription from different promoters. Subsequently, 
q13 
Chromosome 11 ( p ·~ TGA ATG~B ATG~A 
AF-3 ID AF-1 AF-2 
bPR-A <---------- --------------------- ---> 
bPR-B <---- -------------------------------------7 
COOR 
Figure 2.2.3: The human progesterone receptor gene (hPR): locus and protein. The 
hPR-gene was mapped to the long arm of chromosome 11 (Rousseau-Merck et al., 1987).The 
hPR protein is encoded by 8 exons (E1-E8) {Misra hi et al., 1993).Two hPR isoforms, hPRA (94 
kDa) and hPRB (114 kDa), are being translated from two different transcripts. Both proteins 
contain four functional domains: NH
2
-terminal domain (NB), DNA-binding domain (C), hinge 
region (0} and ligand binding region (ElF). Three sub-domains with a transcription activation 
function (AF) have been identified {AF-1,AF-2,AF-3) and one sub-domain with a transcription 
inhibitory function (10). 
25 
Chapter 2 
26 
Kastner et al (Kastner et al., 1990) identified distinct promoters, initiating 
transcription of two different mRNAs. Moreover, exon deletions, in either 
hPRA or hPRB, have been found to give rise to new hPR-protein variants (Wei 
et al., 1990; Graham et al., 1995; Richer et al., 1998; Hirata et al., 2000; 
Leygue et al., 1996). 
Except for the first 164 N-terminal amino-acids, both hPRA and hPRB 
proteins are structural identical (Figure 2.2.3). Both forms have similar DNA 
and ligand binding affinities (Lessey et al., 1983) and both forms mediate 
progesterone-activated gene transcription regulation. However, the transac-
tivation function of hPRA and hPRB appear to differ between cell types and 
target gene promoters used (Tora et al., 1988; Vegeto et al., 1993; Hovland 
et al., 1998). 
Structure of the progesterone receptors 
The progesterone receptor structure is similar to that of the other steroid 
receptors in that it contains four discrete functional domains, an NH2-ter-
minal domain, a DNA-binding domain (DBD), a hinge region and a ligand 
or hormone binding COOH-terminal domain (LBD) (Mangelsdorf et al., 
1995; Katzenellenbogen & Katzenellenbogen, 1996). The DBD is the most 
conserved among the steroid receptors, and the NH2-terminal domain is the 
most variable region (Meyer et al., 1990). 
NH2-terminal domain -The NH2-terminus (domain A/B) is the least con-
served domain among the steroid hormone receptor family. Transcription 
activation of target genes has been shown to depend on sub-domains with 
an activation function (AF). Deletion mapping has identified two specific 
AFs for all members of the steroid hormone receptor family. One ligand-
independent activation function (AF-1) is located within the NH2-ter-
minus and the other, a ligand-dependent AF (AF-2) is found in the LBD. 
The location of the AF-1 and the amino acid composition of the NH2-
terminus differ significantly among the steroid hormone receptor family 
members. This seems to indicate that the NH2-terminus is essential in 
receptor-specific transcription regulation. In the hPR, the NH2-terminus 
contains a third activation function AF-3, which is constitutively active. 
This AF-3 is located in the 164 amino acid B-upstream segment (BUS), 
which is unique to hPRB (Giangrande et al., 1997). The hPRA isoform 
lacks this BUS, and consequently AF-3. An inhibitory domain (!D) has 
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been identified within the first 140 amino acid residues of the hPRA, and 
was show to prevent hPRA from functioning as a transcriptional activator 
and seems to contribute to the function of hPRA as a dominant repressor 
of steroid receptor transcriptional activity (Giangrande et al., 1997). De-
letion of ID from hPRA resulted in a receptor mutant that is functionally 
indistinguishable from hPRB (Giangrande et al., 1997). 
DNA-binding domain - The DNA binding domain (domain C) is located 
in the center of the receptor molecule and consists of two zinc-clusters. 
The DBD binds to specific DNA sequences, hormone response elements 
(HREs), located in or near regulatory regions of target genes (Beato, 1989; 
Bagchi et al., 1988). The DBD is thought to fold into so-called "zinc-
clusters" and only a very limited number of amino-acid residues within 
one of the a helixes of the first zinc cluster are responsible for specific 
recognition of the HRE's (Freedman et al., 1988; Mader et al., 1989). 
Binding of the DBD to the HRE results in activation or repression of gene 
transcription (Beato, 1989; Tsai & O'Malley, 1994). Both direct interac-
tion of the DBD domain with the HRE, as interaction of receptor protein 
complex with other regulatory proteins are involved in this mechanism of 
gene transcription regulation (Ing et al., 1992). 
Hinge region -The hinge region (domain D), located between the DBD 
and LBD domain, is a poorly conserved region among the steroid hor-
mone receptor family members (Evans, 1988). The hinge region contains 
a nuclear localization signal, and in the PR it is thought to be involved in 
homodimerization of the receptor, together with the LED and the NH2-
terminal domain (Tete! et al., 1997). 
Ligand binding region - The LED region (domain E/F) is the COOH-ter-
minal part of steroid receptors. Apart from ligand binding, this region is 
also involved in receptor dimerization and transcription regulation. Li-
gand binding induces receptor dimerization and creates an 'active surface' 
on the LED, exposing a transcriptional activating function (AF-2) (Web-
ster et al., 1988; Kumar & Chambon, 1988; Tora et al., 1989). Ligand 
free LED prevents the DBD from binding to HRE and therewith excludes 
transcription activation. Deletion experiments have shown that steroid 
receptors lacking a LBD act as constitutively active receptors. 
Subcellular localization of the hPRs 
The steroid hormones are synthesized in the cytoplasm. The hinge region 
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of the receptor contains a nuclear localization signal, directing the receptor 
towards the nucleus (Ylikomi et al., 1992). For the hPR, a shuttle model has 
been proposed, in which the receptor enters the nucleus in an energy-de-
pendent manner, and may freely diffuse back into the cytoplasm (Guiochon-
Mantel et al., 1991). However, the hPR appears to be predominantly located 
in the nucleus, even in absence of ligand (Gasc et al., 1989). 
Transcription activation route: 
The mechanism of action of PR is similar to that of other steroid receptors. 
In the absence of ligand, receptors are sequestered in a large complex of 
heat shock proteins (hsp90, hsp70 and hsp56) together with other proteins 
(Smith et al., 1990; Pratt & Toft, 1997). In the complex, the steroid hormone 
receptor is directly bound to hsp 90 and folded in a specific conformation, 
in which the receptor is unable to bind to DNA but capable of receiving and 
responding to hormonal signals (Smith, 1993). Upon hormone binding, 
the receptor undergoes a distinct change in conformation (DeMarzo et al., 
1991), resulting in the dissociation of a monomeric receptor from the heat 
shock complex (Renoir et al., 1990). The receptor dimerizes and becomes 
phosphorylated. Subsequently, the receptor dimer binds to DNA on specific 
hormone response elements (HRE). These HREs are located in or near regula-
tory regions of target genes (Beato, 1989; Bagchi et al., 1988). On binding to 
the HREs, the receptor complex can interact with other proteins and directly 
or indirectly regulate gene transcription. 
Several models have been proposed to explain the mechanism of ste-
roid hormone receptor regulation of gene transcription. In the center of 
transcription activation, basal transcription factors (GTFs) together with 
RNA-polymerase-II (RNA Pol-II) form a complex: the pre-initiation complex 
(PIC). Subsequently, the PIC can recruit several other transcription factors, 
such as the steroid hormones receptors. To start transcription, RNA Pol-11 in-
teracts with the TATA box sequence at the promoter site. In one model, direct 
interaction of steroid hormone receptors with the PIC has been proposed to 
stabilize this PIC assembly and thereupon enhance the transcription activity 
(Ing et al., 1992; Fondell et al., 1996; McEwan & Gustafsson, 1997). A sec-
ond model suggested that the interaction of steroid hormone receptor with 
intermediary factors or co-activators enhances the assembly of a stable PIC 
(Horwitz et al., 1996; Voegel et al., 1996). Subsequently, several coactivators 
have been cloned, that associate with progesterone receptors, and enhance 
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the ability of the progesterone receptor to transactivate target genes (re-
viewed by Rowan & O'Malley, 2000). A third model involves the accessibility 
of DNA to transcription regulating factors. Genomic DNA is packed into 
nucleosomal structures (Candau et a!., 1996), in which the double-helix 
DNA is wound around an octamer of histones. The nucleosomal structure 
of DNA prevents transcription factor binding and represses basal transcrip-
tion activity (Svaren & Horz, 1996). Targeted histone acetylation loosens the 
nucleosomal structure and creates an access for transcription factors to their 
response elements in the target gene promoter regions. Some of the steroid 
receptor associated coactivators, such as steroid receptor coactivator 1 (SCR-
1), coactivator CREB (cAMP response element-binding protein) -binding 
protein (CBP) and p300/CBP-associated factor (P/CAF), have been found 
to possess intrinsic histone acetyltransferase (HAT) activity. Therewith, a 
~ - COFACTORS 
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Figure 2.2.4:Two step model of steroid receptor-induced gene transcription. Uganded 
steroid receptors (R), that are able to bind a steroid response element in chromatin repressed 
DNA, can recruit cofactors such as steroid receptor coactivator 1 (SCR-1 t coactivator CREB 
(cAMP- response element-binding protein)-binding protein (CBP) and p300/CBP-associated 
factor (P/CAF). These cofactors possess intrinsic histone acetyltransferase (HAT) activity that 
can loosen nucleosomal structure by targeted histone acetylation.Coactivators,such as SRC-1 
and CBP, can then initiate stable assembly of the preinitiation complex (PIQ by"coactivation" 
that results in enhanced rates of transcription initiation by RNA polymerase II. The effects of 
targeted histone acetylation may be reversed by histone deacetylation (HD). Furthermore, 
histone deacetylation may be responsible for turning off activated transcription once the PIC 
and/or steroid receptor complex becomes unstable (from Jenster et al., 1997). 
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third model arises, in which co-activator induced chromatin remodeling is 
recognized as an important feature in the steroid receptor transactivation of 
target genes. jenster et al (Jenster et al., 1997) have integrated these different 
models into a "two-step model of steroid receptor transactivation in vivo", 
which is shown in figure 2.2.4. 
Non-genomic regulation of hPR mediated transcription activation 
Progesterone receptor has also been suggested to be involved in indirect regu-
lation of gene transcription. Migliaccio et al (Migliaccio et al., 1998) suggest 
a cross-talk between hPR and hER in stimulation of the c-Src/p21m/MAP 
kinase signaling pathway. hPR could only stimulate this pathway when asso-
ciated with the hER. Direct interaction of the hPR with the c-Src/p21"'/MAP 
kinase pathway could not be observed. Subsequently, the first164 amino acid 
residues of the hPR, which are unique for the hPRB isoform, were identified 
as the domain responsible for association with the hER. Progesterone can 
also influence gene expression via binding to transmembrane receptors. Pu-
tative transmembrane progesterone receptors have been identified in humans 
(Gerdes et al., 1998, Bernauer et al., 2001) and progesterone has been shown 
to bind to the transmembrane uterine oxytocin receptor directly (Grazzini et 
al., 1998). Liganded hPR has also been suggested to interfere with the activity 
of other transcription factors, such as ER, by squelching. Squelching means 
that hPR competes with other transcription factors for binding of common 
coactivators, which then will be less available for the other transcription fac-
tors to activate their target genes (Meyer et al., 1989). 
Transcription regulation differences between hPRA and hPRB 
As mentioned earlier, apart from the first 164 NH2-terminal amino acids, the 
two hPR isoforms (hPRA and hPRB) are structurally identical. However, hPRA 
and hPRB are not functionally identical. In transfection experiments, it has 
been observed that their relative efficiency to activate target genes vary ac-
cording to the promoter and cell context used (Tora et al., 1988; Meyer et al., 
1989). HPRB has been thought to be more transcriptionally active than hPRA. 
Moreover, hPRA has been shown to act as a strong trans-dominant repressor 
of hPRB (and other steroid hormone receptors) mediated transcription in 
specific promoter and cell contexts (Vegeto et al., 1993). However, recently 
Gao et al. (Gao et al., 2000) observed that in endometrial stroma cells hPRA 
acted as a stronger transactivator than hPRB for the IGFBP-1 (insuline-like 
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growth factor binding protein-!) promoter. Moreover, in transgenic mice, 
overexpression of PRA resulted in a significant different phenotype (Shya-
mala et al., 1998) compared to wild-type, and in PRA knockout (PRAKO) 
mice, Mulac-Jericevic demonstrated PRB and PRA specific gene regulation 
(Mulac-Jericevic et al., 2000). 
The mechanisms responsible for the distinct transcriptional properties of the 
two PR isoforms are largely unknown. However, recently several models have 
been proposed to be involved in these functional differences between hPRA 
and hPRB. 
1) Differences in phosphorylation sites between hPRA and hPRB - Reversible 
protein phosphorylation is one of the most important mechanisms of 
regulating intra-cellular processes. Through phosphorylation and dephos-
phorylation, protein functions can be switched on or off. In the hPR sev-
eral serine residues, all located in the NH2-terminal domain, have been 
identified to be phosphorylated (Clemm et al., 2000). Phosphorylation of 
these sites is regulated by different signal transduction pathways (Zhang 
et al., 1994; Zhang et al., 1997). Recently, Clemm et al. (Clemm et al., 
2000) showed that one of the serine sites (Ser 294) exhibited a stronger 
hormone-dependent phosphorylation in hPRB compared to hPRA. This 
Ser 294 is located within the inhibitory domain (!D). Subsequently, 
Clemm et al have suggested that a distinct conformation of the NH2 
terminus of hPRA inhibits phosphorylation of this site and results in dif-
ferential functional properties of hPRA and hPRB. 
2) Differences in AFs (Activation Funtions) between hPRA and hPRB - Hov-
land et al. (Hovland et al., 1998) have shown that the inhibitory domain 
(!D), located in the NH2-terminus, inhibits both AF-1 and AF-2 but not 
AF-3. The AF-3 is located within the first 164 NH2-terminal amino acid 
residues, and is unique for hPRB. Subsequently, Hovland et al. (Hovland 
et al., 1998) hypothesize that hPRA is transcriptionally inactive because, 
in the absence of AF-3, the ID prevents AF-1 and AF-2 from activating 
transcription. Moreover, in hPRB, AF-3 is proposed to overrule the in-
hibitory function of ID, thereby allowing hPRB to activate transcription 
(Giangrande et al., 1997; Hovland et al., 1998). 
3) Differences in interaction with co activators - Recently, it has been shown 
that the amino termini of hPRB and hPRA interact differently with the 
carboxyl terminus of the LBD (Tete! et al., 1999). The NH, terminus of 
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hPRB, but not that of hPRA, interacts efficiently with its LBD in an agonist-
dependent manner. Differential interaction between carboxyl and amino 
termini can regulate the ability of the hPR to interact with co factors in a 
productive manner (Giangrande et al., 2000). Subsequently, Giangrande 
et al. (Giangrande et al., 2000) has shown that, upon agonist binding, 
hPRA, unlike hPRB, is unable to efficiently recruit the transcriptional 
coactivators GRIP1 and SRC-1. This may contribute to the transcriptional 
inactivity of hPRA in specific cell and/ or promoter context. Moreover, 
they observed that hPRA does have a higher affinity for the corepressor 
SMRT compared to hPRB, which could account for the transdominant 
repressor function of hPRA in specific cell/promoter context (as observed 
by Vegeto et al.,(Vegeto et al., 1993). 
2.2.4 Progesterone target genes 
So far, only a small group of progesterone target genes have been identified. 
The hPR gene itself and the ER gene are the most well-known progesterone-
regulated genes (Read et al., 1988). The genes encoding fatty acid synthetase, 
metallothionein-IIa, alkaline phosphatase, monocyte chemotactic proteins, 
vascular endothelial growth factor, the proteases: ADAMTS-1 and cathepsin, 
Sox4, epidermal growth factor and its receptor are other genes reported to be 
target genes for progesterone (Chalbos et al., 1986; Slater et al., 1988; Asse-
lin et al., 2001; Classen-Linke et al., 2000; Robker et al., 2000; Graham et al., 
1999; Musgrove et al., 1991). Ten other progesterone target genes have been 
identified in the breast cancer cell line T47D by Kester et al.,(Kester et al., 
1997), using a differential display technique. They found TSC-22, CD-9, CD-
59, desmoplakin FKBP51, Na/K-ATPasea1 and three ESTs to be up-regulated 
by progestin in these breast cancer cells and annexin-VI down-regulated. 
In the endometrial carcinoma cells ECC-1, only CD-59, desmoplakin and 
FKBP51 were induced by progestin, indicating that the progestin-responsive-
ness of some of these progesterone target genes might be cell type-specific 
(Kester, 1999). In mice, the expression of genes encoding calcitonin, histi-
dine decarboxylase, amphiregulin, Hoxa 10 and lactoferrin was found to be 
progesterone responsive (Zhu et al., 1998; Paria et al., 1998; Das et al., 1995; 
Ma et al., 1998; McMaster et al., 1992). As hPRA and hPRB exhibit distinct 
functions, the existence of hPRA and hPRB specific target genes has been 
suggested. Recently, this hypothesis was supported by the observation in PRA 
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knockout mice (Mulac-jericevic et al., 2000) that the progesterone respon-
siveness of genes encoding calcitonin and amphiregulin is lost in these mice 
compared to wild-type mice, indicating that the regulation of these genes 
might be PRA specific. 
2.3 GENES AND ENDOMETRIAL CANCER 
2.3.1 Genetic models for carcinogenesis 
Most cancers are thought to originate from a single cell, which has escaped 
normal cellular growth control mechanisms. This escape results from func-
tional changes in expression levels of genes, which are key role players in 
controlling cell growth, DNA repair, or programmed cell death. In general, 
three groups of genes are thought to be involved: tumor-suppressor genes, 
(proto-)oncogenes and DNA-repair genes. Tumor-suppressor genes encode 
proteins, which inhibit proliferation. Inactivation of tumor-suppressor genes 
can lead to uncontrolled cell growth and contribute to the development of 
cancer. Proto-oncogenes are genes, which encode proteins that stimulate 
growth factor signaling pathways in cells. Proto-oncogenes will become 
oncogenes when the encoded protein is either overexpressed or hyperactive. 
DNA-repair genes are involved in mending replication errors and maintain-
ing genetic stability. Inactivation of these genes will render the genome 
vulnerable to mutational events and will lead to genetic instability. Genetic 
alterations, such as chromosomal rearrangements, deletions and point mu-
tations, can lead to a complete loss of the gene transcript. However, deletions 
or point mutations in the coding sequences can also result in a hyperactive or 
inactive protein without changes in the expression levels of the correspond-
ing mRNA. Moreover, chromosomal rearrangement can position a gene near 
an enhancer sequence, causing changes in the expression level of the gene 
product or creating either a hyperactive or an inactive fusion product. 
A number of models have been developed to describe the genetic mechanisms 
involved in carcinogenesis. Based on a hereditary form of retinoblastoma, 
Knudson (Knudson, 1971) developed a "two-hit" scenario in which he-
reditary forms of cancer develop according to a fairly simple scheme (Figure 
2.3.1). In this scheme the "first-hit" in the development of hereditary cancer 
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Figure 2.3.1: Knudson's "two~hit" scenario for the development of cancer. The first "hit" 
would be a mutation in a specific cancer gene, in the germ line in a hereditary case, in a so-
matic cell in a non-hereditary case. The second"hit"in both groups would be a somatic muta-
tion in, or loss of, the second copy of the same gene (adapted from Knudson (Knudson, 1985), 
(Knudson, 1993)). 
counts for an already mutated allele of a specific cancer gene in the germline 
cell. Cancer arises only after a "second-hit" has occurred. This "second-hit" 
stands for a mutation in the other allele of the same gene in the somatic cell. 
Knudson's "two-hit" scenario can also be extended to the carcinogenesis of 
sporadic, non-hereditary cancers; the "first-hit" then occurs in a somatic 
cell, which will result in a sporadic, non-hereditary cancer; again only after 
a second-hit has occurred. However, for the majority of cancers the genetic 
mechanisms involved in the carcinogenesis are much more complex. Al-
though inactivation of tumor-suppressor genes does occur in accordance 
with Knudson's two-hit-model, in most cancers an accumulation of genetic 
events is needed before a tumor develops. Already in 1958 Foulds postulated 
such a multi-step model for carcinogenesis. Fearon and Vogelstein (Fearon 
& Vogelstein, 1990) have given an elegant example of a multi-step scenario 
using colorectal cancer as a model. In this model, accumulation of mutations 
in both proto-oncogenes and tumor-suppressor genes direct the progression 
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Figure 2.3.2: A genetic model for colorectal tumorigenesis, Tumorigenesis proceeds through a series of genetic alterations involving onco-
genes and tumor-suppressor genes. The three stages of adenomas represent tumors of increasing size, dysplasia, and villous content. In patients 
with familial adenomatous polyposis (FAP), a mutation on chromosome Sq is inherited. In tumors arising in patients without polyposis, the same 
region may also be lost and/or mutated at a relatively early stage of tumorigenesis.Hypomethylation is present in very small adenomas in patients 
with or without polyposis, and this alteration may lead to aneuploidy, resulting in the loss of suppressor gene alleles. K-ras gene mutations appear 
to occur In one cell of a preexisting small adenoma and, through donal expansion, produce a larger and more dysplastic tumor. The chromomes 
most frequently deleted include Sq, 17p and lBq: the putative target of the loss event (i.e. the tumorsuppressor gene) on each chromosome is in-
dicated as well as the relative timing of the loss event. Allelic deletions of chromosome 17p and 18q usually occur at a later stage of tumorigenesis 
than do deletions of chromosome Sq or K-ras gene mutations. However, the order of these changes is not invariant, and accumulation of these 
changes, rather than their order with respect to one another, seems most important. Tumors continue to progress once carcinomas have formed, 
and the accumulated loss of suppressor genes on additional chromosomes correlates with the ability of the carcinomas to metastasize and cause 
death (adapted from Fearon and Vogelstein (Fearon & Vogelstein, 1990)). 
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of normal colorectal epithelial tissue via pre-malignant stages into a colorec-
tal carcinoma (Figure 2.3.2). 
During the process of DNA replication, many accidental mutations occur in 
a cell. Normally the cellular mismatch repair system will detect and mend 
these lesions. Loss of DNA repair activity will lead to a cell that becomes 
highly at risk for genetic alterations. Loeb et a! described these cells as 
cells with a mutator phenotype (Loeb, 1991). Many events can contribute 
to genetic changes. Mutations can occur as spontaneously arising "errors" 
during the process of mitosis, but can also be caused by environmental fac-
tors such as chemical or physical agents. Moreover, viruses can insert DNA 
into the genome, and subsequently act as an oncogene or as an enhancer to 
nearby proto-oncogenes. Not only genetic but also epigenetic events such 
as imprinting, aberrant methylation, formation of DNA adducts and post-
translational modifications can play a role in tumorigenesis. Also cellular or 
environmental factors that stimulate proliferation of an initiated cell will 
increase the probability of additional mutational or epigenetic changes and 
therewith contribute to the process of carcinogenesis. 
All these observations point to a rather complex multi-step carcinogenesis 
model in which genetic, epigenetic and environmental factors are involved. 
2.3.2 Endometrial cancer 
The molecular processes involved in tumorigenesis of endometrial cancer are 
largely unknown. On basis of histological and clinical characteristics tvvo 
pathways have been suggested in endometrial carcinogenesis (Deligdisch & 
Holinka, 1987, Sherman et a!., 1995b, Nogales, 1996, Esteller et a!., 1999, 
Sherman eta!., 1995a, Zheng eta!., 1996, Kurman Blaustein's Pathology of 
the Female Genital Tract, Springer-Verlag 1994): An estrogen-driven pathway 
leading to atypical hyperplasia of the endometrium which slowly progresses 
into an endometrioid carcinoma (Kurman et al., 1985, Lindahl & Willen, 
1991) and an estrogen-unrelated pathway leading to the aggressive papillary 
serous or clear cell carcinomas. Papillary serous carcinomas are found to 
arise in atrophic endometrium and are associated with a high grade precursor 
lesion: endometrial intraepithelial carcinoma (EIC) (Ambros eta!., 1995). 
The differences in estrogen-sensitivity and the different cellular precursor le-
sions suggest a different genetic pathway for each of the two subtypes. How-
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ever, a genetic background supporting the division of endometrial cancers 
into these two groups, or other groups, has yet to be established. 
2.3.3 Genes in endometrial cancers 
So far, little attention has been paid to heredity in the etiology of endometrial 
cancer. Endometrial cancer is known to be the most common extra-colonic 
cancer in HNPCC (hereditary nonpolyposis colorectal carcinoma) (Mecklin 
& Jarvinen, 1991). Women carrying mutations in the DNA mismatch repair 
genes known to be associated with HNPCC (e.g. hMSH2, hMLH1, hPMS2 
and hMSH6 genes) are found to have a 22-43% lifetime risk of developing 
endometrial cancer, which is significant higher than the lifetime risk in the 
general Dutch or USA female population (1.7-3.3%) (Watson & Lynch, 1993, 
Aamio eta!., 1995, Dunlop eta!., 1997, 0 Visser eta!., Incidence of Cancer 
in the Netherlands 1995, Association of Comprehensive Cancer Centers 
1998). No other germline mutations have been identified in endometrial 
cancer yet. 
Mutations and expression levels of several cancer related genes have been 
studied in sporadic endometrial cancers. The following paragraph and Table 
2.3.1 give an overview of the most frequently studied genes in endometrial 
cancer. 
DNA-repair genes 
DNA-repair or mismatch repair genes are involved in mending DNA repli-
cation errors and maintaining genetic stability. In normal cells errors from 
DNA replication which have escaped the proofreading activity of DNA poly-
merase will be repaired by the DNA mismatch repair system (MMR). Defects 
in this MMR system can result in a RER+ (Replication Errors) or mutator 
phenotype of the effected cell (Loeb, 1991). Randomly throughout the ge-
nome short tandem repeat sequences occur. These repeated sequences are 
called microsatellites. Due to their repeating nature, these microsatellites are 
particularly prone to errors during replication. RER+ cells can be recognized 
by instability of their microsatellites (Ionov eta!., 1993). Microsatellite in-
stability (MSI) has first been detected in hereditary nonpolyposis colorectal 
carcinomas (HNPCC) (Aaltonen et a!., 1993) and subsequently in many 
other tumors. In endometrial cancer MSI has been observed in 15-34% of 
the tumors, suggesting a role for DNA-repair genes in the carcinogenesis of 
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Table 2.3.1: Genes in endometrial cancer. 
type of references number cases/ type+-Siilge 
abnormality studied 
DNA;repalr . · · . ·. .· 
hMSH2, mutation Katabuchi, 1995 12 MSI-positive endomet.rioid 
loss expression Katabuchi, 1995 12 MSI-positive endometrioid 
Parc,2000 21 MSI-positive adenocar~ 
methylation Salvesen, 2000 138 endometrial care 
oromoter 
hPMS2 mutation Basil, 1999 40 MSI-positive adenocarc 
hMLHI methylation Gurin, 1999 14 MSI-positive endometrioid 
promoter Salvesen, 2000 138 endometrial care 
Simpkins, 1999 53 MSI-positive adenocarc 
loss expression Parc,2000 21 MSI-positive adenocarc 
Salvesen, 2000 138 endometrial care 
MSI -c:- .. -c:- . 
MSI Sakamoto, 1998 72 {non-)endoffietriold 
Risinger, 1993 36 (non-)endometrioid 
Burks, 1994 30 (non-)endometrloid 
Duggan, 1994 45 (non-)endometrioid 
Parc,2000 62 endometrial care 
Tibilettl, 1999 51 (non-)endometrioid 
Lim, 1996 28 endometrial care 
Katabuchi, 1995 65 (non-)endometrioid 
Gurin, 1999 57 endometrial care 
. . 
8% 
18% 
-
19% 
1% 
0% 
71% 
23% 
77% 
57% 
14% 
. 
15% 
17% 
23% 
20% 
34% 
20% 
32% 
18% 
25% 
Independent correlation~ 
prognostic with ... 
factorl 
.. . . . · . 
. 
·-· 
- -
- -
- -
- -
- -
- -
no -
- -
- -
no MSI pos., p53, methylation 
. 
-
- -
- early stage 
- hist.type 
--
- hist.type 
- high stage 
- hist.type, not stage/ 
I nrade 
- -
-
hist.type 
- -
n ,. 
~ 
~ 
N 
w 
"' 
Ttim6r-~uppre_ssor 
p53 mutation or 
overexpression 
PTENI mutation 
MMAC1 
DCC mutation or 
loss expression 
IGF-IIR mutation 
IGF-IR 
... 
Kohler, 1992 
Enomoto, 1993 
-c-; Lukes, 1994 
~artz, 1994 
Ito, 1994 
Kohler, 1996 
Zheng, 1996 
Kohlberger, 1996 
Powell, 1999 
Bell, 1997 
Bancher-Todesca, 1998 
Coppola, 1998 
loffe, 1998 
Backe, 1997 
Geisler, 1999 
Lim, 1999 
Silverman, 2000 
Tashiro, 1997 
Risinger, 1997 
Kong, 1997 
-Saegusa, 1999 
Enomoto, 1995 
Gima,1994 
Catasus,2000 
-Ouyang, 1997 
Maiorano, 1999 
. 
... 
. 
107 endometrial care 
40 endometrial care(+ 13 hyperpl) 
100 (non-)endometriOid 
128 (non-)endometrioid 
221 endometrioid 
179 stage III/IV endometrial care 
21 endometrioid I 21 PSC 
92 stage I endometrial care 
179 stage I endometrial care 
48 stage I endometrial care 
23 papillary serous (PSC) 
50 endometrial care 
18 stage I ECJ 36 hyperpl/ 10 normal 
202 endometrial care 
137 (non-)endometrioid 
42 stage I endometrioid 
134 curettage material 
32 (non-)endometrioid 
70 endometrial care 
38 endometrial care 
-
37 endometrial care 
8 endometrial care 
28 endometrial c.lrc 
24 MSI-positive endometrioid 
26 MSI-positive endometrial care 
30 endometria!"Carc 
.·· 
21 o/o multiv.yes 
23% (8%) -
27% unlv.yes 
29% unlv.yes 
21 o/o mUftiv.yes 
35% multiv.yes 
29% /71 o/o -
9% multiv.yes 
6% multiv.yes 
- no 
48% univ.yes 
22% no 
50%1010 -
31% univ.yes 
(94%-) 57% multiv.yes 
24% multiv.yes 
40% multiv.yes 
(Oo/o-)50% -
·-· 
34% -
55% -
35% -
SO% -
SO% no 
12% -
15% -
Oo/o -
. . 
high stage 
high grade 
-
hist. type, stage, grade 
high stage 
black race 
stage EC I not stage PSC 
not hist. type, not S"tage_ .. _ 
-
-
high stage 
not stage 
cell turnover indices 
grade 
-~ .. --~ 
high stage 
-
hist.type,stage, not grade 
MSI-poSitive, hist.type 
-
MSI_ positive 
not stage 
-
not stage 
-
early stage, low gr~de 
-
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Table 2.3.1: Genes in endometrial cancer- continued 
type of 
abnormality 
references number cases/ type+stage 
studied 
Independent 
prognostic 
factor? 
correlation 
with ... 
[Jj\ll)or-suppr~ssor I 
----
TGFbeta· mutation or 'Risinger, 1997 70 endometrial care 0% " " 
R2 loss expression --·~ .. -Gold, 1994 " 0% " , __ 
Myeroff, 1995 MSI-positive endometrial care 17% " 
Catasus,2000 24 MSI-positive endometrioid 0% " " 
Rb mutation or Niemann, 1997 70 endometrial care 6% " high stage 
loss expression Milde-langosch, 1999 36 (non-)endometrioid 3% " not stage, not grade 
Semczuk, 2000 62 (non-)endometrioid 5% " high stage 
Yaginuma, 1996 20 {non-)endometrioid 10% " " 
- -·-
on·cog·ene ", ," """ "", ,","• . " 
K-ras mutation Lax,2000 58EC/42P5C 26%/2% " hist.type, not grade 
Fujimoto, 1993 45 endometrial care 22% " not hi st. type, not stage 
Enomoto,1991/1993 52 endometrial care 29% " " 
Sasaki, 1993 84 endometrial care 18o/o " high in Japanese race 
·-
Duggan,_1994 60 endometrial care 12% " " 
Mutter, 1999 56 endometrial care 15% " also in hyperplasia 
Jones, 1997 32 (non~)endometrioid 19% no " 
Esteller, 1997 55 endometrial care 15o/o no not hi st. type, not stage 
Semczuk, 1997 13 endometrial care 15o/o " high stage 
" 
Semczuk, 1998 57 endometrial care 14o/o no hist.type (clear cell) 
Niederacher, 1999 112 endometrial care 12o/o no not stage, not grade 
c-fms mutation or Leiserowitz, 1993 32 (non-)endometrioid " " high grade 
overexpression Smith, 1995 71 endometrial care 50o/o " " 
Baiocchi, 1991 9 endometrial care 67% " " 
~ 
~ 
>.> 
:": 
c-myc mutation or Niederacher, 1999 112 endometrial care 3% no not stage, not grad·-.--
overexpression Monk, 1994 37 endometrial care 11% - high grade 
c-e·rbB- mutation or Wang, 1993 34 {non-)endometrioid 15% no not stage, not grade 
2/ overexpression Hetzel, 1992 247 endometrial care 15% multiv.yes high stage 
HER-2/ Berchuck, 1991 95 endometrial care 10% - increased mortality 
neu Reinartz, 1994 128 {non-)endometrioid 2% no hist.type 
Silverman, 2000 134 curettage material 12% no early stage, hist.type 
Lukes, 1994 100 (non-)endomeirioid 12% univ.yes -
Rolitsky, 1999 72 endometrial care 21% multiv.yes higher grade, hist.type 
amplification Riben, 1997 63 stage I endometrial care 38% multiv.yes -
-Rolli;ky, 1999 72 endometrial care 17% multiv.yes higher grade, hist.type 
Saffari, 1995 92 endometrial care 21% multiv.yes -
bcl-2 mutation or Zheng, 1996 42 (non-)endometrioid - hist.type 
over expression Joffe, 1998 18 stage 1 endometrial care 38% - high cell turnover 
expressed Coppola, 1998 50 endometrial care 85% no high stage 
Morsi,2000 26 endometrial care - - low grade 
Geisler, 1998 91 EC I 29 non-endometrioid 44%/23% multiv.yes early stage, low grade 
-
Several oncogenes, tumor-suppressor genes and DNA-repair genes have been studied with regard to their possible involvement in tumorigenesis of endome-
trial cancer. This table gives an overview of the most frequently genes studied. Four groups (class) have been made: DNA-repair genes,microsatellite instability, 
tumor-suppressor genes and oncogenes. Named are the genes studied (gene), the type of genetic alteration found in the gene (type abnormality), the refer-
ences (references), the number of patients studied and the histological type and stage of the tumor studied (number of cases/type and stage studied), the 
percentage of cases in which the genetic alteration was found (percentage affected), whether the gene was found to be an independent prognostic factor for 
disease free survival, either by multivariant or univariant analysis (independent prognostic factor) and whether the found gene alteration was correlated with 
any other characteristic of the tumor (correlated with ... ).-= no data were available. Care= carcinoma. EC = endometrioid carcinoma. PSC =papillary serous 
carcinoma. Hyperpl =hyperplasia. Ml = MSI = microsatellite instability. Multlv. =multivariate. Univ.= univariate. Stage and grade refer to the FIGO staging sys-
tem and histological grading. 
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endometrial cancer. Inactivation of the DNA repair genes can result from 
genetic alterations in these genes. In HNPCC, germline mutations in several 
DNA-repair genes (hMSH2, hMLH1, hPMS2 and hMSH6) have been identi-
fied (Fishel et aL, 1993, Bronner et aL, 1994, Papadopoulos et aL, 1994, Mal-
khosyan et al., 1996). However, endometrial tumors rarely show mutations 
in these DNA-repair genes (Kowalski et aL, 1997, Katabuchi et aL, 1995, Ko-
bayashi et aL, 1996, Lim et aL, 1996). Simpkins et aL (Simpkins et aL, 1999) 
have suggested an alternative mechanism for inactivation of DNA-repair 
genes. They found methylation of the hMLH1 promoter in 77% of MSI posi-
tive tumors, and also loss of hMLH1 protein expression but no mutations in 
the genes. Subsequently they suggested that not genetic but epigenetic altera-
tions of DNA-repair genes account for the RER+ phenotype in a large group 
of endometrial cancers. Salvesen et aL (Salvesen et aL, 2000) confirmed 
Simpkins' observations. Studying 138 endometrial carcinomas, they found 
methylation of the hMLH1 promoter in 69% of the tumors with high MSI 
compared to 10% in MSI-negative tumors. Loss of hMLH1 nuclear staining 
was seen in 93% of the methylated MSI-positive tumors. All unmethylated 
tumors showed normal expression of hMLH1. Salvesen et aL (Salvesen et aL, 
2000) conclude that hMHL1 methylation is significantly correlated with loss 
of hMLH1 expression, lack of p 53 overexpression, and with microsatellite 
instability (MSI). 
In endometrial cancers, MSI is found to be restricted to tumors of the 
endometrioid type. No association was found between MSI and tumor stage 
or grade. These observations could indicate that MSI is an early event associ-
ated with the development of endometrioid endometrial cancers and could 
be caused by hyper-methylation of DNA-repair gene promoters. 
Other genes, containing short repeating sequences~ are also prone to 
genetic alterations in a cell with a mutator phenotype. TGF-beta receptor II I 
IGF-II receptor are tumorwsuppressor genes, and known to carry short repeat-
ing sequences. Several groups have studied endometrial tumors for the pres-
ence of mutations in these genes (Table 2.3.1). However, mutations in these 
genes appear to be a rare event in endometrial cancers. Even in endometrial 
tumors carrying microsatellite instability, mutations are only observed in 0-
17% of the tumors. 
Tumor-suppressor genes 
Tumor-suppressor genes are genes normally encoding proteins involved in 
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inhibition of cell proliferation. Complete or partial deletion, mutation or 
chromosomal rearrangement can cause functional damage to the genes, re-
sulting in either complete loss of the gene transcript or production of an ab-
errant protein. p53, PTEN and DCC are the most frequently found mutated 
tumor-suppressor genes in endometrial cancers. 
P53 - Mutations of the tumor-suppressor gene p53 belong to the group 
of ubiquitous genetic alterations in human tumors (Hollstein et al., 
1991). Wildtype p53 functions as a G1-S checkpoint. p53 induces a G1 
arrest, creating extra time for DNA-repair mechanisms. If DNA-repair 
fails, p53 may initiate cell death via apoptosis (Lane, 1992). Mutations in 
the p53 gene can result in a protein with increased stability. Subsequently, 
due to the longer half-life of the mutant protein, the functional inactive 
p53 protein becomes overexpressed in the tumor cell (Finlay eta!., 1988). 
Total loss of p53 protein expression is a relatively uncommon event, but 
can result from non-sense mutations or complete deletion of p53 gene 
(Hollstein eta!., 1991). Several groups have studied the expression level 
of p53 protein in endometrial cancers using immunohistochemical stain-
ing. A significant difference has been found between the expression of 
p53 in the two histological endometrial cancer subtypes: p53 is less fre-
quently found to be overexpressed in endometrioid carcinomas: 17-57 %, 
as compared to the more aggressive papillary serous endometrial carcino-
mas: 47-94% (Kohler eta!., 1992, Geisler eta!., 1999, Ito eta!., 1994, 
Lax eta!., 2000, Bancher-Todesca eta!., 1998). In endometrioid tumors, 
the percentage of tumors with p53 overexpression is significantly lower in 
stage 1/11 tumors as compared to stage Ill!IV tumors (Kohler eta!., 1992, 
Geisler eta!., 1999, Ito eta!., 1994, Lax eta!., 2000). However, in papil-
lary serous carcinomas, p53 overexpression seems to represent an early 
event in carcinogenesis, as the same percentage of p53 overexpression 
is found in all FIGO stages (Geisler eta!., 1999, Bancher-Todesca eta!., 
1998, Zheng eta!., 1996). These observations suggest that p53 expression 
could function as a prognostic marker for disease-free survival. A major-
ity of reports show p53 overexpression to be an independent prognostic 
marker in multivariate analysis, confirming the prognostic value of p53 
(Geisler eta!., 1999, Silverman eta!., 2000, Kohler eta!., 1992, Kohlberg-
er eta!., 1996, Ito eta!., 1994, Powell eta!., 1999 and Lim eta!., 1999). 
However, Lukes eta!. (Lukes eta!., 1994, Blacke eta!., '97 and Reinartz 
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et al., 1994), whilst finding a correlation using univariant analysis, but 
multivariate analysis failed to show a relation in their studies. Contradic~ 
tory results were also observed by Bell et al. (Bell et al., 1997) who studied 
349 stage I endometrial carcinomas and found no relationship between 
p53 expression and disease recurrence. Bancher-Todesca et al. (Bancher-
Todesca et al., 1998) found no significant association between survival 
and p53 expression in papillary serous carcinoma. These last two observa-
tions could be explained as a result of a correlation between p53 expres-
sion and higher stage and aggressive histological subtypes. However, the 
studies of Kohlberger et al. (Kohlberger et al., 1996) and Lim et al. (Lim 
et al., 1999) challenge such a correlation, as they did find, in stage 1 en-
dometrial tumors, p53 to be a multivariate independent prognostic value 
for disease free survival. All studies used immunohistochemical staining 
to evaluate p 53 expression in the tumor samples. However, methods to 
quantify the staining results, cut off levels for defining overexpression 
and the antibodies used, differ between the different studies. These differ-
ences in methodology could influence the obtained results. Moreover, in 
a recent study by Lax et al. (Lax et al., 2000) it was found that in 15% of 
the p53 mutations no immunoreactivity for p53 protein was detectable, 
indicating that immunohistochemical staining studies underestimate p53 
mutation frequency. 
Different roles of p53 in the carcinogenesis of the two histological sub-
types have been proposed. Overexpression of p53 is rare in premalignant 
hyperplastic endometrium: 0-8% (Enomoto et al., 1993, Kohler et al., 
1992, loffe et al., 1998), and in stage 1 endometrioid carcinomas: 0-21% 
(Kohler et al., 1992, Kohlberger et al., 1996, Lim et al., 1999). Therefore, 
p53 mutations appear to be late events in the development of endome-
trioid carcinoma. In contrast, p53 overexpression appears to represent an 
early event in serous carcinomas, as the precursor lesion EIC ( endome-
trial intraepithelial carcinoma) is always associated with p53 overexpres-
sion in p53 positive serous carcinomas (Sherman et a!., 1995a). These 
observations suggest that p53 mutation is associated with an aggressive, 
invasive type of endometrial carcinoma cells and may serve as a prognos-
tic marker for disease~free survival in endometrial cancers. 
PTEN - An other common genetic alteration found in human tumors is 
mutation of the tumor-suppressor gene PTEN/MMAC1. Germline muta-
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tions of the tumor-suppressor gene PTEN are found in Cowden disease, 
an autosomal dominant cancer predisposition syndrome characterized 
by multiple hamartomas in various organs (breast, skin, thyroid) (Liaw 
et a!., 1997) and in the Bannayan-Zonana syndrome characterized by 
macrocephaly lipomas, intestinal hamartomatous polyps vascular malfor-
mations and skin disorders (Marsh eta!., 1997). PTEN has an intrinsic 
phosphatase activity and functions as a tumor suppressor by counter-
acting the oncogenic effects of tyrosine kinases (Furnari et a!., 1997). 
PTEN has been shown to inhibit cell migration. Therefore, loss of PTEN 
function may stimulate tumor progression and metastasis (Tamura et al., 
1998). PTEN mutations were detected in 34%-55% (Tashiro eta!., 1997), 
(Risinger et a!., 1997, Kong et a!., 1997) of endometrial carcinomas. 
Mutations seem to be confined to the endometrioid histological subtype 
(Tashiro et a!., 1997, Risinger et a!., 1997). PTEN is more often found 
mutated in MSI-positive endometrial carcinomas than in MSI-negative 
tumors, and does not appear to be stage related (Tashiro eta!., 1997, Kong 
et a!., 1997, Risinger et a!., 1997). Therefore, it has been hypothesized 
that PTEN mutations occur as an early event in carcinogenesis of endo-
metrioid endometrial carcinomas that already have acquired a mutator 
phenotype. In the development of papillary serous endometrial carcino-
mas, PTEN mutations do not seem to play a significant role. 
DCC - The tumor-suppressor gene DCC (Deleted in Colorectal Carci-
noma) was first found mutated in colorectal cancers. The DCC protein 
plays a role both in cell growth and differentiation (Hedrick eta!., 1994). 
In colorectal cancers, DCC mutations are thought to be a late event in 
carcinogenesis, as low DCC protein expression is found to be associated 
with a increased risk of developing metastases and with lower five-years 
survival rates (Itoh eta!., 1993, Saito et a!., 1999, Schmitt eta!., 1998, 
Gotley et a!., 1996). Similar observations have been made by three dif-
ferent research groups investigating DCC expression in endometrial car-
cinomas (Saegusa eta!., 1999, Enomoto eta!., 1995, Gima eta!., 1994). 
They reported DCC mutations and loss of protein expression in 35-50% 
of the endometrial carcinomas. No association has been found with ei-
ther FIGO stage or disease outcome. However, in all three studies only a 
small number of endometrial carcinoma samples were investigated. 
Rb - The retinoblastoma gene (Rb) was the first described tumor-sup-
pressor gene and was originally found to be the gene responsible for the 
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hereditary retinoblastoma syndrome (Lee eta!., 1987, Friend eta!., 1986, 
Horowitz eta!., 1990). Subsequently, mutations in the Rb gene have been 
detected in a number of other tumors, such as breast, lung, prostate and 
bladder (Ishikawa eta!., 1991, Yokota eta!., 1988, Lee eta!., 1987, Book-
stein eta!., 1990a; Bookstein eta!., 1990b). However, in endometrial 
cancer alterations in the Rb gene seem to be a rare event. Yaginuma et al. 
(Yaginuma eta!., 1996) found LOH at the Rb locus in 10% of endometrial 
carcinomas. Using immunohistochemical staining (Niemann et al., 1997, 
Semczuk et a!., 2000, Milde-Langosch et a!., 1999), loss of Rb protein 
expression has been found in only 3%-6% of the cases. 
Oncogenes 
Proto-oncogenes are genes that normally encode proteins that stimulate 
the growth signaling pathways in cells. They can become tumorigenic either 
when their protein is overexpressed or hyperactive. After this functional 
change their names change accordingly from proto-oncogenes to onco-
genes. Several genetic events may cause this transition. Deletions or point 
mutations in the coding sequence can result in a hyperactive protein, even 
without changing the expression level of the gene. Chromosomal rearrange-
ments can position a gene near an enhancer, increasing the expression level 
of the gene or creating a hyperactive fusion product. Moreover, viruses can 
integrate DNA into the genome, and subsequently act as an oncogene or as 
an enhancer to nearby proto-oncogenes. 
K-ras - The proto-oncogene K-ras is involved in controlling cell prolif-
eration. The activated Ras protein triggers activation of the MAP kinase 
pathway and subsequently stimulates cell proliferation via activation of 
several growth factors (Hill eta!., 1993). In endometrial carcinomas, co-
don 12 of the K-ras gene is the most frequent site of mutations, causing 
a constitutive active product. Mutations in codon 12 have been found in 
12-29% of endometrial tumors. Moreover, race-related differences in mu-
tation rate have been reported, with higher frequency of mutations in Ja-
pan (22-29%) as compared to USA (12-19%) (Sasaki eta!., 1993, Caduff 
eta!., 1995). Activation of K-ras has been suggested to represent an early 
event in the development of endometrial cancer, as mutations have also 
been found in endometrial hyperplasia. K-ras has been shown to cross-
talk with the estradiol signaling pathway, as activation of K-ras has been 
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reported to enhance estrogen-induced and anti-estrogen~induced tran-
scriptional activity of the estrogen receptor activation function (Bunone 
et al., 1996, Kate et al., 1995). This suggests that mutational activation 
of the ras-MAPK cascade may be involved in the development of hormone 
independency in endometrial cancer (Niederacher et al., 1999). However, 
so far no correlation has been found between K-ras mutations and spe-
cific histological characteristics or prognosis of endometrial cancers. 
C-myc - Proto-oncogene c-myc is an early response gene and essential in 
controlling cell proliferation. Mutations in c-myc appear to be a relatively 
rare event in endometrial carcinomas: 3-11% (Niederacher et al., 1999, 
Monk et al., 1994). 
C~fms - Proto~oncogene c-fms encodes a transmembrane tyrosine kinase 
receptor for the colony-stimulating factor 1 ( CSF-1). CSF-1 is a growth 
factor, regulating growth and differentiation of mononuclear phagocytes. 
In the human endometrial adenocarcinoma cell line Ishikawa, CSF was 
found to inhibit growth and induce differentiation (Kimura eta!., 1991). 
Overexpression of the CSF receptor c-fms is found in 50-67% of the endo-
metrial carcinomas and is correlated with high~grade tumors (Leiserowitz 
et al., 1993, Smith et al., 1995, Baiocchi et al., 1991). No correlation has 
been found between c~fms expression and a specific histological subtype 
of the endometrial tumors. 
C-erb B (HER-2/neu) -The proto-oncogene erb-B encodes an EGF (epi-
dermal growth factor) receptor. When EGF binds to the receptor, the 
intracellular tyrosine kinase domain becomes activated and starts a sig~ 
naling pathway leading to cell proliferation. The mutated erbB (c-erbB) 
encodes a truncated form of the EGF receptor that is constitutively active. 
Berchuck et al. (Berchuck eta!., 1991), Hetzel eta!. (Hetzel et al., 1992), 
Lukes et al. (Lukes eta!., 1994) and Rolitsky et al. (Rolitsky eta!., 1999) 
found c-erbB overexpression to be an independent prognostic factor for 
disease free survival in endometrial cancers. In these 4 studies overex-
pression of c-erbB was found in 10-17% of the tumors. Rolitsky et al. 
(Rolitsky et al., 1999), Reinatz eta!. (Reinartz et al., 1994) and Silverman 
et al. (Silverman et al., 2000) found c-erbB overexpression or amplifica-
tion to be strongly associated with the non-endometrioid histological 
subtype. Reinartz et al. (Reinartz et al., 1994) and Rolitsky et al. (Rolitsky 
et al., 1999) even specified these tumors to be mainly clear-cell carcino-
mas. However, Wang et al. (Wang eta!., 1993) found the same frequen-
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des of overexpression but could not confirm the association of c-erbB 
expression with histological nor clinical characteristics of the tumors. 
Reinartz et aL (Reinartz et aL, 1994) reported a much lower overexpres-
sion rate: only 2%, and found no correlation with histological features 
or with prognosis. Using fluorescence in situ hybridization (FISH) Riben 
et aL (Riben et aL, 1997), and Saffari et aL (Saffari et aL, 1995) found 
c-erbB amplification in 21%-38% of the endometrial tumors and found 
c-erbB amplification to be an independent prognostic factor by multivari-
ate analysis. Patients with c-erbB amplification, as demonstrated by FISH, 
had lower overall survival rates, but responded better to adjuvant chemo-
therapy or radiation therapy than patients without c-erbB amplification. 
Normal and hyperplastic endometrium show a normal expression pattern 
of c-erbB (Rasty et aL, 1998). These observations indicate that mutations 
in c-erbB are a late event in the carcinogenesis of endometrial cancer and 
may be associated with a non-endometrioid subtype and poor prognosis. 
bcl-2 - The proto-oncogene bcl-2 is an inhibitor of programmed cell 
death and counteracts the action of p53, which induces apoptosis. Morsi 
et aL (Morsi et aL, 2000) observed cyclic changes of the bcl-2 protein ex-
pression in normal endometrium, with the highest expression during the 
proliferative phase. Bcl-2 expression levels progressively decrease, when 
comparing normal endometrium with hyperplasia and carcinoma (Morsi 
et al., 2000). Moreover, in the endometrial carcinomas, the expression 
levels correlate negatively with differentiation grade (Morsi et aL, 2000, 
loffe et aL, 1998, Geisler et aL, 1998, Zheng et aL, 1996). On basis of 
these observations, Zheng et aL (Zheng et aL, 1996) suggested that fail-
ure to inactivate bcl-2 expression is an early event in the development of 
endometrial carcinoma. It provides the cell with the opportunity to ac-
cumulate genetic mutations and subsequently can lead to the evolution 
of a precursor lesion into a carcinoma. The negative correlation of bcl-2 
activity with endometrial carcinoma differentiation grade was thought to 
indicate that the role of bcl-2-related inhibition of apoptosis is less im-
portant in late-stage endometrial carcinoma (Zheng et aL, 1996). How-
ever, loffe et aL (loffe et aL, 1998) observed that not the quantity, but 
the subcellular localization of bcl-2 expression seems to be an important 
difference between normal endometrial tissues and endometrial carci-
noma. In normal and hyperplastic endometrium, bcl-2 expression was 
mainly found in the cytoplasm, whereas in carcinomas predominantly a 
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nuclear localization of bcl-2 was observed. Moreover, higher proliferative 
rates were found in tumors with a predominantly nuclear localization as 
compared to tumors with a cytoplasmic bcl-2 expression pattern (loffe et 
a!., 1998). 
In conclusion, genes most frequently found to be altered in endometrial 
cancer are the tumor-suppressor genes: p53, PTEN, DCC and the oncogenes: 
K-ras, c-erbB2, c-fms. Two of these genes: p53 and c-erbB2, have been identi-
fied to serve as molecular prognostic markers in endometrial tumors. 
2.3.4 Hormonal influences in the etiology of endometrial cancers 
The endometrium is a highly hormone sensitive tissue. The cyclic changes of 
proliferation, differentiation and subsequently shedding of the endometrium 
are driven by two ovarian hormones: estradiol and progesterone. Stimula-
tion of the endometrium by estrogens, without the differentiating effect of 
progestins, is the primary etiologic factor associated with the development 
of endometrial hyperplasia and adenocarcinoma. Endogenous (anovulation) 
and exogenous (hormonal therapy) sources of unopposed estrogens are gen-
erally considered as the source of increased risk of endometrioid carcinoma 
(Antunes eta!., 1979). Also, the use of the anti-estrogen Tamoxifen (TAM) 
has been associated with an increased risk of endometrial cancer (Bergman 
et a!., 2000). TAM is successfully used in the treatment of women with 
breast cancer. However, long-term use of TAM gives a 2-7-fold increase of 
the relative risk for endometrial cancer (Bergman et a!., 2000, Bernstein et 
a!., 1999). The endometrial tumor, which develops in these patients, is char-
acterized by an association with high-stage, an aggressive histological type, 
overexpression of p53 and a low expression of estrogen receptors (Bergman 
eta!., 2000, Ramondetta eta!., 1998, Kuwashima eta!., 1998). 
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Summary 
The recently developed eDNA expression array technique can be used to generate gene expression finger-
prints of tumor specimen. To gain insight in molecular mechanisms involved in the development and progres-
sion of cancer, this eDNA expression array technique could be a useful tool. However, being a novel technique, 
no established methods for interpreting the results are yet available. We used the Atlas Human Cancer eDNA-
expression array (Clontech, USA) for analyzing total RNA isolated from four human endometrial carcinoma 
samples (two cell lines and two tissue samples), one benign endometrial tissue sample and a human breast 
cancer cell line in order to develop a method for analyzing the array data. The obtained gene expression pro-
files were highly reproducible. XY-scatter plots and regression analysis of the logarithmic transformed data 
provided a practical method to analyze the data without the need of preceding normalization. Three genes 
(Decorin,nMP3 and Cyclin 01) were identified to be differentially expressed between the benign endometrial 
tissue sample and the endometrial carcinoma samples (tissue and cell lines). These three genes may poten-
tially be involved in cancer progression. A higher degree of similarity in gene expression profile was found be-
tween the endometrial samples (tissue and cell-lines) than between the endometrial samples and the breast 
cancer cell line, which is indicative for an endometrial tissue specific gene expression profile. 
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INTRODUCTION 
Tumor development and progression involves a cascade of genetic alterations 
(Fearon & Vogelstein, 1990; Knudson, 1971). Techniques frequently used to 
study gene expression alterations, such as RT-PCR, differential display PCR 
and Northern blot analysis, have their limitations: some need large amounts 
of RNA, others are time consuming and can only study a small number of 
genes simultaneously. With the development of the eDNA expression array 
technique a method has become available to study the expression levels of a 
large range of genes in one single hybridization, requiring only a small amount 
of total RNA. Using this technique a gene expression fingerprint of every 
single tissue sample can be made. Being a novel technique, no established 
methods for interpreting the results are yet available. In recent publications 
mostly two single hybridization experiments are compared and differentially 
expressed genes are identified. Little attention is paid to the method that is 
used to analyze the data (Hoch et al., 1999; Kaiser et al., 1999; Shim et al., 
1998). However, two research groups have described methods to analyze the 
array data: Hilsenbeck et al.(Hilsenbeck et al., 1999) introduce a statistical 
method to compare more than two hybridization experiments and to iden-
tify differentially expressed genes, using a principal components analysis of 
mean-centered log-transformed data. Rhee et al. (Rhee et al., 1999) analyses 
similarity in gene expression patterns between three hybridization experi-
ments using scatter plots and rank tests. 
Endometrial cancer is the most common gynecologic malignancy (Rose, 
1996; Schottenfeld, 1995). In the majority of cases, approximately 75%, the 
tumor is confined to the uterus at time of diagnosis and has a relatively good 
prognosis. Patients with advanced/recurrent disease have a poor prognosis, 
with response rates to therapy of only 10-30% (Lentz, 1994; Rose, 1996). In 
general tumor development and tumor progression are thought to be driven 
by genetic alterations. Therefore insight into the molecular mechanisms in-
volved in progression of endometrial carcinoma is important when searching 
for new tools to improve the outcome of patients with advanced/recurrent 
endometrial carcinomas. Using the eDNA expressing array technique, gene 
expression fingerprints of a variety of endometrial carcinoma tissue samples 
can be produced and differentially expressed genes can be identified. We used 
the Atlas Human Cancer Expression Array (Clontech, USA) on endometrial 
53 
Chapter 3 
54 
carcinoma tissue and cell line samples. The analysis method and the results 
are evaluated in this article. 
MATERIALS AND METHODS 
Cell lines 
Ishikawa cells are derived from a human well-differentiated endometrial ad-
enocarcinoma and were a generous gift from Dr. Masato Nishida (Tsukuba, 
japan). ECC-1 cells are derived from a well-differentiated adenocarcinoma 
of human endometrium transplanted to nude mice and were a generous gift 
from Dr. P.G. Satyaswaroop (Hershey, USA). The T47D cells are derived from 
well-differentiated human breast cancer and were a generous gift from Dr. 
B. van der Burg (Utrecht, The Netherlands). All cells were maintained in 
DMEM/F12 (Dulbecco's modified Eagle's medium/Ham's F12 (1:1 mix) with 
15mM Hepes, with L-glutamine) supplemented with penicillin/streptomycin 
and in the presence of 7.5% fetal calf serum and 10·' M estradiol in a 37°C 
incubator. For the experiments, cells were cultured to a 50% confluency, me-
dium was changed to DMEM/F12 supplemented with 7.5% dextran-coated 
charcoal-treated fetal calf serum and 10·' M estradiol. Subsequently, cells 
were cultured for an other 72h before harvesting. Total RNA was isolated as 
described below. 
Tissue samples 
The endometrial carcinoma tissue samples were obtained from patients at-
tending hospital for treatment of endometrial cancer (department of Ob-
stetrics & Gynecology of the Erasmus M.C. Rotterdam and department of 
Obstetrics & Gynecology of the Saint Franciscus Hospital Rotterdam, The 
Netherlands). The histological type and grading were established by the 
department of Pathology of the Erasmus M.C. Rotterdam according to the 
modified FIGO staging system (Mikuta, 1993). The two human endometrial 
carcinoma tissue samples used were tissue sample 54: moderate well-differ-
entiated (grade 2) endometrioid adenocarcinoma and tissue sample 55: well-
differentiated (grade 1) endometrioid adenocarcinoma. The benign human 
endometrial epithelial tissue sample was obtained from a patient attending 
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the department of Obstetrics & Gynecology of the Erasmus M.C. Rotterdam 
for treatment of uterine myomas (tissue sample 36). The endometrial epithe-
lial samples were excised directly after removal of the uterus from the body 
and frozen in liquid nitrogen. Sandwich sections were made, by the depart-
ment of Pathology of the Erasmus Medical Center Rotterdam, to establish 
percentage of tumor in the studied samples. The carcinoma samples used 
in this study (sample 54 and 55) contained >90% endometrial carcinoma 
tissue, the benign endometrial tissue sample (sample 36) contained >90% 
benign endometrial epithelial tissue. 
RNA isolation 
Total RNA was isolated from the cell lines and the tissue specimen following 
the instructions of the protocol PT3231-1, advised to use in combination 
with the Atlas Human Cancer eDNA expression array by Clontech Laborato-
ries, Inc. (Palo Alto, California, USA). 
Atlas Human Cancer eDNA expression array 
The Atlas Human Cancer eDNA expression array (7742-1) was purchased 
from Clontech Laboratories, Inc. (Palo Alto, California, USA). Two identi-
cal nucleic acid arrays were supplied containing 588 cancer related human 
eDNA's spotted as duplicates on nylon membranes. A list of the genes spot-
ted on the array, including array coordinates, is available at Clontech's web 
site http:/ /www.clontech.com. 
eDNA synthesis and hybridization 
Total RNA was reverse transcribed into eDNA using a mixture of array gene-
specific primers and was labeled with 32P-dATP. Probe purification and hy-
bridization to the array were performed following the array's user manual. 
The array was exposed to a phosphor-imaging screen at room temperature 
for 24 hours and scanned using the Phosphor Imager (Molecular Dynamics, 
Sunnyvale, USA). The results were quantified using lmageQuant software 
(Molecular Dynamics, Sunnyvale, USA). A grid was applied to the image of 
the blot to quantify the intensity of the hybridization of every spot. Back-
ground signal was defined as the average of the hybridization signals pro-
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duced by the nine negative controls on the array. A gene was defined to be 
expressed when the hybridization signal extended the value of two times the 
background signal. According to the Array manufacturer (Clontech Labora-
tories, Palo Alto, CA, USA), the radioactive eDNA signal is linear for RNAs 
present at levels of 0.01-3% of the total RNA population. We did not observe 
saturation of the hybridization signal. 
Statistic analysis 
Logarithmic transformation - The expression data obtained from Phos-
phor Imager analysis were logarithmic (10log) transformed. 
XY-scatter plot - The xy-scatter plot displays the expression levels of the 
genes for tw"o compared experiments. Every dot represents one of the 
genes on the eDNA array. The x-value represents the 10log of the expres-
sion level of the gene in one experiment, the y-value represents the 10log 
of the expression level of the same gene in the other experiment. The xy-
scatter plots were produced using Microsoft Excel 97 software. 
Regression analysis - The least-squares regression line y=ax+b is the line 
with the smallest sum of squared vertical distances betw"een the points of 
the xy-scatter plot and the line. The least-squared regression lines were 
drawn using Microsoft Excel 97 software. 
R-squared value - R-squared value is the Pearson correlation coefficient 
of the least-squares regression line. The R-squared values were calculated 
using Microsoft Excel 97 software. 
Standard deviation - The standard deviation of the distance between the 
points and the least-squared regression line was calculated using Micro-
soft Excel 97 software. An area of standard deviation multiplied with 
1.96 at both sides of the least-squared regression line was drawn in the 
xy-scatter to establish a 95% prediction interval. Genes located outside 
this area were identified as differentially expressed. 
RESULTS 
Using a eDNA expression array technique we established the expression 
profile of 588 genes selected from different areas of cancer research in tw"o 
human endometrial carcinoma cell lines (Figure 3.1 A and 3.1 B), in two 
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Figure 3.1: Gene expression fingerprints of endometrial cells. Atlas Human Cancer eDNA 
Expression Array (Ciontech, USA) was hybridized with 32P-Iabelled eDNA probes obtained 
from total RNA of the Ishikawa endometrial carcinoma cell-line (figure 3.1 A), the ECC-1 en-
dometrial carcinoma cell line (Figure 3.1 B),a benign human endometrial tissue sample (be-
nign tissue sample 36) (Figure 3.1 C) and a well-differentiated human endometrial carcinoma 
tissue sample (tumor sample 54) (Figure 3.1 O).The array contains 588 cancer related human 
cDNAs spotted as duplicates. Nine housekeeping genes are spotted at the bottom line to 
serve as positive controls. Dark gray spots at the outer end of the array represent genomic 
DNA spots, which serve as orientation marks. 1 =Cyclin 01 ,2=Decorin,3= TIMP3. 
human endometrial carcinoma tissue samples (one shown in Figure 3.1 D), 
in one benign human endometrial tissue sample (Figure 3.1 C) and in one 
breast cancer cell line (not shown). Using logarithmic transformed raw data, 
obtained from phosphor imager analysis of eDNA expression array hybridiza-
tion experiments, the gene expression fingerprints of the different tissue and 
cell line samples were compared. Using a xy-scatter plot, similarity in gene 
expression fingerprints between the cell lines and tissue samples was estab-
lished and differentially expressed genes were identified. 
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Normalization of the data 
It seems that comparing gene expression fingerprints between cell lines or 
tissue samples should be conducted only after normalization of the data 
for differences in background signal and for differences in intensity of hy-
bridization. The cancer eDNA expression array contains nine genes known 
as housekeeping genes (liver glyceraldehyde 3-phosphate dehydrogenase, 
tubulin alpha, HLA class1 histocompatibility antigen C-4 a-chain, ~-actin, 
23-kDA highly basic protein, ribosomal protein 59, ubiquitin, phospholipase 
A2, HPRT). All these nine housekeeping genes, or a selection of these genes, 
could be used as standards in normalization. When using a xy-scatter plot 
and regression analysis, the raw data may be analyzed without the need of 
preceding normalization of the data. In the least-squares regression line 
y:=ax+b the slope value a can be considered to represent the differences in 
hybridization intensity and the intercept value b to represent the differences 
in background signal. Expression level of the highest and lowest expressed 
genes on the array varied extensively. Subsequently, when comparing expres-
sion data, the differences between genes with high expression levels will have 
much greater impact than the differences between low expressed genes. Us-
ing a logarithmic transformation of the raw data equalized these differences 
to some extent. 
Reproducible gene expression fingerprints 
Total RNA was isolated from Ishikawa cells. The RNA sample was divided in 
two batches, reversed transcribed and the eDNA was labeled. The two labeled 
eDNA batches were hybridized to two twin membranes. A very high R' =0.92 
was seen (Figure 2A), implying a high level of reproducibility of the eDNA 
array technique. 
Figure 3.2: Pair-wise comparison of gene expression fingerprints using XY-scatterplot. 
A pair-wise comparison of the gene expression fingerprint was made between: the two 
Ishikawa cell hybridizations to the twin array membranes (Figure 3.2 A), between the benign 
human endometrial tissue sample 36 and the human endometrial carcinoma tissue sample 
55 (Figure 3.2 B), between the benign human endometrial tissue sample 36 and the human 
endometrial carcinoma tissue sample 54 (Figure 3.2 C), and between the T47D breast cancer 
cells and the human endometrial carcinoma tissue sample 54 (Figure 3.2 D). 
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Table 3.1: Table of the R~squared values. 
R-squared value Ishikawa Ishikawa ECC-1 T47D 
benign tumour tumour 
1 2 sample36 sample 54 sample 55 
Ishikawa 1 0,92 0.29 0.02 0.33 0.56 0.27 
Ishikawa 2 0,92 nd nd nd nd nd 
ECC-1 0.29 nd 0,33 0,22 0,26 0,42 
T47D 0.02 nd 0,33 0,06 0,05 0,16 
benign sample 36 0.33 nd 0,22 0,06 0,74 0,41 
tumour sample 54 0.56 nd 0,26 0,05 0,74 0,47 
tumour sample 55 0.27 nd 0,42 0,16 0,41 0,47 
logarithmic transformed raw data were plotted in XY-scatter charts, regression analysis was 
performed and R-squared values were calculated using Microsoft Excel 97 software. nd=not 
determined. 
Identification of similarity 
All the hybridization experiments were evaluated in pairs (Figure 3.2). 
R-squared values (=Pearson correlation coefficient) were calculated. The 
R-squared value (R1-value) represents the variation of data around the 
least-squares regression line. Therefore the R2-value can be considered as a 
quantification of similarity between compared data. Table 3.1 gives a sum-
mary of the R2-values. Interesting trends are seen in the R2 -values (Table 3.1). 
Comparing the benign endometrial tissue sample with the two endometrial 
carcinoma tissue samples, resulted in R1=0,74 and R2=0.41 respectively. A 
higher degree of similarity in the gene expression fingerprint was found be-
tween the endometrial samples (tissue and cell line) (average R'~0.36 ±0.13) 
than between the endometrial samples (tissue and cell line) and the breast 
cancer cell line (average R2~0.12 ±0.12), implicating the existence of a tissue 
specific gene expression fingerprint. 
Specific gene expression 
Using the xy-scatter plot and 9 5% prediction interval around the least-squares 
regression line, differentially expressed genes were identified. Comparing the 
benign endometrial tissue gene expression fingerprint with the gene expres-
sion fingerprints taken from endometrial carcinoma tissue and cell lines, 
three consistently differentially expressed genes were identified (Table 3.2): 
TIMP3 and Decorin are down-regulated in all the carcinoma samples (tissue 
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Table 3.2: Endometrial housekeeping genes and differentially expressed genes. 
tumour tumour benign 
Ishikawa ECC-1 sample sample sample T47D 
55 54 36 
Cyclin X X X X X 
CD9 X X X X X 
GRB-2 isoform X X X X X 
c-myc binding protein X X X X X 
c-myc transcription factor (PUF) X X X X X 
BIGH-3 X X X X X 
Notch 2 X X X X X 
Hepatoma-derived growth factor X X X X X 
FAU X X X X X 
Cyclin Dl;BCL-1 oncogene X X X X 
Decorin X 
TIMP3 X 
Gene expression was defined as a hybridisation signal extending the value of two times the 
background signal and are represented by x. 
samples and cell lines), Cyclin D1 is up-regulated in the carcinoma samples, 
except for the endometrial carcinoma tissue sample 54 (Figures 3.2 B and 
3.2 C). These three genes may represent important genes involved in the pro-
gression of endometrial carcinomas. Another group of genes, which showed 
expression at similar levels in all endometrial samples, was identified (Table 
3.2). None of these genes was expressed in the human breast cancer cell 
line T47D. These genes seem to represent endometrial housekeeping genes. 
Comparing the breast cancer cell line T47D with the endometrial carcinoma 
samples (tissue and cell line) (Figure 3.2 D) revealed too many differences 
(R2~0.12 ±0.12; Table 3.1) in gene expression pattern; therefore identifica-
tion of differential expressed genes was not possible (see discussion). 
DISCUSSION 
The expression level of all the 588 genes on the eDNA expression array plus 
the 21 positive and negative control dots were used in the analysis. The 
majority of the gene expression level signals did not exceed two times the 
background hybridization signal level (Figure 3.1). In the xy-scatter plot the 
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least-squares regression line will be highly determined by these signal levels. 
As long as a high degree of similarity exists between the expression pattern 
of the array experiments, the slope value a (in the least-squares regression 
line y=ax+b) can be considered to represent the differences in hybridization 
intensity and the intercept value b to represent the differences in back-
ground signal. Therefore, raw data, obtained from eDNA expression array 
hybridization experiments, can be analyzed without the need of preceding 
normalization of the data (Figure 3.2 A, 3.2 B, 3.2 C). In the same instance 
differentially expressed genes can be identified using a 9 5% prediction inter-
val around the least-squares regression line. The R2-value of the least-squares 
regression line quantifies the degree of similarity. However, when little simi-
larity exists between the compared expression patterns, resulting in a low 
R2-value, the least-squares regression line will be almost randomly chosen. 
Example of this situation is seen in the comparison between the gene expres-
sion fingerprint of the T47D cell line and the endometrial carcinoma tissue 
sample (Figure 3.2 D). Differentially expressed genes cannot be identified in 
this case. The lowest R2-value at which the least-squares regression line and 
9 5% prediction interval around the regression line can be used to identify 
differentially expressed genes has yet to be established. 
A higher degree of resemblance exits between the endometrial samples 
(tissue and cell line samples), than between the endometrial samples and 
the breast cancer cell line, implicating a basic endometrial gene expression 
fingerprint. As tumor behavior is thought to be driven by genetic alterations, 
it is plausible that clinical behavior of carcinomas can be reflected in their 
specific gene expression fingerprints (Blok et a!., 1999; Blok et a!., 1995; 
Chang eta!., 1997). Taking this one step further, a database could be con-
structed containing gene expression fingerprints of various endometrial car-
cinoma tissue samples of different clinical stage, different histological grade 
and different progesterone and estrogen receptor status linked to informa-
tion on clinical follow-up. Comparing the gene expression fingerprint of an 
uncharacterized tumor sample of interest with the database could reveal the 
potential clinical behavior of the uncharacterized tumor. A table of R2-values, 
as shown in Figure 3.2, could be used to establish the degrees of similarity 
between the tumor samples. Using the eDNA expression array to reveal de-
grees of similarity between uncharacterized tumor samples of interest and 
tumor samples of known clinical behavior could have great potential value 
in the diagnosis and prognosis of endometrial cancer. However, to confirm 
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the potential value of the eDNA arrays as a diagnostic and prognostic tool, a 
gene expression fingerprint database of a large group of fully characterized 
endometrial carcinoma tissue samples should be constructed and analyzed. 
The current investigation may provide a practical and useful method to ana-
lyze these data. 
Comparing gene expression fingerprints of different tumor samples will 
also identify differentially expressed genes. Using the xy-scatter plot analysis 
and the 95% prediction interval around the least-squares regression line, 
three genes (Decorin, TIMP3 and Cyclin D1) were identified to be differen-
tially expressed between benign endometrial cells and endometrial carcino-
ma cells. Decorin (smallleucin rich protoglycan) inhibits TGF~ and induces 
p21 resulting in inhibition of proliferation (Iozzo et a!., 1999; Stander eta!., 
1999). TIMP3 (tissue inhibitor of metaloproteinase number 3) inhibits the 
matrix metaloproteinases MMPs. Excess of MMPs stimulates tumor inva-
sion and metastasis (Kugler, 1999; Sato eta!., 1992). Cyclin D1 initiates the 
G1-S phase progression (Chen eta!., 1998). Estrogens are found to induce 
nuclear localization of Cyclin D1 in endometrial cells resulting in increased 
cell proliferation (Tong & Pollard, 1999). In breast cancers Cyclin D1 can act 
as an oncogene (Russell et a!., 1999) and is found to act as a CDK-indepen-
dent activator of the estrogen receptor in breast epithelial cells (Zwijsen et 
a!., 1997). The loss of Decorin and TIMP3 expression and the gain of Cyclin 
D1 expression in the endometrial carcinoma cell lines and tissue samples 
could indicate an important role of Decorin, TIMP3 and Cyclin D1 in the 
development and progression of endometrial cancer. However, the number 
of samples analyzed is too small to draw conclusions. 
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Summary 
Recently, gene expression profiling techniques have been used on several human cancers to classify tumor-
subgroups with specific biological behavior, which were previously undetected by the conventional his-
topathologic staging systems. In the current study the clinical usefulness and diagnostic value of gene expres-
sion profiling in human endometrial carcinomas was studied. The Atlas Human Cancer eDNA array, containing 
cDNAs of 588 genes selected from different areas of cancer research, was used to generate gene expression 
profiles of tumor tissue samples. The gene expression profiles of twelve endometrial cancers, three benign 
(e.g. non-cancer) endometrial tissue samples and three myometrial tissue samples, taken from human surgi-
cal specimen, were compared. The efficacy to generate a gene expression profile of these tissue samples was 
77%.The RNA samples could be randomly taken from the tissue samples and were highly reproducible. Cluster 
analysis of the gene expression profiles of the different samples showed that the benign endometrial and the 
myometrial samples clustered separately from the tumor samples, indicating that the gene expression pro-
files were tissue specific and not patient specific. Cluster analysis of the tumor samples revealed two distinct 
tumor clusters. The ranking of the tumors in the two clusters showed high similarity with the histopathologic 
classification (FJGO grading), indicating that the diagnostic value of classification of endometrial tumors on 
basis of their gene expression profiles can be at least as accurate as the FIGO grading system. 
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INTRODUCTION 
Endometrial cancer ranks among the most common gynecologic malignancies 
in the Netherlands and North America, alongside ovarian cancer (Bristow, 
1999) (Central Office of Statistics of the Ministry of Public Health of The 
Netherlands 1999). In order to predict prognosis and to select optimal thera-
peutic regimes, endometrial carcinomas are divided into subgroups. A surgi-
cal and histological staging system of the International Federation of Gyne-
cology and Obstetrics (FIGO) (Pecorelli et al., 1999)(http:/ /www.figo.org) 
is at present the golden standard. However, patients with the lowest surgi-
cal-pathological stage, stage 1, have a 5-years survival rate of 83%, indicating 
that 17% of stage 1 patients are misguidedly taken to have a good prognosis 
(Abeler & Kjorstad, 1991). Moreover, several studies have shown that the 
prognosis of patients with endometrial cancer is correlated with various fac-
tors other than FIGO stage. Morphometric nuclear grade (Salvesen et al., 
1998), lymph-vascular space invasion (Feltmate et al., 1999), DNA ploidy 
(Evans & Podratz, 1996; Lim et al., 1999), estrogen/progesterone receptor 
status (Creasman, 1993) and p53 overexpression (Soong et al., 1996) have 
been shown to be independent prognostic factors. 
With the development of the eDNA array technology, a method has be-
come available to study the expression levels of a large range of genes in one 
hybridization, requiring only a small amount of RNA. Using this technique, 
a gene expression profile of a single tissue sample can be made. Comparisons 
of gene expression profiles have been performed in several different human 
cancers. These studies show that gene expression profiles can identify tumor-
subgroups with specific biological behavior, which were previously undetect-
ed by the histopathologic staging systems (Alizadeh et al., 2000; Alon et al., 
1999; Perou et al., 2000; Shim et al., 1998; Sorlie et al., 2001). 
Integration of factors related to the biological behavior of the tumor, such 
as gene expression profiles, in order to facilitate an estimation of individual 
prognosis seems promising and may lead to a more accurate classification 
system and better therapeutic regime of cancers. So far, the recent study of 
Mutter et al., (Mutter et al., 2001) is the only report on gene expression pro-
filing in endometrial cancer . Using an Affymetrix GeneChip array, they have 
found that gene expression patterns of endometrial carcinomas resemble 
proliferative rather than secretory normal endometrium. However, neither 
the issue of the diagnostic value of gene expression profiling in endometrial 
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carcinomas nor the feasibility of gene expression profiling techniques in a 
clinical setting was addressed by Mutter eta!., (Mutter eta!., 2001). In the 
current study we investigated the utility and diagnostic value of gene expres-
sion profiling in human endometrial cancers. 
MATERIALS AND METHODS 
Tissue samples 
Between 1997 and 2001 endometrial carcinoma tissue samples were ob-
tained from patients attending hospital for treatment of endometrial cancer 
(department of Obstetrics & Gynecology of the Erasmus Medical Center 
Rotterdam and department of Obstetrics & Gynecology of five affiliated hos-
pitals (Saint Franciscus Hospital Rotterdam, Medical Center Rijnmond Zuid 
(location Clara) Rotterdam, lkazia Hospital Rotterdam, Reinier de Graaf 
Group Delft and Albert Schweitzer Hospital Dordrecht), following approval 
by the human subjects review boards of the participating hospitals. When 
possible, benign endometrial and myometrial samples were taken from the 
same patients. Also benign endometrial samples from hysterectomy material 
of patients with uterine myomas or menstrual bleeding disorders without 
a uterine carcinoma were collected. The histological type and grading were 
established on the hysterectomy specimen, by the department of Pathology 
of the participating hospitals, according to the modified FIGO staging system 
(Pecorelli eta!., 1999)(http://www.figo.org). Directly after removal of the 
uterus from the body, tissue samples with macroscopically high percentage 
of the tissue of interest (tumor, benign endometrium or myometrium) were 
located, excised and flash-frozen in liquid nitrogen. Sandwich sections were 
made of these flash-frozen samples. The parts of the flash-frozen samples in 
between the sandwich sections were used for total RNA isolation. The sand-
wich sections were hematoxylin and eosin stained to analyze microscopically 
the percentage of tumor, benign endometrial or myometrial cells in the stud-
ied samples. The percentage was established by placing a 100-point grid on 
representative areas of the sandwich sections, and identifying the cell type of 
the tissue fragment underlying those points. Only tissue samples containing 
more than 80% of the indicated tissue were used in this study. 
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RNA isolation 
Total RNA was isolated from the tissue specimen following the instructions 
of the protocol PT3231-1, advised to use in combination with the Atlas Hu-
man Cancer eDNA expression array by Clontech Laboratories, Inc. (Palo 
Alto, California, USA). The quality of the total RNA (intact RNA) was judged 
on northern blot by ethidium bromide staining. 
Atlas Human Cancer eDNA expression array 
The Atlas Human Cancer eDNA expression array (7742-1) was purchased 
from Clontech Laboratories, Inc. (Palo Alto, California, USA). eDNA ar-
rays were supplied containing 588 cancer related human eDNA's spotted 
as duplicates on nylon membranes. A list of the genes spotted on the ar-
ray, including array coordinates, is available at Clontech's web site http: 
//www.clontech.com. Ten arrays were used, derived from two different lots. 
Each array was stripped and re-used at a maximum of three times. 
eDNA synthesis and hybridization 
Total RNA was reverse transcribed into eDNA using a mixture of array 
gene-specific primers and was labeled with 32P-dATP. Probe purification and 
hybridization to the array was performed following the array's user manual. 
The array was exposed to a phosphor-imaging screen at room temperature 
for 24 hours and scanned using the Phosphor Imager (Molecular Dynamics, 
Sunnyvale). The results were quantified using lmageQuant software (Mo-
lecular Dynamics, Sunnyvale). A grid was applied to the image of the blot to 
quantify the intensity of hybridization of every spot. According to the Array 
manufacturer (Clontech Laboratories, Palo Alto, CA), the radioactive eDNA 
signal is linear for RNAs present at levels of 0.01-3% of the total RNA popu-
lation. Saturation of the hybridization signal was not observed. 
Analysis of the eDNA expression array data 
Reproducibility of hybridization 
Hybridization of one eDNA pool to two different array membranes showed 
that gene expression profiles, obtained using the eDNA array technique, are 
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highly reproducible (Smid-Koopman et al., 2000). 
Cluster analysis 
The Cluster® software, a hierarchical cluster algorithm, was used to compare 
the gene expression patterns of the different tissue samples. The Cluster and 
Tree View® software is created by Michael Eisen et al (Eisen et al., 1998) and 
is available at http:/ /rana.stanford.edu/software. This cluster algorithm is 
an unsupervised pair-wise average-linkage cluster method and clusters both 
genes and arrays (the algorithm is described in a paper by Michael Eisen et al 
(Eisen et al., 1998) and in the manual provided with the software at http:/ I 
rana.stanford.edu/software). The complete linkage clustering for both genes 
and patients was used. No filter was applied. To compensate for possible 
variations in overall hybridization intensity between the different arrays, the 
intensity of expression level of each eDNA on each array was multiplied by 
the quotient of the sum of expression levels of all genes on that array with 
the average sum of expression levels of all genes for all the arrays. 
RESULTS 
Utility of the Atlas Human Cancer eDNA expression array on human 
endometrial cancer tissue samples 
To examine the feasibility of gene expression profiling as a clinical tool, we 
studied the efficacy, reproducibility and specificity of gene expression profiles 
of human tissues obtained from surgical specimen. We used a commercial 
available macro eDNA array, as the costs are relative low and the technique 
relatively easy to apply. 
Efficacy 
Materials from a human tissue bank, containing endometrial carcinoma, 
myometrial and benign endometrial tissue samples (see Materials and Meth-
ods), were used to generate gene expression profiles of the indicated human 
tissues. Sandwich sections were made of these samples to establish the per-
centages of tumor tissue, benign endometrial epithelium and myometrium 
tissue in the samples. 88% of the tested samples appeared to contain >80% 
of the indicated tissue, and were subsequently used to isolate total RNA. Of 
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these samples 94% generated quantitative and qualitative good (intact) total 
RNA to be used on the Atlas Human Cancer eDNA Array. Generally, 50 mg 
tissue (approximately 15 sections of 30 ).liD) generated 30 ).lg total RNA. One 
hybridization to an Atlas Human Cancer eDNA array membrane required 
approximately 10 ).lg total RNA. The efficacy to perform successful hybridiza-
tion to the array membrane could, in our hands, be optimized to 93%. All to-
gether, the efficacy to generate a gene expression profile from a sample taken 
from a surgical specimen was found to be 77% and appeared to be mainly 
determined by the efficacy of tissue sampling from the surgical specimen. 
Reproducibility 
The tissue bank contained tissue samples from surgical specimen. Macro-
scopically judged, samples containing high percentage of the indicated tissue 
were excised from the surgical specimen and flash-frozen in liquid nitrogen. 
Sections were randomly taken from these tissue samples to isolate RNA. To 
determine whether a gene expression profile, characteristic for an individual 
tumor (or tissue), can be generated from randomly chosen sections taken 
from a tumor (or tissue) sample, two different sections were taken from the 
same tumor sample (patient 42). Total RNA was isolated from these two 
sections and hybridized to two different array membranes. The gene expres-
sion pattern of the nineteen different tissue samples were compared and 
subsequently clustered using a hierarchical cluster algorithm (Cluster® soft-
ware) (Figure 4.1). The two sections from the tumor of patient 42 clustered 
together and showed the highest correlation coefficient. This indicates that 
a gene expression profile, specific for an individual tumor, can be generated 
from different, randomly chosen, parts of the tumor. 
Specificity 
Gene expression profiles generated from the same patient but from different 
tissues, e.g. endometrial carcinoma vs. myometrium (Figure 4.1: patients 48, 
55, and 59) did not cluster together. This indicates that the gene expression 
profiles generated were tissue specific and not patient specific. 
Classification of human endometrial tumor samples using cluster 
analysis on their gene expression profile 
To study the possible prognostic value of gene expression profiling in hu-
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Figure 4.1: Hierarchical clustering of gene expression patterns of 588 
cancer related genes in twelve endometrial carcinoma tissue samples, 
three benign (non-cancer) endometrial tissue samples and three 
myometrial tissue samples. The gene expression data was analyzed 
by hierarchical clustering (using Cluster® software) and the results were 
visualized by using Tree View® software. Each column represents a single 
tissue sample and each row represents a single gene. The expression levels 
of the genes are reflected by a color, ranging from black (no expression) to 
bright red (highest expression).The clustering was performed for both the 
tissue samples and the genes. A) The vertical dendrogram shows the clus-
tering of the 588 genes over the different tissue samples. The pink branch 
indicates the selected endometrial-cancer-specific genes cluster. In B) the 
horizontal dendrogram, representing the clustering of the tissue samples, 
is shown, together with the selected endometrial-cancer-specific gene 
cluster. The two distinct tissue clusters are colored; green = cluster I and 
red =cluster II. Each tissue sample has been numbered (patient number), 
and the nature of the tissue sample and of the tumor samples are men-
tioned (benign = non-cancer endometrial tissue, myom = myometrial 
tissue, G = Histological Grade of the endometrial carcinoma tissue (FIGO 
Staging system), 5 = Surgical Stage of the endometrial carcinoma tissue 
(FIGO Staging system)). 
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Figure 4.2: Hierarchical clustering of gene expres-
sion patterns of 588 cancer related genes in twelve 
endometrial carcinoma tissue samples and three 
benign (non-cancer) endometrial tissue samples. A) 
The vertical dendrogram shows the clustering of the 588 
genes over the different tumor samples. The pink branch 
indicates the selected endometrial-cancer-specific 
genes cluster. In B) the horizontal dendrogram, repre-
senting the clustering of the tissue samples, is shown, 
together with the selected endometrial-cancer-specific 
gene cluster. The two distinct tissue clusters are colored; 
green =cluster l and red =cluster II. Each tissue sample 
has been numbered (patient number), and the nature of 
the tissue sample and of the tumor samples are men-
tioned (benign = non-cancer endometrial tissue, G = 
Histological Grade of the endometrial carcinoma tissue 
(FIGO Staging system),S =Surgical Stage ofthe endome-
trial carcinoma tissue (FIGO Staging system)). 
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Figure 4.3: Hierarchical clustering of gene expression pat~ 
terns of 588 cancer related genes in twelve endometrial 
carcinoma tissue samples. A) The vertical dendrogram shows 
the clustering of the 588 genes over the different tumor samples. 
B) The horizontal dendrogram shows the clustering of the tumor 
samples. The two distinct tumor clusters are colored; green= clus-
ter! and red= cluster II. The tumor samples:patient42 and patient 
19 are not colored (black) as they did not belong to any cluster. 
Each tumor sample has been numbered (patient number); and 
the FIGO Grade and Stage is mentioned (G = Histological Grade, 
S =Surgical Stage). 
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Table 4.1. Clinicopathologic features of the tissue samples. 
Age Tissue type Grade Stage Follow-up 
(years) (years) 
Patient9 75 Endometrioid adenocarcinoma 1 1B 3Y2 
Patient 15 73 Endometrioid adenocarcinoma 2 3A 3 
Patient 17 41 Benign I uterine myomas 
Patient 19 97 Endometrioid adenocarcinoma 1 1B 3 
Patient 26 77 Endometrioid adenocarcinoma 3 1B 2Y2 
Patient 42 53 Endometrioid adenocarcinoma 1A 2 
Patient42B 53 Benign endometrium epithelium 
Patient48 71 Endometrioid adenocarcinoma 1B 2 
Patient48M 71 Myometrium 
Patient 55 63 Endometrioid adenocarcinoma 3 1( llf2 
Patient SSM 63 Myometrium 
Patient 56 71 Papillary serous adenocarcinoma 2 3C 1 Y2 
Patient 57 72 Papillary serous adenocarcinoma 2 1B 1% 
Patient 59 67 Endometrioid adenocarcinoma 1B 1% 
Patient 59M 67 Myometrium 
Patient 63 71 Endometrioid adenocarcinoma 2 1B 
Patient 65 69 Endometrioid adenocarcinoma 2 1B 
Patient66 43 Benign endometrium epithelium 
Age is the age of the patient at time of surgery. Tissue type indicates the histopathologic 
evaluation of the tissue samples. Grade indicates the histological grade ofthe tumors according to 
the modified FIGO staging system (Pecorelli et al., 1 999) (http://www.figo.org).Stage indicates the 
surgical stage ofthe tumors according to the modified F!GO staging system.Foffow-up indicates 
the years of clinical follow up.- indicates not applicable. 
man endometrial cancers, we used a hierarchical cluster algorithm; Cluster® 
software (available at http:/ /rana.stanford.edu/software) to sort the tumor 
samples based their gene expression pattern. 
Classification of the tumor samples 
The Cluster® analysis revealed two distinct tumor clusters (I= green and II = 
red) (Figure 4.2). Two tumor samples did not belong to any cluster (patient 
42 and patient 19 ~black). The division of the tumors between the two clus-
ters showed high similarity with the histopathologic classification (FIGO 
grading) of the tumors (Table 4.1, Figures 4.1-4.3). Cluster II (red) includes 
Grade 2 and Grade 3 tumors, whereas cluster I (green) contains almost ex-
clusively Grade 1 tumors (except for patient 6 5 which has been classified 
as a Grade 2 tumor) (Figure 4.2). The two separate placed tumors (patient 
42 and patient 19; black) are both Grade 1 tumors. Remarkable, the Grade 
2 tumors in cluster B (red) appear to be either of papillary serous histologi-
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cal subtype (patient 56 and 57) and/or of a high surgical stage (patient 15) 
(with exception of patient 63; being a Grade 2 Stage 1b tumor). Moreover, 
the Grade 2 tumor (patient 65) in cluster I (green) is of a low surgical stage. 
These results seem to indicate that the two cluster groups represent tumors 
with specific clinical behavior: cluster II (red) containing tumors with a less 
favorable prognosis compared to the cluster I (green). 
The tumor samples of patient 19 and patient 42 (black) had the lowest 
correlation coefficient with the other tumors in the "only tumors" cluster-
ing (Figure 4.2). In the "all samples" clustering (Figure 4.1) these two tumor 
samples (patient 19 and 42, black) did not belong to any cluster, neither did 
the benign endometrium or the myometrium samples. 
So far, the follow-up of the patients (Table 4.1) has been to short (0-3 1/z 
years) to draw conclusions about the prognostic value of gene expression 
profiling in endometrial cancers. Nevertheless, the present results indicate 
that classification of endometrial tumors using gene expression profiles 
highly resemble classification on basis of the FJGO grading system. 
Stability of the classification 
When entering the benign samples in the clustering, all these benign samples 
clustered outside the tumor cluster and moreover, the tumor clustering was 
not altered (Figure 4.3). Even more, when entering also the myometrium 
samples in the clustering, the tumor clustering was not altered either (Figure 
4.1). This observation supports the stability of the classification. 
The fact that the benign and myometrial samples cluster apart from the 
tumor samples is a further support for the tissue specificity of the gene ex-
pression profiles. 
Identifying endometrial carcinoma specific gene clusters 
To identify genes possibly involved in the development and/ or progression 
of endometrial carcinoma, Cluster® analysis was performed on the genes; 
sorting the genes on basis of their expression pattern in the different tumor 
samples and in the benign and myometrial samples. One endometrial-cancer-
specific gene cluster was identified, containing eight genes down-regulated 
in most tumor samples compared to the benign and myometrial samples 
(Figure 4.1). This cluster consists of genes involved in cellular growth regula-
tion or in controlling cell motility and cell invasion. One of the genes in this 
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cluster is the PDGF-alpha receptor. Down-regulation of this PDGF-alpha 
receptor is known to be important for creating the immortalized phenotype 
of human cancer cells. 
Sorting the genes on basis of their expression pattern in the different 
tumor and benign samples but excluding the myometrium tissue from the 
cluster analysis revealed that the PDGF-alpha receptor is part of an even big-
ger gene cluster (Figure 4.3). This gene cluster consists of nineteen genes, all 
involved in cellular growth regulation or in controlling cell motility and cell 
invasion. Even more, this cluster contained 75% of the genes of the earlier 
mentioned gene cluster (Figure 4.1), supporting the suggested specificity of 
these genes for endometrial cancer tissue. 
It was not possible to identify one or more genes specific for one of the 
tumor subgroups (Figure 4.2). 
DISCUSSION 
In the current study it is shown that, using a commercially available eDNA 
array technique, which is relatively low in cost and easy to use, it is possible 
to generate a tissue specific gene expression profile from surgical specimen 
in 77% of the cases. This indicates the possible utility of gene expression pro-
filing in a clinical setting. The efficacy to generate a gene expression profile 
of a tumor appeared to be mainly determined by the efficacy of the tissue 
sampling from the surgical specimen. 
To interpret the possible biological information present in the gene ex-
pression patterns, we analyzed the gene expression data using a hierarchical 
cluster algorithm. Cluster analysis is an exploratory data analysis tool to sort 
cases (people, things, events, etc) into groups, or clusters, in which the de-
gree of association is strong between members of the same cluster and weak 
between members of different clusters. Cluster analysis is used in many dif-
ferent fields of research (e.g. economics, social science and biology). Several 
molecular biology research groups have used the cluster analysis in combina-
tion with gene expression profiling to classify tumors (Alizadeh et al., 2000; 
Alon et al., 1999; Perou et al., 1999; Perou et al., 2000; Sorlie et al., 2001; 
van 't Veer et al., 2002). Moreover, it was found that classification based 
on cluster analysis of gene expression patterns can be used as a prognostic 
marker with respect to overall and relapse-free survival in patients, even in 
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a subset of patients that was classified in the same group using traditional 
histological classification systems (Alizadeh et al., 2000; Sorlie et al., 2001; 
van 't Veer et al., 2002). Molecular classification of tumors on the basis of 
gene expression may thus identify previously undetected but clinically signif-
icant subtypes of cancer. The current study is the first report addressing the 
diagnostic and prognostic value of gene expression profiling in endometrial 
carcinomas and shows that endometrial tumor clusters, identified by gene 
expression profiling, highly resembles the FIGO grading system. However, 
whether gene expressing profiling is more accurate in predicting prognosis in 
endometrial carcinomas compared to the FIGO classification system is not 
yet possible to determine. So far, the follow-up of the patients studied is too 
short and the group to small to draw conclusions. 
Using gene expression profiling, some researchers have been able to 
identify tissue specific gene clusters (Alizadeh et al., 2000; Golub et al., 
1999; Mutter et al., 2001; Perou et al., 1999; Perou et al., 2000). In endo-
metrial carcinomas Mutter et al., (Mutter et al., 2001), using an Affymetrix 
GeneChip array, have found gene expression patterns of endometrial tumors 
to resemble proliferative rather than secretory normal endometrium. In the 
current study an endometrial-cancer-specific gene cluster was identified. The 
genes in this cluster were down-regulated in the endometrial cancer tissues 
compared to the normal endometrial tissues. 
Two genes in the endometrial-cancer-specific gene cluster are of special 
interest, as they are known to be progesterone regulated (insulin-like growth 
factor binding protein 3 (IGFBP3) and integrin alpha ?B). Endometrium is 
a highly hormonal sensitive tissue; proliferation is stimulated by estrogens, 
while progesterone inhibits proliferation and stimulates differentiation (Cle-
mens et al., 1979; Siiteri et al., 1977; Song & Fraser, 1995). Because of its 
ability to induce differentiation, progesterone can be used to suppress growth 
of endometrial cancer cells (Ehrlich et al., 1981). We have found IGFBP3 and 
integrin alpha 7B to be progesterone regulated in specific endometrial cancer 
sub-cell lines (IGFBP3 was down-regulated by progesterone in an Ishikawa 
sub-cell line expressing only progesterone receptor B and integrin alpha 7B 
was up-regulated by progesterone in an Ishikawa sub-cell line expressing only 
progesterone receptor A) (Smid-Koopman et al., in preparation). Bicsak et al. 
(Bicsak et al., 1990) found IGFBP3 to inhibit granulosa cell proliferation in 
rat ovaries and subsequently to inhibit estradiol and progesterone production 
by the granulosa cells. Down-regulation of IGFBP3 has been found to inhibit 
Utility and diagnostic value of gene expression profiling 
apoptosis (Baxter, 2001; Butt et al., 1999; Grimberg & Cohen, 1999; Shen 
et al., 1999). Furthermore, IGFBP3 down-regulation has also been correlated 
with worst prognosis in ovarian cancer (Katsaros et al., 2002). Decline of 
integrin expression has more frequently been found in poorly differentiated 
endometrial cancers and is associated with metastatic nodal spread (Lessey 
et al., 1995). 
In the current study, it was not possible to find gene clusters associated 
with histological grade or clinical stage of the tumors. This may be due to the 
fact that, in contrast to the earlier mentioned studies (Alizadeh et al., 2000; 
Golub et al., 1999; Perou et al., 1999; Perou et al., 2000) which used micro-
arrays containing thousands of genes, the current study used a selected group 
of only 588 genes. Furthermore, only a small number of tumor samples were 
used in the current study. Increasing the number of endometrial tumor 
samples to generate expression profiles will probably increase the chance of 
finding specific clusters associated with a certain histological grade. 
In conclusion, the current study has established the clinical feasibility 
of the eDNA array technique to generate gene expression profiles of endo-
metrial carcinoma tissue samples. The prognostic value of classification of 
endometrial tumors on basis of their gene expression pattern is at least as 
powerful as the FIGO grading system. Classification of endometrial tumors 
on basis of their gene expression pattern seem to have the potential to serve 
as a classification system more accurate in predicting the biological behavior 
of the tumors than the histopathologic FIGO classification. However, char-
acterization of the gene expression profile of a large number of endometrial 
tumors, combined with a long-term clinical follow-up, is needed to confirm 
this hypothesis. 
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Summary 
High doses of progesterone are used in the treatment of advanced and recurrent endometrial cancer. Unfor-
tunately the response rate is relatively low: 10-30%. The mechanisms involved in the development of insen-
sitivity to progesterone treatment of endometrial cancer tissue are largely unknown. As tumor development 
is thought to be associated with a cascade of genetic alterations, it can be expected that genetic changes are 
involved in the development of progesterone insensitivity in endometrial carcinomas. We therefore started 
an investigation to identify, isolate and characterize progesterone-regulated genes involved in progesterone 
induced growth inhibition in endometrial carcinoma cells. Using differential display PCR eight progesterone 
regulated eDNA clones were identified in endometrial carcinoma cell lines. Four of these progesterone regu-
lated eDNA clones were regulated in the for growth progesterone sensitive cell line IK-3H12and not regulated 
in the for growth insensitive cell line ECC-1. This indicates that these four eDNA clones represent potentially 
important genes, which could be involved in inhibition of growth of endometrial carcinoma tissue by proges-
terone. 
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INTRODUCTION 
Endometrial cancer is the most common gynecologic malignancy, and is 
usually diagnosed at an early stage (Schottenfeld, 199 5). Standard therapy in 
these cases includes abdominal hysterectomy with bilateral salpingo-oopho-
rectomy, sometimes followed by radiotherapy. In most patients this therapy 
is curative (Maneschi et al., 1992). However patients with recurrent disease 
after treatment or patients who have an advanced disease at the beginning of 
treatment (FIGO stage III/IV), have a poor prognosis. Hormonal treatment is 
optionally given to these patients, with response rates of only 10-30% (Lentz, 
1994). In contrast to hormonal treatment of advanced/recurrent endome-
trial carcinomas, the treatment of benign functional endometrial disorders 
and endometrial hyperplasia with progestins is very successful (Lindahl & 
Willen, 1991). It seems that at some stage in the progression of endometrial 
carcinomas, sensitivity to progesterone treatment is lost. The transition from 
hormone sensitive to hormone insensitive tumor growth may be associated 
with genetic alterations (e.g. activation of oncogenes and/or inactivation of 
tumor suppressor genes) (Fearon & Vogelstein, 1990; Knudson, 1993). In 
order to obtain more insight into the molecular mechanisms responsible for 
progesterone insensitive tumor growth, we started to identify, isolate and 
characterize progesterone regulated genes which are differentially expressed 
betvveen the for growth progesterone sensitive endometrial carcinoma cell 
line IK-3H12 and the for growth progesterone insensitive endometrial car-
cinoma cell line ECC-1. In order to do so, a differential display PCR method 
was used (Chang eta!., 1997). With this method several genes were identi-
fied which could be involved in progesterone regulated growth inhibition of 
endometrial carcinoma cells. This insight in molecular mechanisms involved 
in progesterone insensitive tumor growth may lead to new tools for better 
recognition and treatment of progesterone insensitive endometrial carcino-
mas. 
MATERIALS AND METHODS 
Materials 
The synthetic progesterone Medroxyprogesterone-acetate (MPA; Sigma 
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Chemical Co., St Louis, USA) was used at 10·6M concentration because this 
agent is used at comparable serum concentration in the treatment of patients 
with endometrial cancer. Primers used are from Pharmacia Biotech (Roosen-
daal, The Netherlands). 
Cell Culture 
IK-3H12 cell line was a gift from Dr. Masato Nishida (Japan) and represents 
a well-differentiated human endometrial carcinoma cell line, expressing pro-
gesterone receptors. The ECC-1 cell line is a well-differentiated endometrial 
carcinoma cell line derived from a xenograft of human endometrial carci-
noma tissue, expressing progesterone receptors. The ECC-1 cell line was a 
gift from Dr. P.G. Satyaswaroop (Pennsylvania, USA). The T47D cell line was 
a gift from Dr. B. van der Burg (Hubrecht Laboratory, Utrecht, The Nether-
lands). The T47D cell line is a well-differentiated human breast cancer cell 
line, expressing progesterone receptors. The IK-3H12 and the T47D cell lines 
were maintained at 37°C in DMEM/F12 culture medium supplemented 
penicillin/streptomycin, 10% FCS and 10·'M estradiol. The ECC-1 cell line 
was maintained at 37°C in RPM! 1640 culture medium supplemented with 
penicillin/streptomycin, 10% FCS and 10-9M estradiol. For the experiments, 
cells were passaged into indicated media supplemented with 10% stripped 
FCS (dextran-coated charcoal-treated FCS) replacing non-stripped FCS. Cells 
were cultured for the indicated times with or without 10-6M MPA. 
Progesterone induced growth inhibition 
The three cell lines were cultured in the presence or absence of 10-6M MPA 
for four days. Cells were harvested in 0,1M NaOH and DNA concentration 
was measured. 
Differential display PCR 
The three cell lines were cultured for 0, 8 or 48 hours in the presence of 
10-6M MPA. Total RNA was extracted by lyzing the cells with 3 M litium 
chloride/ 6 M urea (Auffray & Rougeon, 1980). Differential display PCR was 
performed as described by Chang eta!., (Chang eta!., 1997) In short: total 
RNA (ZJ.lg) was reverse transcribed into eDNA using arbitrary primers. PCR 
Differential gene expression in endometrial carcinoma cells 
was performed by amplifying the eDNA with the same or with other arbitrary 
primers. PCR products were separated on a 6% denaturing polyacrylamid gel 
in presence of 8 M urea. The gel was dried and exposed to X-ray film. Differ-
entially expressed bands were excised from the gel and stored at -20°C. 
RESULTS 
The IK-3H12 endometrial carcinoma cell line and the T47D breast cancer cell 
line showed a reduction in growth in response to exposure to 10·6 M MPA. 
The ECC-1 endometrial carcinoma cell line did not show a growth response 
to 10·6 M MPA (Figure 5.1). The IK-3H12 and T47D cell lines therefore rep-
resent for growth progesterone sensitive carcinoma cell lines and the ECC-1 
cell line represents a for growth progesterone insensitive cell line. 
The aim of the present study is to identify, isolate and characterize proges-
terone-regulated genes, which are involved in progesterone induced growth 
inhibition in endometrial carcinoma tissue. A prerequisite for a progesterone 
regulated gene involved in growth inhibition is that it should be progesterone 
regulated in the for growth progesterone sensitive endometrial carcinoma 
ECC-1 IK-3Hl2 T47D 
1 
C MPA c MPA C MPA 
Figure 5.1: Medroxyprogesterone induced growth inhibition. The three indicated cell 
lines were cultured in the presence (gray column) or absence {shaded column) of 1 o.oM MPA 
for four days. Cells were harvested in 0,1 M NaOH and DNA concentration was measured and 
calculated as percentage of control. 
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Table 5.1. Progesterone regulated cDNA~clones in the ECC~1,1K-3H12 and T47D cell 
lines 
Clone nr ECC-1 IK-3H12 T47D 
4 not regulated regulated not regulated 
6 not regulated regulated not regulated 
8 not regulated regulated not regulated 
31 not regulated regulated not regulated 
11 regulated regulated not regulated 
33 regulated regulated regulated 
34 regulated regulated regulated 
35 regulated regulated regulated 
cell line IK-3H12; the gene should not be progesterone regulated in the for 
growth progesterone insensitive cell line ECC-1. 
Eight eDNA clones have been found to be progesterone regulated in the 
progesterone sensitive endometrial carcinoma cell line IK-3H12 (Table 5.1). 
Four of these eight progesterone regulated genes were not regulated in the for 
growth progesterone insensitive endometrial cancer cell line ECC-1 (eDNA 
clone 4, 6, 8, 31). An example of such a eDNA clone is clone 31, which is 
shown in figure 5.2. These genes could be potentially important genes, as 
alterations in the expression or function of these genes could be involved 
in determining the degree of progesterone induced cell growth inhibition in 
endometrial carcinoma tissue. To be able to distinguish between early and 
late responsive genes, the expression of the genes was compared between 8 
and 48 hours exposure to 10·' M MPA. Clones 4, 6, 8 and 31 represent early-
regulated genes. The other four of the eight progesterone regulated eDNA 
clones in IK-3H12 (clone 11, 33, 34 and 35) were found to be regulated in 
both endometrial cancer cell lines (Table 5.1). Furthermore, they appeared to 
be early regulated in the IK-3H12 and late regulated in the ECC-1. 
In order to have some indications that the progesterone regulated genes 
are or are not endometrial carcinoma specific involved in growth regulation, 
the expression in the for growth progesterone sensitive human breast cancer 
cell line T47D was also investigated. None of the four progesterone-regu-
lated genes (eDNA clone 4, 6, 8, 31) appeared to be progesterone regulated 
in T47D, indicating that the involvement of these genes in progesterone in-
duced growth inhibition is tissue specific. Apart from the eight differentially 
expressed eDNA clones in the IK-3H12, thirty-seven clones were differen-
Differential gene expression in endometrial carcinoma cells 
0 Sh 0 Sh 48h 0 Sh 48h 
ECC-1 IK-3Hl2 T47D 
not regulated regulated not regulated 
Figure 5.2: eDNA clone 31: a progesterone regulated gene in IK-3H12 and potentially 
involved in growth inhibition. Indicated cell lines were cultured for 0,8 and 4S hours in the 
presence of 1 0-(;M Medroxyprogesterone. mRNA was isolated and reversed transcribed into 
eDNA using arbitrary primers. The eDNA was amplified with arbitrary primers in presence of 
33P-dATP.The products were separated on a sequencing gel and exposed to X-ray film. 
tially expressed in either ECC-1 or T47D or both. As these fragments are not 
differentially expressed in the for growth progesterone sensitive endometrial 
carcinoma cell line IK-3H12, they do not seem to be involved in growth 
regulation. These genes could be interesting progesterone regulated genes 
involved in cellular mechanisms other then growth regulation. 
DISCUSSION 
As tumor development is thought to be associated with a cascade of genetic 
alterations, it can be expected that genetic changes are involved in the devel-
opment of progesterone insensitivity in endometrial carcinomas (Fearon & 
Vogelstein, 1990; Knudson, 1993). The expression and alterations of some of 
the known oncogenes and tumor suppressor have been studied in endometri-
al carcinoma tissue (Berchuck & Boyd, 1995; Esteller et al., 1997; Jones et al., 
1997). For example the tumor suppressor gene P53 is found to be mutated in 
30% and K-ras, a proto-oncogene, in 20% of the endometrial cancers (Ber-
chuck & Boyd, 1995; Esteller et al., 1997; Jones et al., 1997). Little however 
is known about progesterone regulation of these genes or the involvement 
of these genes in progesterone induced growth inhibition. In order to obtain 
more insight in the molecular mechanism involved in the transition of a 
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for grovvth progesterone sensitive endometrial carcinoma into a for grovvth 
progesterone insensitive endometrial carcinoma, the present study aimed 
to identify progesterone regulated genes in endometrial cancer involved in 
progesterone regulated growth inhibition. With the use of ddPCR eight pro-
gesterone regulated genes have been identified in the for growth progesterone 
sensitive endometrial carcinoma cell line IK-3H12. To be involved in growth 
inhibition these progesterone regulated genes should not be regulated in the 
for grovvth progesterone insensitive endometrial carcinoma cell line ECC-1. 
Four of these eight progesterone-regulated genes appeared not to be regulated 
in the ECC-1 cell line. These genes could be the important genes, involved 
in induction of progesterone regulated growth inhibition. Alterations in the 
function or expression of these genes could result in the development of 
insensitivity of endometrial carcinoma tissue to treatment with progester-
one. Currently these four progesterone-regulated genes are being cloned and 
characterized. Identification and characterization of these genes will provide 
more insight in the molecular mechanism involved in progesterone regula-
tion of growth in endometrial cancer. This insight will help to improve the 
treatment of women with advanced I recurrent endometrial carcinomas. 
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Notes 
1. After this paper was published, sequence analysis revealed that three of the four pro-
gesterone regulated cDNAs matched with knovvn genes ( dsRNA adenosine deami-
nase, ninein, endothelin converting enzyme-1). During characterization of these 
genes, it was observed that the IK-3H12 cells lose expression of the human Proges-
terone Receptor (hPR) rapidly. Further characterization of the genes was therefore 
postponed. Subsequently, IK-3H12 were stably transfected with hPR in order to cre-
ate hPR expressing endometrial carcinoma cell lines (see Chapters 6 and 7). 
2. The genes described in this paper are not included in the Atlas Human Cancer eDNA 
array used for the analysis described in Chapters 6 and 7. 
3. For a discussion of the observations on differential gene expression, see Chapter 8. 
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Summary 
To study the functional differences between the two progesterone receptor isoforms (hPRA and hPRB) in 
human endometrial cancer, two new endometrial carcinoma cell lines were created; one expressing hPRA 
and one expressing hPRB. A well differentiated hPR-negative Ishikawa cell line was stably transfected with 
either hPRA or hPRB cDNA.Transfected cells were selected and two cell lines expressing approximately equal 
amounts of receptor were isolated; one expressing hPRA (PRA-14} and one expressing hPRB {PRB-59). Cell 
growth experiments revealed a growth inhibitory response to progestins {MPA and R5020) in the PRB-59 cells, 
but not in the PRA-14 cells. Differences in expression of genes targeted by the two isoforms were studied 
using a eDNA expression array technique. A different set of genes appeared to be progesterone regulated 
in the PRA-14 cells compared to the PRB-59 cells. None of the genes were regulated by both hPRA and hPRB. 
IGFBP3 expression was studied in more detail as an example of a gene regulated in PRB-59 cells and not in 
PRA-14 cells. In conclusion, a new model to study functional differences between the two hPR isoforms in hu-
man endometrial carcinoma cells has been established. This model revealed distinctive differences in target 
gene regulation between the two hPR isoforms.Moreover,antiproliferative actions of progesterone on human 
endometrial cancer cells could only be observed in the PRB expressing cell line. 
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INTRODUCTION 
The ovarian hormone progesterone plays an important role in controlling 
uterine homeostasis. Progesterone initiates transformation of uterine stro-
mal cells to decidual cells in case of pregnancy (Curtis et a!., 1999) and, 
moreover, is involved in a complex cross talk with estradiol in order to 
control proliferation and differentiation of endometrial epithelium during 
the menstrual cycle. Estrogens stimulate proliferation of the endometrial 
epithelium (Quarmby & Korach, 1984), initiate an inflammatory response 
in the stromal part of the endometrium and induce uterine hyperemia (De 
& Wood, 1990). Progesterone has been found to inhibit these estrogen in-
duced changes of the endometrial epithelium and stimulates glandular and 
stromal differentiation (Martinet a!., 1973). These observations have been 
confirmed in the progesterone receptor (PR) knockout mice model showing 
unopposed estrogen-dependent endometrial epithelium hyperplasia, stromal 
hypocellularity, and uterine inflammation (Lydon et a!., 1996; Lydon et 
al., 1995). Moreover, in clinical settings progesterone is effectively used as 
treatment to reverse endometrial hyperplasia and to decrease the growth of 
endometrial tumors (Ehrlich eta!., 1981). 
Progesterone mediates its effects through its nuclear receptor. The human 
progesterone receptor (hPR) belongs to the super family of nuclear receptors, 
which includes steroid, thyroid hormone, vitamin D, and retinoic acid recep-
tors (Evans, 1988). The hPR exists as two isoforms: hPRA (94 kDa) and hPRB 
(114 kDa) (Horwitz & Alexander, 1983). The hPRA is a truncated form of 
the hPRB lacking the first 164 NH2 -terminal amino acids. Both forms have 
similar DNA and ligand binding affinities (Lessey et a!., 1983). However, 
hPRA and hPRB are not functionally identical. Their relative efficiencies 
to activate target genes appear to vary according to the promoter and cell 
context (Meyer eta!., 1989). Moreover, hPRA has been shown to act as a 
strong trans-dominant repressor of hPRB mediated transcription in specific 
promoter and cell contexts (Vegeto eta!., 1993). 
The two isoforms originate from the same hPR gene by transcription 
regulation by two distinct promoters respectively (Kastner et a!., 1990). In 
human target cells both isoforms are coexpressed, generally at the same level 
(Graham & Clarke, 1997). However, the promoters are regulated indepen-
dently, which can give rise to varying hPRA: hPRB ratio in target tissues under 
certain physiological circumstances (Kastner eta!., 1990; Kraus eta!., 1997). 
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In the endometrium, the hPRA predominates in stromal cells throughout the 
menstrual cycle, whereas in epithelial cells, a shift occurs during the early 
secretory phase from hPRA to hPRB (Mote et al., 1999). The varying ratio 
of the two isoforms among different target cells and different physiological 
circumstances suggests that the differential expression level of PRA and PRB 
may determine the cellular response to progesterone. Using PRA knockout 
(PRAKO) mice, Mulac-Jericevic et al. (Mulac-Jericevic et al., 2000) showed 
that progesterone treatment of these animals resulted in PRB specific gene 
regulation and PRB dependent increase in proliferation of endometrial cells. 
These results indicate that imbalance in the expression and/ or activities of 
the tvvo isoforms can have important consequences for normal endometrial 
development and may play a role in the development of endometrial cancer. 
The suggestion that an imbalance in the hPRA: hPRB ratio can be involved 
in carcinogenesis is supported by the observation that in transgenic mice 
overexpressing PRA, the mammary gland exhibits ductal hyperplasia with a 
disorganized basement membrane and decreased cell-cell adhesion; features 
commonly associated with neoplasia (Shyamala et al., 1998). Moreover, in 
in vivo studies high levels of hPRA were observed in a subset of breast tumors 
(Graham et al., 1995), and in vitro studies have suggested that poorly differ-
entiated endometrial cancers express only hPRA (Kumar et al., 1998). 
To gain more insight in the physiological implications of changing PRA: 
PRB ratios during carcinogenesis, understanding of the distinct effects of 
PRA and PRB on cellular function is essential. So far, insights into the dif-
ferences betvveen PRA and PRB transcriptional activity, have been obtained 
by transient cotransfection of PRA and/ or PRB with reporter constructs or 
by knocking out PRA or both PR isoforms in transgenic mice. Furthermore, 
most of these studies have been carried out in cells that are normally not a 
target cell for progesterone (Kraus et al., 1997; Meyer et al., 1989; Tora et al., 
1988; Vegeto et al., 1993). To study the distinct function of hPRA and hPRB 
on cellular processes in endometrial cancer cells, we stably transfected hPRA 
and hPRB eDNA plasmids into (PR-negative) Ishikawa endometrial carci-
noma cells. The effects of progesterone on cell growth and gene expression 
have been studied in these hPRA and hPRB expressing endometrial cancer 
cell lines. 
Functional differences between hPRA and hPRB 
MATERIALS AND METHODS 
Recombinant Plasmids 
The hPR-cDNA cloned into the pSG5 expression vector was a generous gift 
from Dr. E. Milgrom (Kremlin-Bicetre, Paris, France). This vector was used 
to create hPRA and hPRB expression plasmids, respectively. A 3063 bp eDNA 
fragment encoding hPRB was isolated from pSG5-hPR by excision of the 
EcoR1-Xba1 fragment (the EcoR1 site being artificially introduced at position 
+14 upstream from the first AUG codon). A 2982 bp eDNA fragment encod-
ing hPRA was isolated by excision of the BamH1-Xba1 fragment (the BamH1 
site being a hPR restriction site at position -68 downstream from the first 
AUG codon and +424 upstream from the second AUG codon). Subsequently, 
the hPRA and hPRB eDNA fragments were inserted into the pcDNA3.1 ex-
pression vector (Invitrogen Corporation, Carlsbad, CA), containing a cyto-
megalovirus ( CMV) promoter and a neomycin selection marker. Sequence 
analysis of the created plasmids was performed to verify proper ligation of 
the hPR eDNA fragments into the vector. 
Cell culture 
Ishikawa cells are derived from a well-differentiated human endometrial 
adenocarcinoma (Nishida et al., 1996) and were a generous gift from Dr. 
Masato Nishida (Tsukuba, japan). The T47D cells are derived from well-dif-
ferentiated human breast cancer and were a generous gift from Dr. B. van 
der Burg (Utrecht, The Netherlands). Both cell lines were negative for myco-
plasma contamination, determined using Mycoplasma-Plus-PCR-Primer-Set 
(Stratagene, La jolla, CA). All cells were maintained in DMEM/F12 (Dulbec-
co's modified Eagle's medium/Ham's F12 (1:1 mix) with 15mM Hepes, with 
L-glutamine) supplemented with penicillin/streptomycin; in the presence of 
7.5% fetal calf serum and 10·9 M estradiol in a 37°C incubator with 5% C02 • 
The cells transfected with either hPRA or hPRB were cultured under continu-
ous selection pressure with neomycin (G418: 500 !J.g/ml, Invitrogen Corpo-
ration, Carlsbad). For total RNA isolation (northern blots and microarrays), 
cells were cultured for the indicated time in the presence or absence of 10-6 M 
Medroxy Progesterone Acetate (MPA, Sigma Chemical co., St Louis, MO) in 
DMEM/F12 supplemented with 7.5% dextran-coated charcoal-treated fetal 
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calf serum, 10-9 M estradiol and, for the transfected cells, neomycin at 500 
[!g/mL Total RNA was isolated by lyzing the cells with 3M Lithium chloride/ 
6M Urea as described by Auffray and Rougeon (Auffray & Rougeon, 1980). 
The RNA was purified as described by Blok eta! (Blok et aL, 1995). For the 
growth studies the cells were cultured in DMEM/F12 supplemented with 
7.5% dextran-coated charcoal-treated fetal calf serum, 10-9 M estradiol and 
with different concentrations of Medroxy Progesterone Acetate (MPA, Sigma 
Chemical Co., St Louis, USA) or R5020 (NEN Life Science Products, INC, 
Boston, MA) as is indicated in the legends to the figures. 
Construction of two Ishikawa cell lines stably expressing hPRA and 
hPRB, respectively 
Ishikawa cells were plated into 40 em' culture dishes and cultured to 50% 
confluency. The hPRA-pcDNA3.1+ plasmid, the hPRB-pcDNA3.1+ plas-
mid and the control "empty-"pcDNA3.1+ vector (Invitrogen Corporation, 
Carlsbad, CA) were transfected into the Ishikawa cells using FuGENETM 6 
Transfection Reagent (Roche Diagnostics Co. Indianapolis, IN) following 
instructions provided by the manufacturer. The cells were cultured in the 
presence of the selection marker neomycin (500 [!g/ml) and cloned by lim-
ited dilution. Surviving clones were selected and transferred to 24-well plates. 
Thirty lshikawa-hPRA clones, seventy Ishikawa-hPRB clones and seventeen 
lshikawa-pcDNA3.1 +clones were analyzed for hPR expression by a 3H-R1881-
binding assay. A hPRA clone (PRA-14) and a hPRB clone (PRB-59), showing 
high specific binding to 3H-R1881, were selected and further characterized. 
'H-R1881-binding assay 
The cells were cultured in 6-well plates, under standard conditions as de-
scribed above, to 75% confluency. The cells were incubated with 8nM 3H-
R1881 (NEN Life Science Products, Inc, Boston, MA) in presence or absence 
of 4[!M non-labeled R1881 (NEN Life Science Products, Inc, Boston, MA) 
for 2 h in a 37°C incubator. The cells were washed five times with phosphate 
buffered saline (PBS) at 0°C. The cells were lysed in 1M NaOH for 30 min 
at 60°C. Radioactivity was measured in a liquid scintillation counter and 
protein concentrations were measured using Bradford's reagents. 
Functional differences between hPRA and hPRB 
Hormone binding assay (Scatchard analysis) 
Receptor binding parameters were determined as described under R1881-
binding assay, with the exception that different amounts of 3H-R1881 (16 
nM, 8nM, 4 nM, 2 nM, 1 nM, 0.5 nM, 0.25 nM, 0.125 nM, 0.06 nM, 0.03 
nM, 0.015 nM, 0.008 nM) were used in the presence or absence of 2000-
fold unlabelled R1881. Scatchard plots were constructed using Excel software 
(Microsoft) and Kd and Bm~ values were calculated. 
Northern-blotting 
For total RNA isolation, cells were cultured for 48 hours in the presence or 
absence of 10·6 M Medroxy Progesterone Acetate (MPA, Sigma Chemical co., 
StLouis, MO) in DMEM/F12 supplemented with 7.5% dextran-coated char-
coal-treated fetal calf serum, 10·9 M estradiol and, for the transfected cells, 
neomycin at 500 ~g/ml. Total RNA was isolated by lyzing the cells with 3M 
Lithium chloride/ 6M Urea as described by Auffray and Rougeon (Auffray & 
Rougeon, 1980). The RNA was purified as described by Blok eta! (Blok eta!., 
1995). Northern blotting was performed as described by Chang eta! (Chang 
eta!., 1997). As a probe, to detect JGFBP3 mRNA on the northern blot, a 
2.4 kb EcoR1 eDNA fragment containing the complete mouse JGFBP3 coding 
sequence was used. This eDNA was kindly provided by Dr. S.L.S. Drop (De-
partment of Pediatrics, division of Endocrinology,Erasmus Medical Center 
Rotterdam, The Netherlands). To detect PR mRNA on the northern blot, a 
0.5 kb Bgl1 eDNA fragment was used, containing coding sequence present in 
both the hPRA and the hPRB. The complete hPR eDNA was a generous gift 
from Dr. E. Milgrom (Kremlin-Bicetre, Paris, France). 
Western immuno-blotting 
The cells were cultured as described before to 75% confluency. The cells 
were washed twice with PBS, lysed in RIPA buffer (40mM Tris-HCL (pH 7.4), 
5mM EDTA (pH 8.0), 10% glycerol, 10 mM Sodiumphosphate, 10 mM So-
diummolybdate, 50 mM Sodiumfluoride and 0.5 mM Sodiumorthovanadate 
10mM DTT, 1% Triton, 0.08% SDS, 0.5% Deoxycholate, and protease inhibi-
tors: 6 mM PMSF, 5 mM Bacitracin, 5 roM Leupeptin) and centrifuged for 10 
min at 350.000 g, 4'C. The proteins were separated on a SDS polyacrylamid 
gel and transferred to nitrocellulose (Schleicher & Schuell GmbH, Dassel, 
Germany). The PR (C-20) rabbit polyclonal antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) was incubated with the membrane as follows: The 
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membrane was rinsed with PBS-tween and blocked for 1 h with blocking so-
lution. The PR (C-20) antibody was diluted 1: 2000 in blocking solution and 
incubated with the membrane for 1 h. The membrane was washed four times 
15 min with PBS-tween. Antibody-peroxidase conjugate was diluted 1: 2000 
in blocking solution and incubated with the membrane for 1 h. The mem-
brane was washed four times for 15 min with PBS-tween. The PR bands were 
detected by using Luminol chemiluminescence procedure (NEN Life Science 
Products, INC, Boston, MA) and visualized by exposing the blot to X-ray film 
(Kodak X-Omat, New Haven, CT) for at least 1 min. 
Cell Growth Experiments 
The cells were seeded at 20,000 cells per well in 24-well plates and cultured 
for the indicated time in the presence or absence of the indicated concentra-
tion of Medroxy Progesterone Acetate (MPA, Sigma Chemical Co., St Louis, 
USA) or R5020 (NEN Life Science Products, INC, Boston, MA) in DMEM/ 
F12 supplemented with 7.5% dextran-coated charcoal-treated fetal calf se-
rum, 10·9 M estradiol and, for the transfected cells, neomycin at 500 ~g/ml. 
The cells were washed twice in PBS (10 min.), lysed in 150 ~11M NaOH for 
30 min at 60°C, the lysates were further diluted 1:9 in H 20 and growth dif-
ferences were obtained by measuring OD 260 values of the lysates. 
Statistical analysis 
The experiments described in Figure 6.3B were performed three times and 
paired sample t-tests were performed using the SPSS programme. Differences 
betvveen control and treatments were considered significant when p < 0.01. 
Transcriptional activity 
Atlas Human Cancer eDNA expression array. The Atlas Human Cancer eDNA 
expression array (7742-1) was purchased from Clontech Laboratories, Inc. 
(Palo Alto, California, USA). Two identical nucleic acid arrays were supplied 
containing 588 cancer related human eDNA's spotted as duplicates on nylon 
membranes. A list of the genes spotted on the array, including array coor-
dinates, is available at Clontech's web site http:/ /www.clontech.com. Total 
RNA was reverse transcribed into eDNA using a mixture of array gene-specif-
ic primers and was labeled with "P-dATP. Probe purification and hybridiza-
tion to the array was performed following the array's user manual. The array 
was exposed to a phosphor-imaging screen at room temperature for 24 hours 
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and scanned using the Phosphor Imager (Molecular Dynamics, Sunnyvale). 
The results were quantified using ImageQuant software (Molecular Dynam-
ics, Sunnyvale). A grid was applied to the image of the blot to quantify the 
intensity of hybridization of every spot. According to the array manufacturer 
(Clontech Laboratories, Palo Alto, CA), the radioactive eDNA signal is linear 
for RNA's present at levels of 0.01-3% of the total RNA population. 
Numerical analysis of the eDNA expression array data 
Numerical analysis of the eDNA expression array data was performed as 
described previously (Smid-Koopman eta!., 2000). In short: The expression 
data obtained from Phosphor Imager analysis were logarithmic ("log) trans-
formed. Hybridization of one eDNA pool to two twin array membranes con-
firmed that gene expression profiles, obtained using this eDNA array tech-
nique, are highly reproducible (Smid-Koopman eta!., 2000). Using xy-scatter 
plot the expression levels of the genes for two experiments can be compared 
without the need for preceding normalization of the data. The least-squares 
regression line y=ax+b is the line with the smallest sum of squared vertical 
distances between the points of the xy-scatter plot and the line. In the least-
squares regression line (y~ax+b) the slope value a represent the differences 
in hybridization intensity and the intercept value b represent the differences 
in background signal. R-squared value is the Pearson correlation coefficient 
of the least-squares regression line and can be considered as a quantification 
of similarity between compared data. 
The perpendicular-line distance d {d~[11'1(1+a2)l[y-(ax+b)]} of every 
point to the least-squares regression line represents the difference in expres-
sion level of the specific gene for the two conditions compared. Using per-
centile ranking of the distances d, the genes located outside the ninety-seven 
percentile were defined as differentially expressed. 1Qd represents the order of 
magnitude of the differential regulation of the gene. 
Using the 97% interval to identify differentially expressed genes will al-
ways result in a fixed amount of differential expressed genes, regardless of 
the order of magnitude of the regulation. It seems preferable to select genes 
only after weighing the degree of regulation. The order of magnitude at which 
the regulation of gene expression has functional biological effects however, 
has yet to be established. Hybridization of one eDNA pool to two twin array 
membranes showed that variation within one experiment could be as much 
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as 1.5 fold (Smid-Koopman et al., 2000). Therefore, genes with expression 
difference less than 2.0 fold were not considered to be regulated genes. 
RESULTS 
Establishment of two Ishikawa sub-cell lines: PRB-59 and PRA-14 
To study the distinct functions of the two hPR isoforms, hPR-negative Ishi-
kawa endometrial cancer cells were stably transfected with hPRA or hPRB ex-
pression plasmids. Using northern and western blot analysis (Figure 6.1) the 
hPR-negative status of the parental Ishikawa cells was established. Further-
more, using a 3H-R1881-binding assay, significant specific binding could not 
be detected, indicating the absence of progesterone receptors in the parental 
cells. In order to measure potential binding of the 3H-R1881 to the androgen 
receptor (Zava et al., 1979), a 500 fold molar access triamcinolone aceton-
ide was used to block any progesterone receptors. No specific binding above 
background could be detected, indicating that the parental Ishikawa cell line 
do not express androgen receptors. Thirty hPRA transfected clones, seventy 
hPRB transfected clones and seventeen empty vector transfected clones were 
analyzed for hPR expression with a 3H-R1881-binding assay. One hPRA clone 
(PRA-14) and one hPRB clone (PRB-59), both showing the highest specific 
binding of 'H-R1881, were selected for further characterization. The empty 
vector clones and the parental Ishikawa cells (IK-par) showed no specific 
3H-R1881 binding. The hPR expression of the two sub-cell lines (PRA-14, 
PRB-59) was verified on northern and western blot, and T47D breast cancer 
cells expressing both hPRA and hPRB were used as a positive control (Fig-
ure 6.1). Both the PRA-14 and the PRB-59 sub-cell line were positive for 
PR-mRNA and protein (Figure 6.1). The relatively poor resolution of the 
northern blot prevents detection of a difference in transcript length between 
the PRA and PRE transcripts (the PRE transcript is 81 bp longer than the PRA 
transcript). 
Using Scatchard analysis a Kd value of: 0.1 ± 0.1 nM, Bm~ 0.05 ± 0.003 
nM and 12.0 pmoles/mg protein: equals 22000 sites per cell for the hPRA 
was established in the PRA-14 cells. In the PRB-59 cells a Kd value of: 0.2 ± 
0.2 nM, Bm~ 0.08 ± 0.003 nM and 12.7 pmoles/mg protein: equals 23500 
sites per cell was established for the hPRB (Figure 6.2). These Kd values are 
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11 kbPRm.RNA 
Transfected m.RNA 
Bactin mRNA 
B IK-par PRA-14 PRB-59 T47D 
+--PRA 
Figure 6.1: Expression hPRA and hPRB mRNA (A) and protein (B) in the cell lines. The 
RNA expression pattern of the transfected human progesterone receptors was verified on 
northern blot (A) and on western blot (B) for both Ishikawa sub-cell lines: PRA-14 and PRB-59. 
The parental Ishikawa c-ells (lK-par) and the T47D breast cancer cells were used as negative 
and positive controls, respectively. Before RNA isolation, the cells were cultured for 4S hours in 
the presence(+) or absence(-) of 1 J.l.M MPA.The T470 cells express endogenous hPR (11 kb 
PR mRNA). The transgenes both run at 3kb (transfected mRNA). Equal amounts of RNA were 
loaded on the northern blot as indicated by ethidium bromide staining of total RNA (not 
shown). Hybridization to j3-actin mRNA indicates that equal amounts of mRNA were loaded 
for each cell line cultured either in the presence or absence of MPA (1 J.l.M). For the western 
blot (B) equal amounts of protein lysate were loaded to the gel for the IK-par, PRA-14 and 
PRB59 cells.ForT470 cells 4-fold less protein was loaded because the PR-protein expression 
is approximately 5-fold higher in this cell line compared to the PRA-14 and PRB-59 cells. PRB 
and PRA protein bands are indicated by arrows in the left and right margin and by asterixes 
in the figure. 
99 
Chapter 6 
100 
PRA-14 
0.4 Kd=0.1 nM 
~ ~ ~ 0.3 ~ .._ " 0.2 c" 0.1 Figure 6.2: Scatchard analysis of 0 Ill the hPRA and hPRB expressing 
0 Ishikawa sub-lines: PRA-14 and 
0 20 40 60 80 PRB-59. Cells were incubated with 
Bound {PM) different amounts of 3H-R1881 (16 
nM, SnM, 4 nM, 2 nM, 1 nM, 0.5 nM, 
0.25 nM,0.125 nM,0.06 nM,0.03 nM, 
PRB-59 0.015 nM, 0.008 nM) in presence or 
0.4 Kd= 0.2 nM absence of 2000 fold non-labeled 
• 
R1881. Scatchard plots were con-
• 0.3 structed using Excel software. 
-"-~ 
" 
0.2 
c , 
0 0.1 Ill 
0 
0 20 40 60 80 
Bound (pM) 
within the range of published hPR-Kd-values for endometrial cells (De Goeij 
et al., 1988; Satyaswaroop et al., 1982). 
Progestins inhibit growth of Ishikawa cells expressing hPRB 
Progesterone is known to inhibit estrogen-induced proliferation of endo-
metrial epithelial cells (Martin et al., 1973). Whether PR can also have an 
estrogen independent effect on cell proliferation in endometrium cells is 
unknown. Moreover, whether the PR effects are generated via PRA, via PRB 
or via both isoforms is also unknown. To determine the distinct effects of 
the two liganded hPR isoforms on growth regulation of endometrial epithe-
lial cells, the PRA-14 and PRB-59 cell lines were cultured in the presence of 
different progestins, e.g. Medroxy Progesterone Acetate (MPA) and R5020, 
in varying concentrations. MPA was used because this compound is applied, 
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at high concentrations (1~M), for treatment of advanced and/or recurrent 
endometrial cancer in clinical practice. 
It was observed that 1 ~M MPA effectively inhibited estrogen-induced 
growth ofT47D cells (Figure 6.3 A and 6.3 B). Furthermore, 1 ~M MPA could 
also inhibit growth of PRB-59 cells irrespective of the presence or absence 
of estrogen in the culture medium (Figure 6.3 B). Interestingly, neither the 
parental Ishikawa cells nor the PRA-14 cells showed growth inhibition dur-
ing culture in the presence of progestins (Figure 6.3 A and 6.3 B). A concen-
tration curve of PRB-59 cells cultured in the presence of different amounts 
of MPA for 10 days showed an ED 50 of between 0.01nM and 0.1 nM (Figure 
6.3 C), indicating that also at low MPA concentrations growth inhibition is 
observed. As expected, when PRB-59 cells were cultured in the presence of 1 
nM MPA in combination with 0.1 ~M RU486 (anti-progestin) the progester-
one-induced growth inhibition became impaired (Figure 6.3 D). 
Distinct differences in gene expression regulation between PRA and 
PRB 
In order to determine the effects of the two PR isoforms on physiological 
gene expression in endometrial cancer cells, gene expression profiles of the 
PRA-14 and PRB-59 endometrial cancer cell lines were compared. The cells 
were cultured with or without 1 ~M MPA for 48 hours. The 48 h time point 
was chosen on the basis of a study in T47D cells showing marked expression 
differences at this time-point (Kester et al., 1997). Relatively high concen-
trations of MPA were used (l~M), as this resembles the concentration of 
MPA used for treatment of advanced and/ or recurrent endometrial cancer 
in clinical practice. Gene expression profiles were generated, using the Atlas 
human cancer eDNA expression array (Clontech Laboratories, Inc., Palo 
Alto, California, USA) containing eDNA's of 588 cancer related genes. Typi-
cal expression patterns for the cells under the different conditions are shown 
in Figure 6.4. Progesterone regulated genes were identified using XY-scatter 
plots (Smid-Koopman et al., 2000). 
It was observed that gene expression profiles of the PRA-14 and PRB-59 
cells resembled each other fairly well (Figure 6.4). Furthermore, there is also 
a high degree of similarity between the current arrays and earlier arrays per-
formed on parental Ishikawa cell RNA (Smid-Koopman et al., 2000), imply-
ing small genetic differences between the different cell clones. To establish 
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Figure 6.3: Growth characteristics of parental Ishikawa cells, T47D celts, PRA-14 and 
PRB-59 cells cultured in the presence or absence of progestins, estradiol and/or RU486. 
Cell growth was measured after different culture periods (2, 4, 7, 8 and 10 days) in the pres-
ence (shaded bars) or absence (open bars) of Medroxy Progesterone Acetate (1 J-lM MPA).This 
figure represents a single experiment were each point in the curve represents the mean + 
SD measurements of four wells (A}.Cells were grown for six days in medium containing MPA 
(1 J-lM} in the presence (shaded bars) or absence (open bars) of estradiol (1 nM), after which 
cell growth was measured. These experiments were performed three times and paired sam-
ple t-tests were performed. Differences between control and treatments were considered 
significant(*) when p < 0.01. Each bar represents the average of three different experiments 
+ SO (B). Growth was measured of PRB-59 cells cultured for 6 days in the presence of differ-
ent concentrations of MPA (0,01 pM, 1 pM, 0,1 nM, 1 0 nM, 1 J-lM, combined with (shaded bars) 
or without (open bars) 1 nM estradiol. This figure represents a single experiment were each 
point in the curve represents the mean+ SO measurements offourwells (C). In order to verify 
involvement of the progesterone receptor, PRB-59 cells were cultured in the presence or ab-
sence of MPA (1 nM) in combination with or without RU486 (1 OOnM). This figure represents a 
single experiment where each point in the curve represents the mean+ SO measurements of 
four wells (D). The error bars in each figure represent the standard deviations. 
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Figure 6.4:Progesterone regulated genes in PRA-14,PRB-59 andT470 cells. Atlas Human 
Cancer eDNA Expression Array (Ciontech, USA) was hybridized with 31P~Iabeled eDNA probes 
obtained from total RNA of the PRA~14, PRB-59 and T47D cells. All cell lines were cultured in 
the absence (-MPA) or presence (+MPA) of 1 J.LM MPA. The array contains 588 cancer related 
human cDNAs spotted as duplicates. A complete list of the names of the eDNA's spotted on 
the array is available at CLONTECH's web site (http:\\www.atlas.clontech.com.). 
the potential of the array technique for identification of progesterone regu-
lated genes, T47D breast cancer cells were used as positive controls (Figure 
6.4). The T47D cells are known to express progesterone target genes (Kester 
et aL, 1997). Using differential display technique, Kester et aL, (Kester et aL, 
1997) identified ten progesterone-regulated genes in the T47D cells. Three 
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Table 6.1: Genes differential regulated by MPA in T470, PRA-14 and PRB-59 cell lines, 
respectively. 
T47D Fold PRA-14 Fold PRB-59 Fold 
UP- CD59 3.7 Retinoic acid 
REGULATED Desmoplakin 1 3.1 receptor gamma 2.2 
Notch 2 2.6 lntegrin beta 4 2.0 
Notch group MAP kinase P97 2.0 
protein (N) 2.6 MTS 1;p16-INK4 2.0 
Cytokeratin 19 2.2 
DOWN- Cyclin; PCNA 2.0 Cytokeratin 8 3.3 IGFBP3 3.4 
REGULATED Cyclin D1;BCL-1 Replication 
oncogene 2.0 protein A 2.0 
Results are based on the Xi scatter plot and percentile ranking of the perpendicular-line distance 
d of every gene to the !east-squares regression line. The genes regulated by a factor 2 or more 
are shown in this table. The order of magnitude of the regulation of the gene on the array are 
indicated. 
of these genes (CD9, CD 59, desmoplakin) are spotted on the Atlas human 
cancer eDNA expression array and were also identified to be progesterone 
regulated with the currently used array technique. 
The gene expression profiles of the PRA-14 and PRB-59 endometrial can-
cer cell lines, cultured for 48 hours in presence or absence of 1 ~M MPA, were 
compared using XY-scatter plots (for details see Materials and Methods). On 
the basis of manufacturers protocol, a 2.0-fold up- or down-regulation was 
considered to be significant. A different set of genes appeared to be progester-
one regulated in the PRA-14 cells as compared to the PRB-59 cells (Table 6.1). 
Five genes are up-regulated by progesterone in PRA-14 (retinoic acid receptor 
gamma, integrin beta 4, MAP-kinase p 97, p16-INK4 and integrin alpha 7B) 
and none in PRB-59 cells. Three genes were down-regulated in the PRB-59 
cells (lGFBP3, fibronectin and replication protein A), and two in the PRA-14 
cells (cytokeratin 8 and cyclin D1). None of the genes were regulated by both 
hPRA and hPRB. The parentallshikawa cells and one empty vector clone were 
used as negative controls. No progesterone-regulated genes could be identi-
fied in these cells (data not shown). These observations indicate distinct dif-
ferences in transcriptional activity between the two hPR isoforms. 
IGFBP3 expression was markedly down-regulated in the PRB-59 cells and 
showed different expression level in PRB- 59 cells as compared to PRA-14 
and T47D cells (Figure 6.4, indicated by the arrows). To confirm the re-
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suits obtained using the eDNA array technique, the expression of this gene 
(IGFBP3) was studied on northern blot. IGFBP3 eDNA was used as a probe 
on a northern blot containing total RNA isolated from parental Ishikawa 
(IK-par), PRB-59, PRA-14 and T47D cells cultured for 48 hours in the pres-
ence or absence of 1 f!M MPA. The same expression pattern of IGFBP3 was 
observed on the northern blot as on the eDNA expression arrays: IGFBP3 is 
regulated by MPA in PRB-59 cells, and not regulated by MPA in PRA-14 and 
parental Ishikawa cells (IK-par). In T47D cells IGFBP3 expression appears to 
be absent (Figure 6.5). 
Cells JK-oar T47D PRB-59 PRA-14 
l.,MMPA - + - + - + - + 
Relative sional 100/120 nd I nd 104 I 20 220 I 260 
IGFBP3 m.RNA 
J3 actin m.RNA 
Figure 6.5: IGFBP3 mRNA expression in parental Ishikawa (IK-par), T47D, PRA-14 and 
PRB-59 cells. The RNA expression pattern of IGFBP3, as observed in figure 4, was verified on 
northern blot for both Ishikawa sub-cell lines: PRA-14 and PRB-59. The parental Ishikawa cells 
(IK-par) and the T470 breast cancer cells were used as controls. The radioactive signal was 
measured using a phosphor-imager and indicated as a signal relative to RNA isolated from 
IK-par cells cultured in the presence of MPA (this amount is given as 1 OO).IGFBP3 expression 
in T470 cells could not be detected (nd). Equal amounts of RNA were loaded on the blot as 
indicated by ethidium bromide staining of total RNA (not shown). Hybridization to 13-actin 
mRNA indicates that equal amounts of mRNA were loaded for each cell line cultured either in 
the presence or absence of MPA. 
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DISCUSSION 
In a recent paper, Dai eta!. (Dai eta!., 2001) report on the re-establishment 
of progesterone control of endometrial cancer cell proliferation using an 
adenoviral infection system. These authors could show that re-introduction 
of very high levels of either PRA or PRE into two poorly differentiated endo-
metrial carcinoma cell lines, HEC50 and KLE, restores progesterone induced 
inhibition of anchorage independent growth. They were also able to show a 
marked difference between growth of the PRA-expressing cells and the PRE-
expressing cells: progesterone induced inhibition of anchorage independent 
growth was about 50% in PRA-expressing cell lines, while growth was com-
pletely abolished in the PRE-expressing cells. As in the current investiga-
tions, the level of PRA versus PRE expression in the different cell lines was 
comparable (Dai eta!., 2001). The fact that Dai eta!. (Dai eta!., 2001), in 
contrast to the current investigation, could show some growth inhibition 
in PRA-expressing cell lines can be explained by differences in expression 
( adenoviral systems usually reach a high level of trans gene expression) or by 
the difference in measured end-parameter (anchorage independent growth 
versus growth on a culture disk in the present investigations). 
The implications of the functional differences between the two hPR iso-
forms for carcinogenesis of endometrial tissue are currently not very clear. 
There is one report in literature, using RT-PCR and based on very low num-
ber of patients, which seems to point to a more predominant appearance of 
PRE in more advanced endometrial tumors (Fujimoto eta!., 1995); a second 
report indicated that both PRA and/ or PRE may be lost in advanced endo-
metrial cancer (Arnett-Mansfield eta!., 2001); and a third in vitro study has 
suggested that poorly differentiated endometrial carcinoma cell lines only 
express hPRA (Kumar eta!., 1998). 
Recently, Mulac-Jericevic et a!. (Mulac-Jericevic et a!., 2000) performed 
a study in which they have investigated the progesterone response of the 
endometrium in PRA knockout animals. The authors observed progester-
one-induced proliferation of the mouse endometrium, which could only 
be accounted for by the PRB. The current investigations, however, seem to 
contradict these observations; showing that progesterone induces an estro-
gen-independent growth inhibition of the PRE-59 endometrial cancer cells, 
and therefore indicating growth inhibitory properties of PRB. It is clear that 
there is discrepancy between the outcome of the different studies, which may 
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be explained by the large differences between the above mentioned studies: 
human (Kumar eta!., 1998)(current study) vs. mouse (Mulac-jericevic eta!., 
2000; Shyamala eta!., 1998), in vivo (Mulac-jericevic eta!., 2000; Shyamala 
eta!., 1998), vs. in vitro (Kumar eta!., 1998)(current study) and normal 
growth (Mulac-jericevic eta!., 2000; Shyamala eta!., 1998), vs. carcinogenic 
growth (Kumar eta!., 1998) (current study) . Furthermore, in the absence of 
PRA during the development of the reproductive tract, compensatory changes 
may have occurred resulting in an enhancement of the proliferative effects 
of PRB. Another point of consideration is the fact that the currently used cell 
lines do not express estrogen receptors while in vivo these receptors do play 
an important role in progesterone signaling. These observations indicate that 
more research into growth inhibiting and -stimulating actions of liganded 
PRA and PRB is needed. 
In the current study only the cells expressing PRB (PRB-59) were found 
to be growth responsive to progesterone. In these cells the expression level 
of three genes (IGFBP3, fibronectin and replication protein A) were down-
regulated by progesterone. These three genes may therefore be involved in 
progesterone induced growth regulation of endometrial carcinoma cells. The 
function of IGFBP3 in cell growth has been studied by other research group 
and is known to play a putative role in the development of cancer (Giovan-
nucci, 1999). Relatively high plasma IGF-1 and low IGFBP3 levels have been 
independently associated with a greater risk of cancer development in pros-
tate, breast (in pre-menopausal women), colorectal epithelium and possibly 
lung. It has been hypothesized that the mitogenic and anti-apoptotic effects 
of !GF-1 are normally balanced by binding to its major binding protein 
(IGFBP3). When the levels of IGFBP3 drop, automatically the amount of 
freely available IGF-1 increases and enhanced cell turnover, with the risk of 
cellular transformation, may be the result. However, IGFBP3 may also exert 
growth regulatory effects independently of IGF-1 via its own cellular mem-
brane receptor (Yamanaka eta!., 1999). In this way IGFBP3 can induce apop-
tosis (Baxter, 2001; Butt et a!., 1999; Grimberg & Cohen, 1999). Arguing 
along these lines, progesterone induced down-regulation of IGFBP3 would 
then result in decreased apoptosis and potentially increased growth. 
The present investigations, however, do not show an increase in growth 
with decreased IGFBP3 expression, but rather the opposite. Support for the 
hypothesis that decreased expression of IGFBP3 may result in growth inhibi-
tion comes from research with transgenic animals. Two transgenic models 
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have been developed for IGFBP3: Neuenschwander et al. (Neuenschwander 
et al., 1996) reported on a mammary gland targeted IGFBP3 overexpressing 
mouse model, and Murphy et al. (Murphy et al., 199 5) report on a non-tis-
sue specific, inducible IGFBP3 mouse model. When IGFBP3 is overexpressed 
in the mammary gland, the process of gland-involution after pregnancy is 
modified by a reduction of apoptosis in transgenic animals (here higher lev-
els ofiGFBP3 are correlated with decreased levels ofapoptosis). In the mouse 
model, which harbors inducible IGFBP3 expression, organomegaly was found 
in the spleen, liver and heart (suggesting that higher levels of IGFBP3 are 
correlated with increased organ size). It is clear that future research will be 
necessary to reveal the putative role that IGFBP3 may play in progesterone-
induced growth inhibition in the PRB expressing endometrial cancer cell 
lines. 
With the establishment of the two Ishikawa cell lines stably transfected 
with either hPRA or hPRB, a model to study the possible functional differ-
ences of the two hPR isoforms on biological behavior and gene expression 
of human endometrial cancer cells has been created. Although only a rela-
tively small set of 5 88 cancer related genes has been examined in this study, 
distinct differences in progesterone receptor target genes have been found 
between the two hPR-isoforms. 
The present results emphasize the hypothesis that the relative distribution 
of hPRA and hPRB in endometrial cancer cells may have great implications 
on human endometrial tumor behavior. 
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Summary 
Progesterone plays an important role in controlling proliferation and differentiation of the human endometri-
um. Using stablytransfection techniques, both human progesterone receptor isoforms (hPRA and hPRB) were 
reintroduced into a well-differentiated human endometrial cancer cell line (a hPR negative sub-clone of the 
Ishikawa cell line). Several Ishikawa sub-cell lines were constructed each expressing different levels of hPRA, 
hPRB or both hPRA and hPRB. These Ishikawa sub-cell lines showed a marked progesterone-induced growth 
inhibition. Upon measuring growth inhibition, it was observed that the sub-cell lines expressing low levels 
of hPRA were less responsive to progesterone treatment compared to the sub-cell lines expressing similar 
levels of hPRB. However, cells expressing high levels of the hPR isoforms were all equally growth responsive 
to progesterone. Using a eDNA microarray,IGFBP3 was shown to be a progesterone regulated gene. The hPRB 
expressing cells were found to exhibit a more pronounced progesterone induced down regulation of IGFBP3 
expression compared to the hPRA expressing cells. 
In conclusion, a model system has been generated to investigate progesterone-induced growth inhibition 
and progesterone-modulated gene expression in human endometrial cancer cells. Furthermore, using this 
model the distinct functions of the two human progesterone receptor isoforms (hPRA and hPRB) in human 
endometrial cancer cells can be investigated. 
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INTRODUCTION 
Progesterone controls growth of human endometrial epithelium cells by an-
tagonizing the proliferative activity of estradiol and induces differentiation 
of endometrial epithelium and stromal cells (Martinet a!., 1973). Because 
of its ability to inhibit proliferation and to stimulate differentiation, proges-
terone has been used to suppress growth of endometrial cancer cells (Ehrlich 
eta!., 1981). 
In clinical practice, progesterone is used in a palliative setting as treatment 
of advanced and recurrent endometrial cancer. However, the response rate 
of progesterone treatment in these patients is not very high (10-15%) (Lentz, 
1994; Rose, 1996). The low response rate is probably due to a transition from 
hormone-controlled growth towards hormone independent growth in ad-
vanced endometrial tumors. In less advanced tumors progesterone treatment 
can, in theory, be fairly effective. Although surgery is in general curative in 
these patients and therefore the treatment of choice, progesterone, as a pri-
mary treatment, has been used in a small group of pre-menopausal women 
suffering from well differentiated endometrial cancer and determined to 
preserve fertility. The response-rate in these patients to treatment with high 
dose progestins appeared to be in the order of 60% (Kim eta!., 1997). 
The human progesterone receptor exists as two isoforms, hPRA and hPRB 
(Horwitz & Alexander, 1983). hPRA and hPRB are not functionally identical. 
Their relative efficiencies to activate target genes appear to vary according 
to the promoter and cell context (Meyer et a!., 1989). The two isoforms 
originate from the same hPR gene by transcriptional regulation of two dis-
tinct promoters (Kastner eta!., 1990). In human target cells both isoforms 
are coexpressed, generally at comparable levels (Graham & Clarke, 1997). 
However, the promoters are regulated independently, which can give rise to 
varying hPRA: hPRB ratio in target tissues under certain physiological cir-
cumstances (Kastner eta!., 1990; Kraus eta!., 1997). The varying ratio of the 
two isoforms among different target cells and under different physiological 
circumstances suggests that the differential expression level of PRA and PRB 
may affect the cellular response to progesterone. 
Several research groups have investigated the relative distribution and 
the putative function of these receptors in the endometrium cells. Using RT-
PCR, Fujimoto eta!. (Fujimoto eta!., 1995) found loss of hPRA in advanced 
endometrial tumors. Kumar eta!. (Kumar et a!., 1998) showed that endo-
113 
Chapter? 
114 
metria! cancer cell lines only expressed hPRA. Recently Arnett-Mansfield et 
al. (Arnett-Mansfield et al., 2001) used specific hPRA and hPRB antibodies 
to study progesterone receptor expression levels in normal and hyperplastic 
endometrium compared to endometrial cancer. These authors observed that 
in tumor tissues the staining for progesterone receptors was significantly 
lower as compared to normal or hyperplastic endometrial tissues. Further-
more, normal glands expressed both progesterone receptor isoforms while in 
hyperplastic tissue a predominance of either one of the receptor isoforms was 
observed. In 60% of the tumors either hPRA or hPRB was lost. A few endo-
metrial tumors (10/46) still expressed both progesterone receptor isoforms; 
interestingly these tumors were all well differentiated tumors (FIGO grade 
1). In another study, selective loss of PRB expression, largely due to CpG is-
lands hypermethylation of the PRB promoter region, was observed in 85% of 
the investigated tumors (Sasaki et al., 2001). 
It is difficult to present a clear picture with respect to PR-isoform expres-
sion patterns, mainly due to the use of different research materials (cell lines 
vs. tissues) and/or research methods (RT-PCR [gene transcription] vs. im-
munohistochemical staining [protein expression]). 
In the current investigation, we have used the well-differentiated Ishi-
kawa cell line (Nishida et al., 1996) to generate several hPRA, hPRB and 
hPRA/hPRB expressing cell lines. It was established that hPR expression in 
the parental Ishikawa cells was undetectable and addition of progesterone 
had no effect on growth or gene expression patterns in these parental cells. 
This hPR-negative sub-clone of the Ishikawa cell line was used to generate 
hPR expressing cell lines. Eight hPR expressing cell lines were established; 
expressing hPRA-only, hPRB-only or both progesterone receptor isoforms. 
These cell lines were characterized in several different ways and provide an 
accessible tool to investigate progesterone regulated growth inhibition and 
gene regulation in human endometrial cancer cells. 
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MATERIALS AND METHODS 
Construction of Ishikawa cell lines stably expressing hPRA, hPRB or 
both (hPRA and hPRB) 
Recombinant Plasmids 
The hPR-cDNA cloned into the pSG5 expression vector was a generous gift 
from Dr. E. Milgrom (Kremlin-Bicetre, Paris, France). This vector was used 
to create hPRA and hPRB expression plasmids, respectively. A 3063 bp eDNA 
fragment encoding hPRB was isolated from pSG5-hPR by excision of the 
EcoR1-Xba1 fragment (the EcoR1 site being artificially introduced at position 
+14 upstream from the first AUG codon). A 2982 bp eDNA fragment encod-
ing hPRA was isolated by excision of the BamH1-Xba1 fragment (the BamH1 
site being a hPR restriction site at position - 68 downstream from the first 
AUG codon and +424 upstream from the second AUG codon). Subsequently, 
the hPRA and hPRB eDNA fragments were inserted into the pcDNA3.1 ex-
pression vector (Invitrogen Corporation, Carlsbad, CA), containing a cyto-
megalovirus ( CMV) promoter and an eucaryotic selection marker. Sequence 
analysis of the created plasmids was performed to verify proper ligation of 
the hPR eDNA fragments into the vector. Furthermore, transient transfec-
tion experiments in parental Ishikawa cells showed clear transcriptional up 
regulation of a MMTV-luc construct by both receptor constructs (data not 
shown). 
Cell culture 
Ishikawa cells were derived from a well-differentiated human endometrial 
adenocarcinoma (Nishida et al., 1996) and were a generous gift from Dr. 
Masato Nishida (Tsukuba, japan). The cells were negative for mycoplasma 
contamination, as determined using Mycoplasma-Plus-PCR-Primer-Set 
(Stratagene, La jolla, CA). The cells were maintained in DMEM/F12 (Dul-
becco's modified Eagle's medium/Ham's F12 (1:1 mix) with 15 mM Hepes, 
with L-glutamine) supplemented with penicillin/streptomycin; in the pres-
ence of 5% fetal calf serum in a 37°C incubator with 5% C02 . During the 
experiments, all cell lines were cultured in DMEM/F12 supplemented with 
5% dextran coated charcoal treated fetal calf serum, in the presence of 
penicillin/ streptomycin. The cells transfected with either hPRA or hPRB or 
both were cultured under continuous selection pressure with neomycin (500 
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[lg/ml) and/or hygromycin(250 [lg/ml). For total RNA isolation, cells were 
cultured for the indicated time in the presence or absence of 10-7 M Medroxy 
Progesterone Acetate (MPA, Sigma Chemical co., StLouis, MO). Total RNA 
was isolated by lyzing the cells with 3M Lithium chloride/ 6M Urea as de-
scribed by Auffray and Rougeon (Auffray & Rougeon, 1980). The RNA was 
purified as described by Blok eta!. (Blok eta!., 1995). 
Stably transfeetion of Ishikawa cell lines with hPRA, hPRB or both (hPRA 
and hPRB) 
Ishikawa cells were plated on 40 cm2 culture dishes and cultured to 50% con-
fluency. The hPRA-pcDNA3.1+ plasmid, the hPRB-pcDNA3.1+ plasmid and 
the control "empty-"pcDNA3.1 + vector (Invitrogen Corporation, Carlsbad, 
CA) were transfected into the Ishikawa cells using FuGENE™ 6 Transfection 
Reagent (Roche Diagnostics Co. Indianapolis, IN) following instructions 
provided by the manufacturer. The cells were initially transfected with neo-
mycin selectable hPRA or hPRB constructs, and after several passages, two 
cell lines were selected. These two cell lines showed highest expression levels 
of hPRA and hPRB, respectively (cell line PRA-14 and PRB-59). In order to 
obtain cells expressing hPRA and hPRB, or cells expressing even higher levels 
of hPRA or hPRB alone, PRA-14 and PRB-59 cells were subsequently trans-
fected with hPRA or hPRB expression vectors selectable for hygromycin. 
Characterization of the Ishikawa cell lines stably transfected with 
hPRA, hPRB or both 
'H-R1881-binding assay 
The cells were cultured in 6-well plates, under standard conditions as de-
scribed above, to 75% confluency. The cells were incubated with 8nM 3H-
R1881 (NEN Life Science Products, Inc, Boston, MA) in presence or absence 
of 4[!M non-labeled R1881 (NEN Life Science Products, Inc, Boston, MA) 
for 2 h in a 37°C incubator. The cells were washed five times with phosphate 
buffered saline (PBS) at 0°C. The cells were lysed in 1M NaOH for 30 min 
at 60°C. Radioactivity was measured in a liquid scintillation counter and 
protein concentrations were measured using Bradford's reagent. 
Western immuno-blotting 
The cells were cultured as described above to 75% confluency. The cells were 
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washed twice with PBS, lysed in RIPA buffer (40mM Tris-HCL (pH 7.4), 
5mM EDTA (pH 8.0), 10% glycerol, 10 mM Sodiumphosphate, 10 mM So-
diummolybdate, 50 mM Sodiumfluoride and 0.5 mM Sodiumorthovanadate 
10mM DTT, 1% Triton, 0.08% SDS, 0.5% Deoxycholate, and protease inhibi-
tors: 6 mM PMSF, 5 mM Bacitracin, 5 mM Leupeptin) and centrifuged for 10 
min at 350.000 g, 4°C. The proteins were separated on a SDS polyacrylamid 
gel and transferred to nitrocellulose (Schleicher & Schuell). The hPR (C-20) 
rabbit polyclonal antibody (Santa Cruz Biotechnology) and human IGFBP3 
(C-19) goat polyclonal antibody (Santa Cruz Biotechnology) were incubated 
with the membrane as follows: The membrane was rinsed with PBS-Tween 
and blocked for 1 h with blocking solution. The hPR (C-20) antibody was 
diluted 1:2000 in blocking solution (IGFBP3 diluted 1:4000) and incubated 
with the membrane for 1 h. The membrane was washed four times 15 min 
with PBS-Tween. Antibody-peroxidase conjugate was diluted 1:2000 in block-
ing solution and incubated with the membrane for 1 h. The membrane was 
washed four times for 15 min with PBS-Tween. The PR and IGFBP3 bands 
were detected by using Dupont/NEN's Luminal chemiluminescence's proce-
dure and visualized by exposing the blot to X-ray film (Kodak X-Omat, New 
Haven, CT) for at least 1 min. 
Immunohistochemical analysis 
The cells were pre-cultured in DMEM/F12 supplemented with 5% stripped 
fetal calf serum for 3 days before being seeded in collagen gels (collagen 
kindly provided by Dr. H. Nederbragt, Veterinary Pathology, Utrecht, The 
Netherlands) at a cell concentration of 2·106 cells/mi. 1 ml gels were cul-
tured in 24-well plates for 7 days in DMEM/F12 supplemented with 5% 
stripped fetal calf serum. The gels were fixed in 3.7% buffered formaldehyde 
for 24 hours and embedded in paraffin. Sections of the gels were immunohis-
tochemical stained with mouse monoclonal antibodies recognizing PRB spe-
cifically (hPRa2) or PRA and PRB both (hPRaS) (both NeoMarkers, Fremont, 
CA, USA) in a dilution of 1:200. Staining was indirectly visualized using 
StreptABComplex/ HRP (1:1:200 in PBS) (DAKO, Denmark) and DAB/metal 
concentrate (Pierce, Rochford, IL, USA). 
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Progesterone-induced growth inhibition in PRA and/ or PRB express-
ing Ishikawa cells 
Cell growth studies 
The cells were seeded at 20,000 cells per well in 24-well plates and cultured 
for the indicated time in the presence or absence of the indicated concentra-
tion of Medroxy Progesterone Acetate (MPA, Sigma Chemical Co., St Louis, 
USA) or R5020 (NEN Life Science Products, INC, Boston, MA) in DMEM/ 
F12 supplemented with 5% dextran-coated charcoal-treated fetal calf serum, 
and for the transfected cells also supplemented with neomycin at 500 ~g/ml 
and/or hygromycin at 250 ~g/ml. The cells were lysed in 150 ~I 1M NaOH 
for 30 min at 60°C and growth differences were obtained by measuring OD 
260 values of the lysates. 
Analysis of apoptosis 
PRAB-36 cells were cultured for 28 or 35 days in the absence or presence of 1 
~M or 10 nM MPA. Subsequently the cells were stained with Hoechst 33342 
or Propidium Iodide (PI) (Darzynkiewicz et al., 1994). Hoechst 33342 can 
enter living cells and stains the DNA blue when exposed to 352 nm light. 
Apoptosis is detected as condensed DNA stains very intense. PI stains the 
DNA of cells with disrupted cellular membranes (plasma and nuclear mem-
branes), and can therefore be used to detect apoptotic cells. PI dyed DNA 
stains red when exposed to 530 nm light. 
Progestercne regulated gene expression in Ishikawa cells 
Atlas Human Cancer eDNA expression array 
The Atlas Human Cancer eDNA expression array (7742-1) was purchased 
from Clontech Laboratories, Inc. (Palo Alto, California, USA). Two identi-
cal nucleic acid arrays were supplied containing 588 cancer related human 
eDNA's spotted as duplicates on nylon membranes. A list of the genes spot-
ted on the array, including array coordinates, is available at Clontech's web 
site http:/ /wv.rw.clontech.com. Total RNA was reverse transcribed into eDNA 
using a mixture of array gene-specific primers and was labeled with 32P-dATP. 
Probe purification and hybridization to the array was performed following 
the array's user manual. The array was exposed to a phosphor-imaging screen 
at room temperature for 24 hours and scanned using the Phosphor Imager 
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(Molecular Dynamics, Sunnyvale). The results were quantified using Im-
ageQuant software (Molecular Dynamics, Sunnyvale). A grid was applied to 
the image of the blot to quantify the intensity of hybridization of every spot. 
According to the Array manufacturer (Clontech Laboratories, Palo Alto, CA), 
the radioactive eDNA signal is linear for RNA's present at levels of 0.01-3% 
of the total RNA population. 
Northern-blotting 
For total RNA isolation, cells were cultured for 48 hours in the presence or 
absence of 0.1 ~M Medroxy Progesterone Acetate (MPA, Sigma Chemical 
co., StLouis, MO) in DMEM/F12 supplemented with 7.5% dextran-coated 
charcoal-treated fetal calf serum, and, for the transfected cells, neomycin at 
500 ~g/ml and hygromycin at 250 ~g/ml. Total RNA was isolated by lyzing 
the cells with 3M Lithium chloride/ 6M Urea as described by Auffray and 
Rougeon (Auffray & Rougeon, 1980). The RNA was purified as described by 
Blok et al. (Blok et al., 1995). Northern blotting was performed as described 
by Chang et al. (Chang et al., 1997). As a probe, to detect IGFBP3 mRNA 
on the northern blot, a 2.4 kb EcoR1 eDNA fragment containing the mouse 
IGFBP3 coding sequence was used. The mouse IGFBP3 sequence has a 80% 
homology with the human IGFBP3 sequence, and can therefore be used to 
identify the human IGFBP3 mRNA. This eDNA was kindly provided by Dr. 
S.L.S. Drop (Department of Pediatrics, division of Endocrinology, Erasmus 
M.C. Rotterdam, The Netherlands). 
RESULTS 
Generation of PRA en PRB expressing cell lines 
lshikawa-3H12 cells were obtained from Nishida et al (Nishida et al., 1996). 
Upon culture for 6 passages these cells were analyzed for progesterone recep-
tor contents. Using specific ligand binding, Northern blotting and western 
blotting no progesterone receptor levels could be detected (Figure 7.1, lane 
IK-par, and Smid-Koopman et al., submitted). Subsequently, stably transfec-
tions with constructs containing human progesterone receptor A (hPRA) 
and/or human progesterone receptor B (hPRB) were performed. The cells 
were initially transfected with neomycin selectable hPRA or hPRB constructs, 
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figure 7.1: PRA and PRB expression in different cell lines. The PRA or PRB expressing cells 
were cultured under continuous selection pressure with neomycin (500 IJg/ml} and/or hygro-
mycin (250 IJg/ml) in DMEMJF12 culture medium supplemented with 5% fetal calfserum.Cel! 
!ysates were prepared and analyzed on 505-PAGE. The western blot was incubated with a PR 
specific polyclonal antibody detecting PRB as well as PRA. Arrows in the margin of the figure 
indicate the position of PRA and PRB. Molecular weight markers are indicated on the left. 
and after several passages, two cell lines were selected (cell line PRA-14 and 
PRB-59). In order to obtain cells expressing hPRA and hPRB, and cells ex-
pressing even higher levels of hPRA or hPRB alone, PRA-14 and PRB-59 cells 
were subsequently transfected with hPRA or hPRB expression vectors select-
able for hygromycin. This lead to the generation of a panel of nine cell lines 
expressing different amounts of only hPRA (PRA-1, PRA-6, PRA-10, PRA-14), 
or only hPRB (PRB-1, PRB-23, PRB-59) or both hPRA and hPRB (PRAB-18, 
PRAB-36). The PRA-6 and PRA-14 cells appeared to express equal amounts of 
hPRA. Therefore, only one of the two was used for further characterization 
(PRA-6). 
Initially specific radioactive ligand (3H-R1881) binding was used to select 
progesterone receptor expressing clones. A single-point-binding assay was 
performed to select clones with a relatively high progesterone receptor con-
tent. Subsequently, western blot analysis was used to analyze receptor protein 
expression and to discriminate between hPRA and hPRB (Figure 7.1). 
For the Ishikawa cells expressing high levels of PRA and/ or PRB an im-
munohistochemical analysis was performed. The parental cell line (IK-par), 
the PRA-1, PRB-1 and PRAB-36 cell lines were cultured in collagen, fixed and 
stained with a hPRA/B specific antibody or a hPRB specific antibody. It was 
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c PRB-1 D 
E F I PRAB-361 
G PRB-1 H PRA-1 
Figure 7.2: lmmunodetection of PRA, PRB and PRA/B in stably transfected Ishikawa 
cells. Parental Ishikawa cells (IK-par), and progesterone receptor containing clones (PRAB-36, 
PRB-1 and PRA-1) were cultured in collagen, fixed, sectioned and stained using an antibody 
that detected hPRA and hPRB (Figure 7.2 A-D) or stained with an antibody that detected only 
hPRB (Figure 7.2 E-H). 
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figure 7.3: Progesterone induced growth-inhibi-
tion of different PRA1 PRB and PRA/B expressing 
cell lines. The different clones were cultured in the 
presence or absence of different concentrations of 
MPA (1 pM, 0.1 nM, 1 OnM, 1 uM) or R5020 (1 uM) for 12 
days. Cells were harvested in 1M NaOH and 00260 
values were measured in diluted samples. 
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Figure 7.4: Growth inhibition of PRAB-36 cells induced by Medroxyprogesterone Ac-
etate {MPA) or R5020 for different time periods. PRAB-36 cells were cultured for 3,6, 9 and 
12 days in the absence or presence of 1 pM,O.l nM, 1 OnM or 1 p.M MPA or 1 p.M R5020.Ce!ls were 
harvested in 1M NaOH and 00260 values were measured in diluted samples. 
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Figure 7 .S.Growth ofPRAB-36 cells in the presence or absence of progestins for 28 days. 
PRAB-36 cells were cultured for 28 days in the absence or presence of 1 OnM or 1 J..lM MPA. For 
the top figure, cells were harvested in 1M NaOH and 00260 values were measured in diluted 
samples. Photographs are from control cells {A-C) and cell cultured for 28 days {D-F) in the 
presence of 1 J..lM MPA.A and D represent the phase-contrast image of the cells. In the Figures 
Band E represent the cells were stained with Hoechst 33342 to identify the nuclei. Hoechst 
33342 can enter living cells and stains the DNA blue, when exposed to 352 nm light. In the 
apoptotic cells Hoechst stains the condensed DNA more intense (seen as white). C and F rep-
resent cells stained with Propidium Iodine {PI}. PI is used to detected apoptosis as it stains the 
DNA of cells with disrupted cellular membranes (plasma and nuclear membranes) red, when 
exposed to 530 nm light. 
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observed that with the hPRA/B antibody hPR staining was detectable in all 
three cell lines (PRAB-36, PRB-1 and PRA-1) cells (Figure 7.2 B-D). With 
the hPRB-specific antibody staining was observed only in the cells expressing 
hPRB (PRAB-36 and PRB-1) (Figure 7.2 F & G) and not in the hPRA express-
ing cells (PRA-1) (Figure 7.2 H). !K-par cells showed no significant proges-
terone receptor staining with either antibody (Figure 7.2 A & E). 
Progesterone-induced growth inhibition in hPRA and/ or hPRB ex-
pressing Ishikawa cells 
Progesterone treatment of early stage endometrial cancer usually results in 
growth inhibition of the tumor (Kim et al., 1997). To study these effects of 
progesterone on endometrial carcinoma cell growth, all isolated hPR express-
ing clones were cultured in the presence of different concentrations Medroxy 
Progesterone Acetate (MPA). Growth was measured and it was observed that 
cells expressing low levels of hPRA (PRA-6 and PRA-10) showed the low-
est response to MPA, while in cells expressing comparable levels of hPRB a 
marked progesterone-induced growth inhibition could be observed. However, 
all sub-cell lines expressing high levels of hPRA (PRA-1) or hPRB (PRB-1) or 
hPRA+hPRB (PRAB-36) showed a clear progesterone-induced growth inhibi-
tion (Figure 7.3). In order to verify progesterone's ability to induce growth 
arrest, growth of PRAB-36 eel! line was measured after 3, 6, 9 and 12 days 
in culture in the presence of MPA. It was observed that growth became se-
verely inhibited (Figure 7.4). Moreover, apoptosis could be observed in the 
PRAB-36 cells when the cells were cultured in the presence of 1uM MPA for 
a prolonged period oftime (28 days) (Figure 7.5). 
Progesterone regulated gene expression in Ishikawa cells 
To study progesterone regulated gene expression in endometrial carcinoma 
cells, PRAB-36 cells were cultured in the presence of MPA for 48 h. Sub-
sequently, RNA was isolated and radioactively labeled using RT-PCR. The 
radioactive probe was used on a eDNA micro-array containing 588 cancer 
related genes (the Atlas Human Cancer eDNA expression array, Clontech 
Laboratories, Inc. (Palo Alto, California, USA)). Several genes were found to 
be regulated by progesterone. The gene with the clearest expression difference 
was !GFBP3 (Figure 7.6, indicated by the arrow and circle). Because of its 
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PRAB36 cultured in 
the absence of 
medroxy progesterone 
acetate 
PRAB36 cultured in 
the presence of 0.1 J.!M 
medroxy progesterone 
acetate 
Figure 7.6: eDNA microarray of PRAB-36 cells cultured in the presence or absence of 
0.1 ~o~M medroxy progesterone acetate. The Atlas Human Cancer eDNA expression array 
containing 588 cancer related human eDNA's (Ciontech Laboratories, Inc. (Palo Alto, Califor-
nia, USA)) was used. A list of the genes spotted on the array, including array coordinates, is 
available at Clontech's web site http://www.clontech.com. For total RNA isolation, PRAB-36 
cells were cultured for 48 hours in the presence or absence of 0.1 J.!M Medroxy Progesterone 
Acetate. Probe purification and hybridization to the array was performed following the array's 
user manual. The array was exposed to a phosphor-imaging screen at room temperature for 
24 hours and visualized using the Phosphor Imager (Molecular Dynamics, Sunnyvale). 
clear progesterone induced down-regulation, IGFBP3 was chosen for further 
expression analysis using Northern blotting. 
From sub-cell lines cultured for 48h in the presence or absence of MPA 
mRNA expression of 1GFBP3 was measured. Although all hPR expressing 
cell lines showed down-regulation of IGFBP3 mRNA expression, significant 
differences in the level of progesterone-induced down-regulation of IGFBP3 
!::j 
Cell line IK-par PRA-6 PRA-10 PRA-1 PRB-59 PRB-23 PRB-1 PRAB- PRAB- T47D 
36 18 
Progesterone 
- I + - I + . I + . I + - I + - I + - I + - I + - I + - I + (10-7 MMPA) 
JF:~~~~a~;:~- I 1 Jl I 4J 2 I - 6 I >9 -~ >9 I 8 I 8 I - I 
IGFBP3 mRNA 
Figure 7.7: Progesterone induced down-regulation of IGFBP3 mRNA. For total RNA isolation, the indicated cells were cultured for 48 hours in 
the presence or absence of 0.1 J..tM Medroxy Progesterone Acetate. Northern blotting analysis was performed using a mouse /GFBP3 probe and a 
hamster ~-actin probe, Using a Phosphor Imager the IGFBP3 and actin expression signal level was established. Subsequently, the fold-regulation 
was calculated. 
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Oh 8h 24h 48h 72h 
75kDa--
50 kDa--
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25 kDa--
Figure 7.8: IGFBP3 protein is down~regulated by progesterone in the PRAB-36 cell line. 
PRAB-36 cells were cultured for the indicated time in the presence of 0.1 ~M Medroxy Proges-
terone Acetate. The western blot was incubated with a IGFBP3 specificantibody.Arrows in the 
margin of the figure indicate PRA and PRB. Molecular weight marker is indicated on the left. 
were observed between the two hPR isoforms. The hPRB expressing cell lines 
(PRB-59, PRB-23, PRB-1, PRAB-36, PRAB-18) showed at least a 6-fold down-
regulation of lGFBP3, while the hPRA-only expressing lines (PRA-6, PRA-10 
and PRA-1) showed a much more moderate level of progesterone-induced 
down-regulation of IGFBP3 (3-, 4- and 2-fold, respectively) (Figure. 7.7). 
The time-dependency of the progesterone-induced down-regulation of 
IGFBP3 protein was studied in the PRAB-36 cells. The down-regulation of 
the IGFBP3 protein concentration appeared to be time-dependent. Marked 
down-regulation could be observed after 24 hours culturing of the cells in 
the presence of 0.1 ~M MPA (Figure. 7.8). 
DISCUSSION 
During dedifferentiation of endometrial cancer, progesterone-regulated 
growth inhibition is often lost. For advanced or recurrent endometrial can-
cer this limits treatment options. Understanding endometrial cell growth 
regulation by progesterone may provide tools to improve therapeutic options 
for patients with advanced or recurrent endometrial cancer. 
Dedifferentiation of malignant tumor cells is correlated with changes 
in expression of several genes. The genes which are known to be frequently 
mutated or whose expression is otherwise changed in endometrial cancer are 
Progesterone regulation of growth and gene expression 
hMLHI (DNA repair) (Pare eta!., 2000; Salvesen eta!., 2000), PTEN (tumor 
suppressor) (Kong et a!., 1997; Risinger et a!., 1997; Tashiro et a!., 1997), 
P53 (tumor suppressor) (Geisler eta!., 1999; Ito eta!., 1994; Kohler eta!., 
1996; Silverman eta!., 2000), bcl-2 (oncogene) (Ioffe eta!., 1998; Zheng et 
a!., 1996) and K-ras (oncogene) (Enomoto eta!., 1993; Fujimoto eta!., 1993; 
Lax et al., 2000). Several research groups have studied progesterone receptor 
expression in endometrial cancer but a clear picture has not emerged from 
these studies. All studies show reduced expression of the progesterone recep-
tor in a great number of advanced endometrial cancers. However, whether 
either hPRA or hPRB is selectively lost in endometrial cancer remains debat-
able. (see Introduction section). 
Inhibition of endometrial cell growth by progesterone has been studied re-
cently in HecSO and KLE endometrial carcinoma cell lines (Dai et al., 2001). 
These cells were infected with either hPRA or hPRB using adenoviral vectors. 
A marked effect of progesterone treatment on anchorage independent cell 
growth was observed in the hPR-infected cells: the hPRA cells showed SO% 
inhibition of anchorage independent cell growth in response to progesterone 
treatment, while in hPRB expressing cells 90% inhibition was found. Dif-
ference between hPRA-mediated and hPRB-mediated effects on cell growth 
inhibition could also be observed in the current investigations. Progesterone-
induced growth inhibition in cells expressing low levels of hPRA (PRA-6 and 
PRA-10) was found to be less profound compared to progesterone-induced 
growth inhibition in cells expressing similar low levels of hPRB (PRB-59 and 
PRB-23). However, in cells with high expression levels of hPR (PRA-1 and 
PRB-1), no difference in the growth inhibiting properties of the two differ-
ent hPR isoforms could be observed. In endometrial cancer it is known that 
the expression of the progesterone receptor is reduced in a great number of 
advanced endometrial cancers (Kerner et a!., 1995; McCartY et al., 1979; 
Nyholm eta!., 1992). The current results suggest that selective reduction of 
hPRA expression may have more impact on sensitivity of endometrial car-
cinoma cells for progesterone-induced-growth inhibition than reduction of 
hPRB. For clinical practice this could mean that the relative expression level 
of hPRA may serve as a prognostic marker. Research on human endometrial 
carcinoma tissue samples combined with clinical outcome will have to be 
performed to confirm this hypothesis. 
In an earlier study by our group (Smid-Koopman et al., submitted) it 
was also observed that in the hPRA-expressing cell lines different genes were 
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regulated compared to the hPRB-expressing cell lines. Together with data ob-
tained in other cell systems there is substantial evidence that hPRA express-
ing cells behave different compared to hPRB or hPRA/B expressing cells (with 
respect to gene regulation, growth inhibition, anchorage independent growth 
and metastasis (Graham et al., 1995; Kumar et al., 1998; Mulac-jericevic et 
al., 2000; Shyamala et al., 1998)). In endometrial cancer patients there has 
been observed that losing both progesterone receptor isoforms is associated 
with dedifferentiation of endometrial cancers (Kerner et al., 1995; Kleine et 
al., 1990; McCarty et al., 1979; Rakar et al., 1988). However, so far it is not 
clear what the consequences for cellular functions are upon loss of one or 
both hPR-isoforms. The currently presented sub-cell lines may provide an ac-
cessible tool to investigate this aspect of endometrial cancer development. 
One gene (IGFBP3-gene) was shown to be down-regulated by proges-
terone in tvvo independent eDNA-array experiments. Using Northern and 
western blotting the progesterone regulation of 1GFBP3 could be confirmed. 
IGFBP3 could be an important gene in cancer development as down-regula-
tion has been correlated with a bad prognosis in ovarian cancer (Katsaros 
et al., 2002). Furthermore, down-regulation of IGFBP3 is also associated 
with inhibition of apoptosis (Baxter, 2001; Butt et al., 1999; Grimberg & 
Cohen, 1999; Shen et al., 1999). The current investigations seem to be in 
conflict with these reports, as a correlation betvveen progesterone induced 
down-regulation of cell growth and progesterone induced down-regulation 
of IGFBP3 expression is observed. However, in a recent publication it was ob-
served that bovine mammary epithelial cells expressing high levels of IGFBP3 
were in fact much more sensitive to IGF-induced growth stimulation than 
cells expressing low levels of IGFBP3 (Grill & Cohick, 2000). Furthermore, 
in transgenic animals overexpression of IGFBP3 resulted in organomegaly in 
spleen, liver and heart. From these results it can be extrapolated that pro-
gesterone induced reduction of IGFBP3 levels is involved in modulation of 
endometrial cell growth. 
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8.1 A GENETIC MODEL FOR ENDOMETRIAL 
TUMORIGENESIS 
Today, molecular genetics is an essential part of our growing knowledge and 
understanding of the etiology and biological behavior of cancer. A review of 
literature learns that genes most frequently found to be altered in endome-
trial cancer are the tumor-suppressor genes: p53, PTEN, DCC and the onco-
genes: K~ras, c-erbB2, c-fms. Two possible molecular prognostic markers have 
been identified so far: p53 and c-erbB2 (Chapter 2.3.3 Table 2.3.1). 
On basis of histological and clinical characteristics two pathways in en-
dometrial carcinogenesis have been suggested: an estrogen-driven pathway 
leading to atypical hyperplasia of the endometrium which slowly progresses 
into an endometrioid carcinoma (Kurman et a!., 1985; Lindahl & Willen, 
1991) and an estrogen-unrelated pathway leading to the aggressive papillary 
serous or clear cell carcinomas (Ambros et a!., 199 5). The available infor-
mation on the molecular profiles of endometrial cancer seem to support 
a two pathway theory in the etiology of endometrial cancer: PTEN, K-ras 
mutations and microsatellite instability are shown to be strongly associated 
with the prognostic more favorable endometrioid subtype of the endometrial 
cancers, whereas the aggressive serous carcinomas seem to be associated with 
p53 and c-erbB mutations. When using this information in combination 
with Fearons and Vogelsteins model of carcinogenesis (Fearon & Vogelstein, 
1990), a two way model for the carcinogenesis of endometrial cancers can 
be constructed. 
However, most endometrial tumors show a genetic profile that only par-
tially fits one of the models presented in Figure 8.1.1. As tumor development 
seems to be a multi-step process (Chapter 2.3.3-2.3.4), involving many dif-
ferent genetic, epigenetic, and hormonal factors, it seems logical to presume 
that expression profiles of larger gene clusters may be needed to fully charac-
terize subgroups of endometrial tumors. This has been studied in Chapter 4 
and will be discussed below. 
8.2 TUMOR CLASSIFICATION USING eDNA ARRAY 
TECHNIQUES 
Recently, the rapid progression of the Human Genome Project in mapping 
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Figure 8,1.1: A genetic model for endometrial tumorigenesis. Tumorigenesis is thought to proceed through a series of genetic alterations 
involving oncogenes and tumor suppressor genes. Endometrial tumors can roughly be divided In two histological sub-types: endometr!old and 
non-endometriold. In the etiology of endometrial cancer two pathways have been suggested: an estrogen-driven pathway leading to atypical 
hyperplasia of the endometrium which slowly progresses into an endometrioid carcinoma (1), and an estrogen-unrelated pathway leading to 
the aggressive papillary serous or clear cell carcinomas (non-endometrioid carcinoma) via the precursor lesion EiC (endometrial intraepithelial 
carcinoma) (II). The mutated genes involved in the development of endometrial cancer are indicated. p53 mutations are thought to be an early 
event in the tumor development in the estrogen unrelated pathway. However, in the estrogen related pathway it seems to occur in a later stage 
of tumor development and may be responsible for the metastatic property of the tumor. Not only genetic events but also epigenetic events are 
thought to play a role in endometrial carcinogenesis. Hormonal influences {estradiol and Tamoxifen) and the methylation state have been found 
to be involved in carcinogenesis. 
=epigenetic events. E2 =estradiol. DCC= deleted in colo rectal carcinoma. EIC = endometriallntraepithellal carcinoma. 
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the human genome and the development of new techniques to study gene 
expression have created new tools to expand our knowledge of tumorigenesis. 
The eDNA-array technique has made it possible to study the expression level 
of thousands of genes in one single experiment. In this way gene expression 
profiles can be made of every specific tissue type and for every specific condi-
tion (e.g. during cell cycle, in response to specific stimuli). 
These eDNA array techniques generate a large amount of data, creating 
a new problem: how to analyze the data. The simplest objective is to com-
pare two distinct condition (e.g. normal cells vs. tumor cells, or treated vs. 
untreated cells) and identify differentially expressed genes and the degree 
of similarity between the gene expression profiles. In Chapter 3 a method 
is described to compare two gene expression profiles. The most innovative 
property of this method is the fact that it uses raw (e.g. not normalized) 
hybridization data. Normalization of the eDNA array data for differences in 
background signal and for differences in intensity of hybridization is a dif-
ficult issue. Local background signal can be subtracted from each hybridiza-
tion spot, but how to determine local background? Differences in intensity 
of hybridization can be identified and normalized by using the expression 
levels of so-called housekeeping genes. However, the expression of house-
keeping genes is not guaranteed to be stable in all cell types and during all 
circumstances. The method described in Chapter 3 bypasses these problems 
as preceding normalization of the data for differences in background signal 
and for differences in intensity of hybridization is not needed. 
A higher level of interpreting gene expression profiles is required when 
the objective is to monitor changes in expression profiles during several steps 
of a dynamic process, such as tumor development, cell cycle or response 
to specific stimuli. These experiments require the interpretation of several 
gene expression profiles simultaneously. Analysis of such massive data sets 
can only be performed using complex statistical analysis methods. Recently 
several bioinformatic analysis methods of gene expression data have been 
established (e.g., Principal components analysis (Hilsenbeck et al., 1999), 
Boolean genetic networks (Huang, 1999), Self-organizing maps (Tamayo et 
al., 1999), Hierarchical cluster algorithms (Eisen et al., 1998), Support vec-
tor machines (Brown et al., 2000)). Eisen et al. (Eisen et al., 1998) have de-
veloped a hierarchical clustering-based algorithm and visualization software 
package (freely available on http:/ /rana.stanford.edu/software), which is 
currently one of the most frequently used tools for analyzing gene expression 
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data. The goal of clustering is to group together objects (genes or samples) 
with similar properties. Subsequently, several research groups have used hier-
archical clustering-based analysis methods on gene expression data obtained 
from human tissue samples. lyer et al. (Iyer et al., 1999) used hierarchical 
cluster analysis on gene expression data from human fibroblasts and found 
distinct gene clusters each associated with genes with particular biologic 
functional roles. Alon et al. (Alon et al., 1999) used a two-way clustering 
method on tumor and normal colon tissues. They found that clustering anal-
ysis on basis of gene expression patterns is able to separate cancerous from 
non-cancerous tissue and cell lines from in vivo tissue. Alizadeh et al. (Aliza-
deh et al., 2000) identified two molecularly distinct forms of diffuse large 
B-cell lymphoma (DLBCL), which had gene expression patterns indicative 
of different stages of B-cell differentiation. Moreover, these two groups cor-
related with patients' survival rates. Also in breast cancer distinct molecular 
subclasses, correlated with patients' survival rates, have been identified using 
gene expression profiles and clustering analysis (Perou et al., 2000; Sorlie et 
al., 2001). Even more, using eDNA array technique and clustering analysis, 
Scherf et al. (Scherf et al., 2000) found a gene-drug relationship and were 
able to show that variations in the transcript levels of particular genes relate 
to mechanisms of drug sensitivity and resistance. 
Another method used to analyze gene expression data is supervised clus-
tering of expression data. The goal of supervised analysis is to construct 
classifiers, which assign predefined classes to a given expression profile. 
Unsupervised clustering of samples with known characteristics may identify 
gene clusters, which can subsequently be used as a classifier in supervised 
analysis of a group of uncharacterized samples. Van 't Veer et al. (van 't Veer 
et al., 2002) performed such a supervised cluster analysis on gene expression 
profiles of 117 breast tumors, in order to classify breast tumors according to 
their clinical behavior. They were able to identify a gene cluster predictive of 
a short interval to distant metastases. This cluster consisted of genes regulat-
ing cell cycle, invasion, metastasis and angiogenesis. They were also able to 
establish a gene cluster that identifies tumors of BRCA-1 mutation carriers. 
They predict that gene expression profiling will outperform all currently used 
clinical parameters in predicting disease outcome and selecting patients for 
specific therapy. 
So far, neither the issue of the diagnostic value of gene expression profil-
ing in endometrial carcinomas nor the feasibility of gene expression profiling 
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techniques in a clinical setting has been studied. To examine the feasibility 
of gene expression profiling as a clinical tool, in the current thesis the ef-
ficacy, reproducibility and specificity of gene expression profiles of human 
endometrial carcinoma tissues obtained from surgical specimen was studied 
(Chapter 4). The efficacy to generate a gene expression profile of a tumor 
appeared to be mainly determined by the efficacy of the tissue sampling from 
the surgical specimen. Tissue sampling was performed guided by macroscopic 
judgment of the tissue. Most likely the efficacy can be improved when the 
sampling would be performed on basis of microscopic judgment of fresh fro-
zen slides of the sample. 
In this thesis a commercial eDNA array is used to generate gene expres-
sion profiles from endometrial carcinoma tissue samples (Atlas Human 
Cancer eDNA Expression Array, Clontech, USA). The array contains 588 
genes. The genes are selected by the manufacturer on basis of their known 
involvement in cancer development. It includes oncogenes, tumor suppressor 
genes, cytokines and other genes related with cell cycle regulation, growth 
regulation, apoptosis, DNA repair, cell adhesion and motility, angiogenesis, 
invasion regulation or cell-cell interaction. It was hypothesized that these 
genes, on basis of their known functional roles in tumorigenesis, could serve 
as a classifier in human cancers. To study the diagnostic and prognostic value 
of gene expression profiling in human endometrial carcinoma tissue samples, 
this eDNA array was used and subsequently a supervised cluster analysis of 
the obtained gene expression data was performed (Chapter 4). Large-scale 
gene expression monitoring to select a classifier was not possible, as at the 
time, large scale gene expression monitoring was not yet available in re-
search laboratories in the Netherlands and too expensive to obtain commer-
cially. Eisen's software for a hierarchical clustering-based algorithm (http: 
//rana.stanford.edu/software) seemed promising in providing an useful tool 
to analyze large masses of gene expression data (Alizadeh eta!., 2000; Eisen 
eta!., 1998; Perou eta!., 1999; Perou eta!., 2000; Ross eta!., 2000; Scherf et 
a!., 2000; Sorlie eta!., 2001). Moreover, it is supplemented with a software 
package that visualizes the clustering results and is freely available on the 
Internet. Using Eisen's software, supervised analysis was performed and two 
distinct endometrial cancer clusters were found. It was not possible to iden-
tify a smaller group of genes within the array genes, with a higher specificity 
as classifier. The two endometrial tumor clusters highly resembled the FIGO 
grading system. However, whether gene expressing profiling will outperform 
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all currently used clinical parameters in predicting disease outcome and se-
lecting patients for specific therapy, as hypothesized by van 't Veer et al. (van 
't Veer et al., 2002), is not yet possible to determine. 
8.3 PROGESTERONE-INDUCED GROWTH INHIBITION 
OF ENDOMETRIAL CANCER CELLS 
In the endometrium, the growth inducing properties of estradiol and the 
growth inhibiting properties of progesterone coexist in a delicate balance. In 
endometrial carcinomas this fine balance may be lost. Subsequently, due to 
loss of progesterone-sensitivity during tumor progression, the response rate 
of hormonal treatment in patients with advanced or recurrent endometrial 
cancer is low (10-15%). For the treatment of advanced or recurrent endome-
trial cancer this creates a problem, as treatment options are limited in these 
tumors. Understanding of the regulation of endometrial cell growth inhibi-
tion by progesterone may provide tools to improve therapeutic options for 
patients with advanced or recurrent endometrial cancer. 
The human progesterone receptor exists as two isoforms, hPRA and hPRB. 
The relative distribution of these two isoforms varies in target tissues and 
under certain physiological circumstances (Kastner et al., 1990; Kraus et 
al., 1997). In the endometrium, the hPRA predominates in stromal cells 
throughout the menstrual cycle, whereas in epithelial cells, a shift occurs 
during the early secretory phase from hPRA to hPRB (Mote et al., 1999). The 
varying ratio of the two isoforms among different target cells and different 
physiological circumstances suggests divergent putative function for these 
two receptors. 
Using stable transfection techniques, the human progesterone receptor 
was reintroduced into a hPR negative sub-clone of the Ishikawa endometrial 
carcinoma cell line. Either one or both progesterone receptor isoforms (hPRA 
and hPRB) were transfected. In this way several Ishikawa sub-cell lines were 
constructed, each expressing different levels of hPRA, hPRB or hPRA and 
hPRB, respectively. These Ishikawa sub-cell lines provide a new model to 
study the possible functional differences of these two receptors. All cell lines 
were characterized with regard to progesterone induced growth response and 
progesterone regulated gene expression. Remarkable differences were found 
between the cells expressing different hPR isoforms. Upon measuring growth 
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inhibition, it was observed that the sub-cell lines expressing low levels of 
hPRA were less responsive to progesterone treatment compared to the sub-
cell lines expressing similar levels of hPRB or hPRA/hPRB. However, cells 
expressing high levels of the hPR isoforms were all equal growth responsive 
to progesterone (Chapter 7). Differences in expression of genes targeted by 
the two isoforms were studied using eDNA expression array technique. A dif-
ferent set of genes appeared to be progesterone regulated in the hPRA cells 
compared to the hPRB cells (Chapter 6). 
These observations support the hypothesis of distinct functional dif-
ferences between the two progesterone receptor isoforms. Moreover, these 
results seem to implicate that relative loss of expression of the B isoform is 
involved in the loss of progesterone induced growth inhibition in endome-
trial cancers. Subsequently, this could mean that tumors with relative loss 
of hPRB expression have a worse prognosis compared to tumors showing 
high hPRB expression levels. Several studies support this hypothesis. Kumar 
et ai.(Kumar et a!., 1998) showed that poorly differentiated endometrial 
cancer cell lines expressed hPRA only. Sasaki eta!. (Sasaki eta!., 2001) in-
vestigated the CpG hypermethylation status of human endometrial cancer 
cell lines and patient tissues, and observed selective loss of PRB expression, 
largely due to hypermethylation, in 85% of the investigated tumors (Sasaki 
eta!., 2001). Dai D eta!. (Dai eta!., 2001) infected endometrial carcinoma 
cell lines (KLE and Hec 50) with adenoviral vectors encoding the genes for 
progesterone receptor isoforms A and B. They found that expression of the 
progesterone receptor isoform B caused a much more dramatic decrease in 
cell growth compared to expression of the progesterone receptor isoform A. 
In breast tumor similar results were found. Shyamala et a!. (Shyamala et 
al., 1998) found that in transgenic mice overexpressing PRA, the mammary 
gland exhibits ductal hyperplasia with a disorganized basement membrane 
and decreased cell-cell adhesion; features that are commonly associated with 
neoplasia. Other studies contradict the hypothesis that PRB is predominantly 
responsible for the progesterone induced cell growthinhibition. Using PRA 
knockout (PRAKO) mice, Mulac-Jericevic eta! (Mulac-Jericevic eta!., 2000) 
showed that progesterone treatment of these animals resulted in PRB de-
pendent increase in proliferation of endometrial cells of these PRAKO-mice. 
The conflicting results may be due to differences in research models: human 
(present thesis, (Dai eta!., 2001)) vs. mice (Mulac-Jericevic eta!., 2000). 
Knowledge of the relative distribution of hPRA and hPRB in human en-
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dometrial carcinoma tissues combined with clinical outcome or FIGO stage 
would be informative for the clinical implications of loss of one of the hPR-
isoforms in endometrial tumors. However, this has not been studied very ex-
tensively yet. There is one report in the literature, using RT-PCR and based on 
a very low number of patients, which seems to point to a more predominant 
appearance of hPRB in more advanced endometrial tumors (Fujimoto et al., 
1995). Arnett-Mansfield et al (Arnett-Mansfield et al., 2001) used specific 
hPRA and hPRB antibodies to study progesterone receptor expression levels 
in normal and hyperplastic endometrium compared to endometrial cancer. 
They observed that in tumor tissues the staining for progesterone receptors 
was significantly lower as compared to normal or hyperplastic endometrial 
tissues. Furthermore, normal glands expressed both of the progesterone re-
ceptor isoforms while in hyperplastic tissue a predominance of one of the re-
ceptor isoforms was observed and in 60% of the tumors either hPRA or hPRB 
was lost. However, no relation was found between the isoforms lost and the 
differentiation grade of tumor. In breast cancer, Graham et al. (Graham et 
al., 1995) found low levels of hPRB in a subset of the tumors, however nei-
ther histological grade nor clinical outcome were provided. 
Identifying genes involved in the downstream cascade following proges-
terone binding to its receptor may help to understand the molecular mecha-
nism behind progesterone-induced growth-inhibition of endometrial cancer 
cells and provide tools to restore the progesterone-induced growth inhibition 
of hormone resistant endometrial cancer. In Chapter 5 a differential display 
PCR method (ddPCR) was used to identify progesterone-regulated genes in 
endometrial carcinoma cells. Only genes progesterone-regulated in the cells 
growth responsive to progesterone (Ishikawa endometrial carcinoma cells 
(Nishida et al., 1996)) and not regulated in the cells not growth responsive 
to progesterone (ECC-1 endometrial carcinoma cells) were selected. Genes 
selected in this way could be genes exclusively involved in progesterone-in-
duced growth inhibition. One EST and three known genes ( dsRNA adenosine 
deaminase, ninein, endothelin converting enzyme-1) matched these criteria. 
Further characterization of the clones, with respect to their involvement in 
progesterone-induced growth-inhibition of endometrial cancer cells, was not 
performed. The Ishikawa cells appeared to lose their progesterone receptor 
already after few cell culture passages, making further characterization of 
the clones difficult. All other Ishikawa sub-cell lines tested, were not stable 
in their expression of the progesterone receptor. Subsequently, new Ishi-
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kawa sub-cell lines had to be established, exhibiting stable expression of the 
progesterone receptor. As mentioned earlier, using stably transfection tech-
niques, the human progesterone receptor was reintroduced into a hPR nega-
tive sub-cell line of the Ishikawa cell line. In this way several new Ishikawa 
sub-cell lines were created, which showed a marked progesterone-induced 
growth-inhibition (Chapters 6 and 7). 
The rapid progression of the development of techniques to study gene ex-
pression is reflected in this thesis. At the start of the research for this thesis, 
ddPCR was a frequently used method to study differential gene expression 
(Chapter 5). However, only a few years later the ddPCR method had been 
replaced by the eDNA array techniques. Subsequently, when the new proges-
terone receptor expressing Ishikawa cell lines were established, differences in 
gene expression were studied using eDNA arrays (Chapters 6 and 7). 
Using eDNA array technique, IGFBP3 was identified as a progesterone 
down-regulated gene in all Ishikawa sub-cell lines (Chapter 7). Reports on 
the possible role of IGFBP3 in tumor behavior are conflicting. Down-regu-
lation of IGFBP3 has been associated with inhibition of apoptosis (Baxter, 
2001; Butt et al., 1999; Grimberg & Cohen, 1999; Shen et al., 1999) and with 
worst prognosis in ovarian cancer (Katsaros et aL, 2002). These observations 
suggest that IGFBP3 expression is associated with inhibition of cell growth. 
However, in the current investigations (Chapter 7) the hPRB expressing 
cells were found to exhibit a more pronounced progesterone induced down 
regulation of IGFBP3 expression compared to the hPRA expressing cells. This 
suggests a correlation between progesterone-induced down-regulation of cell 
growth and progesterone induced down regulation of IGFBP3 expression. A 
recent publication of Grill and Cohick (Grill & Cohick, 2000) supports 
these findings. They stably transfected bovine mammary epithelial cells 
with IGFBP3 and observed that high IGFBP3 levels were correlated with an 
increased IGF-induced cell growth rate. Even more, in transgenic animals 
a correlation was found between high levels of IGFBP3 and increased cell 
growth: overexpression of IGFBP3 resulted in organomegaly of spleen, liver 
and heart. 
The current results emphasize distinct functional differences for the two 
progesterone receptor isoforms in human endometrial carcinoma cells. The 
two isoforms regulate different sub-sets of genes. At relatively low expression 
levels, hPRB seem to be more effective in inhibiting cell growth. Whether 
interaction between the isoforms is important in generating progesterone 
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actions in target tissue is unknown. On basis of the observations described in 
this thesis it can be hypothesized that the relative distribution of hPRA and 
hPRB in endometrial cancer cells has great implications on human endome-
trial tumor behavior. Still, the specific action of two isoforms on progester-
one target tissues such as endometrial cells remains to be clarified. 
8.4 CONCLUSIONS 
This thesis has concerned itself with the possible role of molecular genet-
ics in improvement of the outcome of endometrial cancer patients. In this 
respect four questions were assigned. This paragraph addresses the answers 
obtained with the studies performed in the thesis. 
1. What degree of clinical utility and subsequent diagnostic value of gene expres-
sion profiling of endometrial tumors can be ascertained? 
Using a commercially available eDNA array technique, gene expression 
profiles can be generated from human endometrial carcinoma tissue 
samples with high efficacy ( 77%). The gene expression profiles seem to 
be tissue specific and not patient specific. As a result of these observa-
tions, it can be concluded that gene expression profiling seems to be a 
clinical feasible tool. 
Ranking endometrial tumors on basis of their gene expression profiling 
showed high similarity with FIGO grading, indicating that the diagnostic 
value of gene expression profiling matches the FIGO grading system. 
2. Is it possible to identi.fir genes that are differential expressed between proges-
terone-sensitive and progesterone-insensitive endometrial cancer cells? 
Using differential display PCR technique four genes have been identified 
to be differential expressed between progesterone-sensitive and proges-
terone-insensitive endometrial cancer cells: dsRNA adenosine deaminase, 
ninein, endothelin converting enzym.e-1 and one EST. These four genes 
may be involved in the development of progesterone insensitivity in en-
dometrial cancers. 
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3. What functional differences between the two human progesterone receptor 
(hPR) isoforms (hPRA and hPRB) in endometrial cancer ce11s can be estab-
lished? 
Distinct differences in progesterone regulated gene expression and in 
progesterone induced cell growth inhibition were observed between hPRA 
and hPRB expressing endometrial cancer cells. 
4. What effects of progesterone can be measured on gene expression and cell 
growth of endometrial cancer ce11 lines expressing hPRA or hPRB or both? 
With regard to cell growth inhibition, endometrial cancer cells expressing 
relative low levels of hPRA are found to be less responsive to progesterone 
treatment compared to cells expressing similar levels of hPRB. However, 
cells expressing relative high levels of one or both hPR isoforms are 
equally growth responsive to progesterone. Upon gene expression regula-
tion, progesterone is found to regulate a different set of genes in hPRA 
expressing cells compared to hPRB expressing cells. 
8.5 fUTURE DIRECTIONS 
To determine whether gene expressing profiling will outperform all currently 
used clinical parameters (e.g. FIGO staging system) in predicting disease 
outcome and selecting patients for specific therapy, as hypothesized by van 't 
Veer eta!. (van 't Veer eta!., 2002), a larger group of endometrial tumor gene 
expression profiles will have to be combined with clinical long term follow 
up data. Unsupervised clustering of genome wide expression data may help to 
select a more specific cluster of genes to use as classifier in supervised clus-
tering. Insertion of genes, identified to be involved in progesterone induced 
growthinhibition, in the classifier cluster may help to subtract sub-groups of 
patients responsive to hormonal treatment. 
Studying the relative distribution of hPRA and hPRB expression in the 
human endometrial cancer tissue samples and subsequently combining these 
data with long term clinical follow-up may help to establish the prognostic 
implication of selective loss of one of the progesterone receptor isoforms. 
To illuminate the specific functions of the hPRA and hPRB in endometrial 
cancer cells, the recent established Ishikawa sub-cell lines provide a useful 
model. The functional role of the five progesterone-regulated genes (one EST, 
Discussion and Conclusions 
dsRNA adenosine deaminase, ninein, endothelin converting enzyme~ 1 and 
IGFBP3) will have to be further characterized in these cells. 
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SuMMARY 
In the Netherlands approximately 370 women die of endometrial cancer 
every year. Part of these deaths is accounted for by patients who were mis-
guidedly taken to have a good prognosis as they were classified in the low 
surgical-pathological stage (stage 1 and 2) group (FICO staging system). The 
other part of the deaths is accounted for by patients with advanced disease. 
In these patients the response rates to treatment (surgery combined with ra-
diotherapy) is low (26% five years survival rate). Hormone therapy (e.g. pro-
gesterone) is given to these patients as a palliative treatment. However, due 
to loss of progesterone sensitivity during tumor progression, the response 
rate of hormonal treatment in these patients is also low (10-15%). 
Genetic alterations are thought to play a major role in tumor develop-
ment and tumor progression. The recent rapid progression of the Human 
Genome Project in mapping the human genome and the development of 
new techniques to study gene expression have created new tools to expand 
our knowledge of tumorigenesis. Several genes have been identified to be 
associated with tumor development in human tissues. Recently, it has been 
shown that gene expression profiling can be used to identify distinct tumor 
subclasses, which correlate with the biological behavior of the tumor, and 
which were previously undetected by the surgical and histological classifica· 
tion methods. 
In this thesis the possible role of molecular genetics in improvement 
of the outcome of endometrial cancer patients is investigated. To improve 
tumor classification the value of gene expression profiling in classifying hu-
man endometrial tumors is studied. To find tools to restore the progesterone-
induced grovvth inhibition of endometrial cancer, the molecular mechanisms 
involved in progesterone-induced grovvth inhibition of endometrial cancer 
cells are studied. 
In Chapter 2.1 an overview is given of the characteristics and the biological 
behavior of normal human endometrium and of human endometrial cancer. 
Chapter 2.2 describes the mechanism of action and functional character-
istics of the human progesterone receptors (hPRA and hPRB). The General 
Introduction ends with a review of literature studying genetic events in en-
dometrial cancer (Chapter 2.3). Genes most frequently found to be altered 
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in endometrial cancer are the tumor-suppressor genes: p53, PTEN, DCC and 
the oncogenes: K-ras, c-erbB2, c-fms. Two possible molecular prognostic 
markers have been identified so far: p53 and c-erbB2. 
In Chapter 3 the Atlas Human Cancer eDNA expression array is used to 
generate gene expression profiles of human endometrial cancer and benign 
endometrial tissue samples. Subsequently, a method to compare two gene ex-
pression profiles was introduced. The most innovative property of this analy-
sis method is the fact that it uses raw hybridization data; normalization of 
the data for differences in background signal and for differences in intensity 
of hybridization is not needed. Three genes (Decorin, TIMP3 and Cyclin D1) 
are identified to be differentially expressed between benign endometrial and 
endometrial carcinoma tissue. Decorin and TIMP3 are down-regulated and 
Cyclin D1 is up regulated in tumor tissue samples. 
In Chapter 4 the utility and diagnostic value of gene expression profil-
ing in human tissue samples is studied. The Atlas Human Cancer eDNA ar-
ray containing 588 cancer related genes is used to generate gene expression 
profiles of hysterectomy specimen. The efficacy to generate a gene expression 
profile of a tumor appears to be mainly determined by the efficacy of the tis-
sue sampling from the surgical specimen. A clustering analysis is performed. 
Two distinct endometrial cancer clusters are found on the basis of their gene 
expression profile. These two clusters highly resemble classification accord-
ing to the FIGO grading system. 
In Chapter 5 four eDNA clones are identified to be progesterone regu-
lated and differential expressed between a progesterone sensitive and a pro-
gesterone insensitive endometrial carcinoma cell line. The eDNA clones are 
identified using a differential display PCR method. Sequence analysis reveals 
that three eDNA clones match with known genes (dsRNA adenosine deami-
nase, ninein, endothelin converting enzyme-1). 
Chapters 6 and 7 describe the establishment of several new endometrial 
carcinoma cell lines. Using stably transfection techniques, the human pro-
gesterone receptors (hPRA and hPRB) are reintroduced into a hPR negative 
sub-clone of the Ishikawa endometrial carcinoma cell line. In this way sev-
eral Ishikawa sub-cell lines are constructed, each expressing different levels 
of hPRA, hPRB or hPRA and hPRB. These Ishikawa sub-cell lines provide a 
new model to study the possible functional differences of these two receptor 
isoforms. All cell lines are characterized with regard to progesterone induced 
growth response and progesterone regulated gene expression. In Chapter 6 
differences in gene expression between hPRA and hPRB are studied using two 
of the newly created Ishikawa cell lines (PRA-14 and PRB-59). A different set 
of genes appears to be progesterone regulated in the PRA-14 cells compared 
to the PRB-59 cells. None of the genes are regulated by both hPRA and hPRB. 
Chapter 7 describes the establishment and characterization of nine Ishikawa 
sub-cell lines (four expressing hPRA, three expressing hPRB and two express-
ing hPRA + hPRB). Remarkable differences in progesterone induced growth 
response are found between the cells expression different hPR isoforms. The 
sub-cell lines expressing low levels of hPRA appear to be less responsive to 
progesterone treatment compared to the sub-cell lines expressing similar 
levels of hPRB or hPRA/hPRB. Using the Atlas Human Cancer eDNA array 
progesterone regulated genes are identified in a hPRA and hPRB expressing 
Ishikawa sub-cell line (PRAB-36). Several genes are found to be regulated 
by progesterone. The gene with the most significant expression difference is 
IGFBP3. IGFBP3 is down-regulated by progesterone. IGFBP3 mRNA appears 
to be progesterone regulated in all Ishikawa sub-cell lines. However, all hPRB 
expressing cell lines show a more profound down-regulation of IGFBP3 com-
pared to the hPRA expressing lines. 
In the Discussion and Conclusions section (Chapter 8) a genetic model 
for endometrial tumorigenesis is presented. The prognostic/diagnostic value 
of gene expression profiling of endometrial tumor samples is discussed. Fur-
thermore, distinct functional differences between the two hPR isoforms in 
endometrial cancer cells are discussed. Finally, suggestions are given con-
cerning possible future directions of the research related to this thesis. 
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SAMENVATTING 
In Nederland sterven jaarlijks ongeveer 370 vrouwen ten gevolge van en-
dometriumkanker. Voor een deel betreft dit vrouwen die aanvankelijk, met 
behulp van het chirurgisch/histologische FIGO stageringssysteem, geclassifi-
ceerd waren in een prognostisch gunstige groep (FIGO Stadium 1 en 2). Het 
andere deel van de sterfgevallen betreft patienten met een gemetastaseerde 
tumor. Deze patH!nten worden, indien mogelijk, behandeld met chirurgische 
verwijdering van de tumor gecombineerd met bestralingstherapie. De gene-
zingskans voor deze vrouwen is laag (vijfjaars overleving slechts 26%). Hor-
monale therapie (progesteron) kan als een vorm van palliatieve behandeling 
gegeven worden. Echter, tijdens het voortschrijden van de tumorontwikke-
ling blijken endometrium tumorcellen hun gevoeligheid voor progesteron te 
verliezen. Door dit verlies aan progesterongevoeligheid is de kans op succes 
van de palliatieve therapie dan ook laag (bij slechts 10-15% van de patienten 
wordt een verbetering waargenomen). 
Aan genetische veranderingen wordt een grote rol toebedeeld in de ont-
wikkeling en progressie van humane tumoren. Het Human Genome Project 
heeft recent grote vooruitgang geboekt in het ontcijferen van het humane 
genoom. Dit heeft, samen met de ontwikkeling van nieuwe onderzoeks-
technieken, gezorgd voor nieuwe middelen om onze kennis van kanker uit 
te breiden. Van verschillen genen is betrokkenheid bij de ontwikkeling van 
kanker vastgesteld. Bovendien is recentelijk ontdekt dat met behulp van gen 
expressie profielen, nieuwe tumor subklassen aan te wijzen zijn. Deze nieuwe 
subklassen correleren met specifiek biologisch gedrag van de tumoren. De 
voorheen gebruikelijke chirurgisch/histologische stageringssystemen zijn 
niet in staat deze subklassen te onderscheiden. 
In dit proefschrift is de rol die de moleculaire genetica zou kunnen spelen 
in het verbeteren van de overleving van vrouwen met endometriumkanker 
onderzocht. De overleving van deze patienten zou verbeterd kunnen worden 
door optimalisatie van de tumorclassificatie. Moleculaire classificatie mid-
dels gen expressie profielen zou een verbetering van deze classificatie kunnen 
geven. In dit proefschrift is de diagnostische waarde van moleculaire classifi-
catie middels gel?- expressie profielen in endometriumtumoren bestudeerd . 
Daarnaast zijn in dit proefschrift de moleculaire mechanismen betrok-
ken bij progesterongeinduceerde groeiremming van endometriumcellen 
onderzocht. Inzicht in deze mechanismen zou kunnen helpen om middelen 
te vinden waarmee de progesteron geinduceerde groeiremming in endome-
trium tumoren kan worden hersteld. Hiermee zouden nieuwe therapeutische 
mogelijkheden voor patienten met endometrium kanker ontvvikkeld kunnen 
worden. 
In de Algemene Introductie (Hoofdstuk 2.1) wordt een overzicht gegeven van 
de karakteristieken en het biologisch gedrag van normaal endometrium weef-
sel en van endometriumtumoren. Hoofdstuk 2.2 beschrijft het functioneren 
van de humane progesteron receptoren (hPRA and hPRB). Tevens wordt een 
overzicht van de literatuur betreffende moleculair genetische veranderingen 
in endometrium kanker gegeven (Hoofdstuk 2.3). In endometriumtumoren 
worden veranderingen in expressie niveau het meest frequent gevonden voor 
de tumor-suppressor genen: p53, PTEN en DCC en voor de oncogenen: K-ras, 
c-erbB2, c-fms. Van twee genen (p53 en c-erbB2) b!ijkt dat zij als prognosti-
sche markers kunnen fungeren. De moleculair genetische informatie die tot 
nu toe over endometriumkanker beschikbaar is, ondersteunt de theorie dat 
in de etiologie van endometriumkanker tvvee subgroepen aan te wijzen zijn: 
1) een oestrogeengerelateerde etiologie waarbij veranderingen in PTEN, K-ras 
en microsatelliet instabiliteit betrokken zijn (het endometrioid subtype), 2) 
een niet oestrogeengerelateerde etiologie welke leidt tot de meer agressieve 
papillair sereuse en clear cell tumoren (non-endometrioid subtype), en waar-
bij p53 en c-erbB2 mutaties betrokken lijken te zijn. 
In Hoofdstuk 3 wordt beschreven hoe met behulp van een "eDNA array" 
techniek, gen expressie profielen gemaakt worden van endometriumtumor 
weefsel en van normaal endometriumweefsel. Vervolgens wordt een methode 
beschreven om gen expressie profielen van tvvee verschillen weefsels te ver-
gelijken. Het meest innovatieve aan deze nieuwe analyse methode is het feit 
dat gebruik gemaakt wordt van onbewerkte hybridisatie data; normalisatie 
van de data voor verschillen in achtergrondsignaal of voor verschillen in 
intensiteit van de hybridisatie is niet nodig. Van drie genen (Decorin, TIMP3 
en Cycline D1) is aangetoond dat zij differentieel tot expressie komen tussen 
normaal endometrium weefsel en endometriumkankerweefsels. Het expres-
sieniveau van Decorin en TIMP3 is laag in de tumorweefsels in vergelijking 
tot het normale weefsel. De expressie van Cycline D1 daarentegen is hoog in 
tumorweefsel en laag in het normale (niet-tumor) weefsel 
In Hoofdstuk 4 wordt de bruikbaarheid en de diagnostische waarde van 
gen expressie profilering in humane weefsels bestudeerd. Een eDNA array, 
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welke 588 kanker gerelateerde genen bevat, is gebruikt om gen expressie 
profielen te generen uit hysterectomie materiaal. Een clustering-analyse van 
de verkregen data is verricht. Twee endometriumkanker clusters worden op 
basis van verschillen in gen expressie profielen geldentificeerd. De verdeling 
van de tumoren over deze twee clusters blijkt grote gelijkenis te vertonen met 
de verdeling van de tumoren op basis van het FIGO graderingssysteem. 
In Hoofdstuk 5 zijn vier progesterongereguleerde eDNA's geidentificeerd, 
welke differentieel tot expressie komen tussen een voor progesteron groeige-
voelige endometriumcarcinoom cellijn en een voor progesteron groeionge-
voelige endometriumcarcinoom cellijn. De eDNA's zijn geidentificeerd met 
behulp van een differential display PCR methode. Sequence analyse Jaat zien 
dat drie van deze eDNA's overeenkomen met reeds bekende genen (dsRNA 
adenosine deaminase, ninein, endothelin converting enzyme-1). 
In de Hoofdstukken 6 en 7 wordt de ontwikkeling van een groep nieuwe 
endometriumcarcinoom cellijnen beschreven. Met behulp van stabiele trans-
fectietechnieken werden de humane progesteronreceptoren (hPRA and hPRB) 
getransfecteerd in een hPR negatieve subkloon van de Ishikawa endometrium 
carcinoom cellijn. Hiermee zijn verschillende nieuwe Ishikawa subcellijnen 
gecreeerd. Deze subcellijnen vertonen elk een verschillend expressie niveau 
van hPRA, hPRB of hPRA en hPRB. Met deze cellijnen is de mogelijkheid 
gecreeerd om de functionele verschillen tussen de twee progesteron receptor 
isovormen te kunnen bestuderen. Aile cellijnen zijn gekarakteriseerd met 
betrekking tot progesterongeinduceerde groeiremming en progesteron ge-
reguleerde gen expressie. In Hoofdstuk 6 zijn twee van de nieuwe Ishikawa 
cellijnen (PRA-14 en PRB-59) gebruikt om verschillen in gen expressie pro-
fie! tussen hPRA en hPRB te bestuderen. In de PRA-14 cellen blijken andere 
genen door progesteron gereguleerd te worden dan in de PRB-59 cellen. Er 
worden geen genen gevonden die zowel in de PRA-14 als in de PRB-59 cellen 
door progesteron gereguleerd worden. In Hoofdstuk 7 wordt de ontwikkeling 
en karakterisering van negen Ishikawa subcellijnen (vier hPRA, drie hPRB en 
twee hPRA + hPRB) beschreven. Tussen de hPRA en de hPRB bevattende cellij-
nen worden opmerkelijke verschillen gevonden in gevoeligheid voor proges-
terongereguleerde groeiremming. De subcellijnen met lage expressieniveaus 
van hPRA blijken minder gevoelig voor progesteron gereguleerde groeirem-
ming dan de cellijnen met vergelijkbare niveaus van hPRB of hPRA en hPRB 
expressie. Met behulp van eDNA array techniek zijn progesterongereguleerde 
genen geidentificeerd in een hPRA en hPRB bevattende Ishikawa subcellijn 
(PRAB-36). Verschillende progesterongereguleerde genen zijn geidentificeerd. 
IGFPB3 is het gen met het meest duidelijke progesteron gereguleerde expres-
sie niveau. Het expressieniveau van IGFBP3 daalt na toediening van proges-
teron. Northern blot analyse is gebruikt om het expressieniveau van IGFBP3 
te bestuderen in de hPRA en de hPRB bevattende Ishikawa cellijnen. JGFBP3 
blijkt progesterongereguleerd in aile Ishikawa subcellijnen. Echter, de hPRB 
cellijnen Iaten een meer uitgesproken regulatie van IGFBP3 expressie zien 
dan de hPRA cellijnen. 
In Hoofdstuk 8 wordt een moleculair-genetisch model voor endometrium 
carcinogenese gepresenteerd. Vervolgens wordt de prognostische en diagnos-
tische waarde van tumor gen expressie profielen bediscussieerd. Tevens wor-
den de functionele verschillen tussen de twee hPR isovormen besproken. De 
in dit proefschrift gevonden resultaten worden geinterpreteerd in het Iicht 
van de beschikbare literatuur over dit onderwerp. Ten slotte worden sugges-
ties gedaan ten aanzien van mogelijk vervolgonderzoek. 
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